Codes for the GHO Dimension

2024-01-19

Available codes for the GHO dimension:

Code Title
Adult_curr_cig_smoking Prevalence of current cigarette smoking among adults (%)
Adult_curr_e-cig Prevalence of current e-cigarette use among adults (%)
Adult_curr_smokeless Prevalence of current smokeless tobacco use among adults (%)
Adult_curr_tob_smoking Prevalence of current tobacco smoking among adults (%)
Adult_curr_tob_use Prevalence of current tobacco use among adults (%)
Adult_daily_cig_smoking Prevalence of daily cigarette smoking among adults (%)
Adult_daily_e-cig Prevalence of daily e-cigarette use among adults (%)
Adult_daily_smokeless Prevalence of daily smokeless tobacco use among adults (%)
Adult_daily_tob_smoking Prevalence of daily tobacco smoking among adults (%)
Adult_daily_tob_use Prevalence of daily tobacco use among adults (%)
Adult_nonsmoked_age_grp Age range of latest adult prevalence survey (nonsmoked)
Adult_nonsmoked_national Representation of latest adult prevalence survey (nonsmoked)
Adult_nonsmoked_svy_title Name of latest adult prevalence survey (nonsmoked)
Adult_nonsmoked_svy_yr Year of latest adult prevalence survey (nonsmoked)
Adult_survey_title Title of most recent survey of adults
Adult_svy_age_range Age range of most recent survey of adults
Adult_svy_national Representativeness of most recent survey of adults
Adult_svy_yr Year of most recent survey of adults
AIR_1 Ambient air pollution attributable deaths (please see AIR_41)
AIR_10 Ambient air pollution attributable DALYs per 100’000 children under 5 years
AIR_11 Household air pollution attributable deaths
AIR_12 Household air pollution attributable deaths in children under 5 years
AIR_13 Household air pollution attributable deaths per 100’000 capita
AIR_14 Household air pollution attributable deaths per 100’000 children under 5 years
AIR_15 Household air pollution attributable DALYs
AIR_16 Household air pollution attributable DALYs in children under 5 years
AIR_17 Household air pollution attributable DALYs (per 100 000 population)
AIR_18 Household air pollution attributable DALYs per 100’000 children under 5 years
AIR_2 Ambient air pollution (Annual PM10 [ug/m3])
AIR_2_1 Ambient air pollution in urban areas (Annual PM10 [μg/m3])
AIR_3 Percentage of the total population living in cities > 100’000 inhabitants
AIR_3_1 Percent of urban inhabitants living in cities covered by PM measurements
AIR_35 Joint effects of air pollution attributable deaths
AIR_36 Joint effects of air pollution attributable deaths in children under 5 years
AIR_39 Household air pollution attributable DALYs (per 100 000, age-standardized)
AIR_4 Ambient air pollution attributable deaths in children under 5 years
AIR_41 Ambient air pollution attributable deaths
AIR_42 Ambient air pollution attributable death rate (per 100 000 population, age-standardized)
AIR_43 Ambient air pollution attributable DALYs (please see AIR_7)
AIR_44 DALYs attributable to ambient air pollution (age-standardized)
AIR_45 Ambient air pollution attributable YLLs
AIR_46 Ambient air pollution attributable YLL in children under 5 years
AIR_5 Ambient air pollution attributable death rate (per 100 000 population)
AIR_50 Ambient air pollution attributable deaths (per 100 000 population, age-standardized)
AIR_51 Household air pollution attributable death rate (per 100 000 population)
AIR_52 Household air pollution attributable death rate (per 100 000 population, age-standardized)
AIR_6 Ambient air pollution attributable deaths per 100’000 children under 5 years
AIR_60 Household and ambient air pollution attributable DALYs (’000)
AIR_61 Household and ambient air pollution attributable DALYs (per 100 000 capita)
AIR_62 Household and ambient air pollution attributable DALYs (per 100 000 capita, age-standardized)
AIR_63 Household and ambient air pollution attributable DALYs in children under 5 years (’000)
AIR_7 Ambient air pollution attributable DALYs
AIR_71 Ambient air pollution attributable DALYs in children under 15 years
AIR_72 Ambient air pollution attributable deaths in children under 15 years
AIR_73 Ambient air pollution attributable YLL in children under 15 years
AIR_74 Household air pollution attributable deaths in children under 15 years
AIR_75 Household air pollution attributable DALYs in children under 15 years
AIR_8 Ambient air pollution attributable DALYs in children under 5 years
AIR_9 Ambient air pollution attributable DALYs (per 100 000 population)
AIR_90 Ambient air pollution attributable DALYs (per 100 000 population, age-standardized)
AMR_GI_001 Status of countries enrolled in GLASS
AMR_GI_002 Status of National coordination center establishment
AMR_GI_003 Status of National plans to implement and strengthen antimicrobial surveillance
AMR_INFECT_ECOLI Proportion of bloodstream infection due to Escherichia coli resistant to third-generation cephalosporins (%)
AMR_INFECT_MRSA Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) (%)
AMRGLASS_COORD01 Functioning national AMR surveillance plan
AMRGLASS_COORD02 Establishment of National Coordination Centre (NCC)
AMRGLASS_COORD03 Nomination of National Focal Point (NFP)
AMRGLASS_COORD04 Establishment of national reference laboratory (NRL)
AMRGLASS_QA01 External Quality Assessment (EQA) provided to the national reference laboratory (NRL)
AMRGLASS_QA02 External Quality Assessment (EQA) provided for bacterial identification and Antimicrobial Susceptibility Testing (AST)
AMRGLASS_QA03 External Quality Assessment (EQA) provided to local laboratories participating in GLASS
AMRGLASS_QA04 GLASS pathogens testing covered by External Quality Assessment (EQA)
AMRGLASS_QA05 Types of Antimicrobial Susceptibility Testing (AST) standards followed by countries
AMRGLASS_SURVL01 Number of surveillance sites reporting to GLASS: Hospitals
AMRGLASS_SURVL02 Number of surveillance sites reporting to GLASS: Outpatient facilities
AMRGLASS_SURVL03 Number of local clinical laboratories supporting national AMR surveillance sites
AMRGLASS_SURVL04 Number of surveillance sites reporting to GLASS: In- and outpatient facilities
AMRGLASS_SURVL05 Total number of surveillance sites reporting to GLASS
anc1 Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%)
anc15 Antenatal care coverage - at least one visit (in the five years preceding the survey) (%)
anc4 Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%)
anc45 Antenatal care coverage - at least four visits (in the five years preceding the survey) (%)
asfr1 Adolescent fertility rate (births per 1000 women aged 15-19 years)
ASSISTIVETECH_BARRIERAT Barriers to accessing assistive products (%)
ASSISTIVETECH_METNEED Met need of assistive products as proportion of need (%)
ASSISTIVETECH_PAYERSAT Funding for assistive products (%)
ASSISTIVETECH_Q01 Existence of legislation on access to assistive technology
ASSISTIVETECH_Q02 Coverage of people in need of assistive technology by legislation
ASSISTIVETECH_Q03 Availability of public funding for assistive technology
ASSISTIVETECH_Q04 Existence of responsible ministry/authority on assistive technology
ASSISTIVETECH_Q05 Availability of government/registered services for assistive technology
ASSISTIVETECH_Q06 Workforce availability for assistive technology
ASSISTIVETECH_Q07 Availability of education/training for assistive technology
ASSISTIVETECH_Q08 Existence of financial mechanisms for assistive technology
ASSISTIVETECH_Q09 Existence of regulations/standards/guidelines/protocols on assistive technology
ASSISTIVETECH_Q10 Existence of initiatives/collaborations on assistive technology
ASSISTIVETECH_SATISFACTIONACTIVITIES Satisfaction with assistive products for different environments and activities (%)
ASSISTIVETECH_SATISFACTIONSERVICES Satisfaction with assistive products and related services (%)
ASSISTIVETECH_SOURCESOFAT Sources of assistive products (%)
ASSISTIVETECH_TOTALNEED Prevalence of need of assistive products (%)
ASSISTIVETECH_TRAVELDISTANCEAT Travel distance to obtain assistive products (%)
ASSISTIVETECH_USEPREVALENCE Prevalence of use of assistive products (%)
bcgv (see vbgc)
bfearly Early initiation of breastfeeding (in the two years preceding the survey) (%)
bmi30wm Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%)
BP_03 Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate)
BP_04 Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate)
BP_05 Mean systolic blood pressure (crude estimate)
BP_06 Mean systolic blood pressure (age-standardized estimate)
Camp_airtime Process evaluation was employed to assess implementation
Camp_aud_research Formative research was conducted prior to the campaign
Camp_eval_impact Outcome evaluation was employed to assess effectiveness of the campaign
Camp_gov_prog Campaign was part of a comprehensive tobacco control programme
Camp_mat_tested Campaign was pre-tested
Camp_media_monitor Process evaluation was employed to assess implementation of the campaign
Camp_media_planning Campaign utilized media planning
Camp_nat At least one national mass media campaign ran during the survey period
Camp_news Earned media/public relations were used to promote the campaign
Camp_tv_radio Campaign ran on both national television and radio
CARE_SEEK Care-seeking by type of patient and source of care (%) (see CARE_SOURCE)
CARE_SOURCE Care-seeking by type of patient and source of care (%)
carep Children aged < 5 years with pneumonia symptoms taken to a health facility (%)
CaseCS Congenital syphilis number of cases, reported
CATARACTSURGICAL Cataract surgical coverage of adults aged 50 and over (%)
CATARACTSURGICALEFFECTIVE Effective cataract surgical coverage of adults aged 50 and over (%)
CC_1 Climate change attributable deaths
CC_2 Climate change attributable DALYs (’000)
CC_3 Climate change attributable deaths per 100’000 capita
CC_4 Climate change attributable DALYs per 100’000 capita
CC_5 Climate change attributable deaths (’000) in children under 5 years
CC_6 Climate change attributable deaths per 100’000 children under 5 years
CC_7 Climate change attributable DALYs (’000) in children under 5 years
CC_8 Climate change attributable DALYs per 100’000 children under 5 years
CCH_SURVEY_AGREEMENT_MOH_OTHERSECTORS Agreement in place between the Ministry of Health and other sector(s) in relation to health and climate change policy or programs
CCH_SURVEY_MOH_FOCALPOINT Designation of a focal point responsible for health and climate change within the Ministry of Health
CCH_SURVEY_MULTISTAKEHOLDER_MECHANISM_EXISTS Existence of a multi-stakeholder mechanism on health and climate change
CCH_SURVEY_PLAN_STRATEGY_DEVELOPED National health and climate change plan or strategy developed
CCH_SURVEY_SURVEILLANCE_SYSTEM_EXISTS Existence of an health surveillance system
CCH_SURVEY_SURVEILLANCE_WHICH_METEOROLOGICAL Existence of a health surveillance system which includes meteorological information
CCH_SURVEY_VULNERABILITY_ADAPTATION_ASSESSMENT Climate change and health vulnerability and adaptation assessment conducted
cci Composite coverage index (%)
cci2030 (see cci)
CCO_1 Poverty headcount ratio at $1.25 a day (PPP) (% of population)
CCO_2 Human development index rank
CCO_3 Gender inequality index rank
CCO_WHS9_85 Literacy rate among adults aged >= 15 years (%) (void CCO_WHS9_85)
CHILDMORT_DEATHS_10TO14 Number of deaths among children ages 10 to 14 years
CHILDMORT_MORTALITY_10TO14 Mortality rate among children ages 10 to 14 years (per 1000 children aged 10)
CHILDMORT10TO19 Adolescent mortality rate (per 1 000 age specific cohort)
CHILDMORT5TO14 Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years)
CHILDVIOL Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month
CHOLERA_0000000001 Number of reported cases of cholera
CHOLERA_0000000002 Number of reported deaths from cholera
CHOLERA_0000000003 Cholera case fatality rate
CM_01 Number of deaths among children under-five
CM_02 Number of infant deaths (between birth and 11 months)
CM_03 Number of neonatal deaths (0 to 27 days)
CM_04 Number of deaths among children ages 5 to 9 years
cpmo (see cpmowho)
cpmowho Contraceptive prevalence - use of modern methods (%)
cpmt Contraceptive prevalence - use of modern and traditional methods (%)
csection Births by caesarean section (in the two or three years preceding the survey) (%)
csection5 Births by caesarean section (in the five years preceding the survey) (%)
DEVICES00 Total density per 100 000 population: Hospitals
DEVICES01 Total density per 100 000 population: Health posts
DEVICES02 Total density per 100 000 population: Health centres
DEVICES03 Total density per 100 000 population: District/rural hospitals
DEVICES04 Total density per 100 000 population: Provincial hospitals
DEVICES05 Total density per 100 000 population: Specialized hospitals
DEVICES06 Availability of national standards or recommended lists of medical devices
DEVICES07 Types of lists recommending health technology for high burden diseases
DEVICES08 Total density per million population: Magnetic Resonance Imaging
DEVICES09 Total density per million population: Computed tomography units
DEVICES10 Total density per million population: Positron Emission tomography
DEVICES11 Total density per million population: Gamma camera or Nuclear medicine
DEVICES12 Total density per million population: Linear Accelerator
DEVICES13 Type of nomenclature system
DEVICES14 Use of nomenclature system
DEVICES15 Health technology (medical device) national policy
DEVICES16 Unit in the Ministry of Health responsible for the management of medical devices
DEVICES17 Procurement of medical devices carried out at the national level
DEVICES18 Availability of national list of approved medical devices for procurement or reimbursement
DEVICES19 National guidelines, policies or recommendations on the procurement of medical devices
DEVICES20 Availability of technical specifications of medical devices to support procurement or donations
DEVICES21 Total density per million population: Telecobalt Unit
DEVICES22 Total density per million population: Radiotherapy units
DEVICES23 Total density per million females aged from 50 to 69 years old: Mammography units
DEVICES24 National authority responsible for regulating medical devices
DEVICES25 National Health Technology Assessment (HTA) unit including the assessment of medical devices, and diagnostics
dptv (see vdpt)
E_compl_all_dir Overall compliance with bans on direct advertising (score)
E_compl_e_all_indir Overall compliance with bans on promotion and sponsorship (score)
E_compl_e1 Compliance with ban on advertising on national television and radio (score)
E_compl_e10 Compliance with ban on promotional discounts (score)
E_compl_e11 Compliance with ban on use of brand name of non-tobacco product for tobacco product (score)
E_compl_e12 Compliance with ban on indentifying non-tobacco products with tobacco brand names (score)
E_compl_e13 Compliance with ban on appearance of tobacco brands in TV and/or films (score)
E_compl_e14 Compliance with ban on appearance of tobacco products in TV and/or films (score)
E_compl_e15 Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score)
E_compl_e3 Compliance with ban on advertising in local magazines and newspapers (score)
E_compl_e5 Compliance with ban on billboard and outdoor advertising (score)
E_compl_e6 Compliance with ban on advertising at point of sale (score)
E_compl_e9 Compliance with ban on free distribution in mail or through other means (score)
E_comprehensive_subnat Subnational bans on advertising, promotion and sponsorship - at least one jurisdiction has a comprehensive ban in place
E_Group Enforce bans on tobacco advertising
E1_compliance Compliance of ban on advertising on national TV and radio
E1_nat_tv_radio Ban on advertising on national television and radio
E10_compliance Compliance of ban on promotional discounts
E10_promo_discounts Ban on promotional discounts
E11_brand_stretching Ban on identifying non-tobacco products with tobacco brand names
E11_compliance Compliance of ban on non-tobacco goods AND services identified with tobacco brand names
E12_brand_sharing Ban on use of brand name of non-tobacco product for tobacco product
E12_compliance Compliance of ban on brand name of non-tobacco products used for tobacco product
E13_brand_placement Ban on appearance of tobacco brands in TV and/or films (product placement)
E13_compliance Compliance of ban on appearance of tobacco brands in TV and/or films (product placement)
E14_compliance Compliance of ban on appearance of tobacco products in TV and/or films
E14_prod_tv_films Appearance of tobacco products in TV and/or films
E14a_prod_tv_films Ban on appearance of tobacco products in TV and/or films
E14b_movies_anti_tob_ads Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images
E15_compliance Compliance of ban on sponsored events
E15_sponsored_events Sponsored events
E15a_sponsorship Ban on sponsorship (contributions and/or publicity of contributions)
E15b_sponsor_contribution Ban on any form of contribution (financial or other support) to any event, activity or individual
E15c_sponsor_publicity Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals
E15d_csr_ban Ban on Corporate Social Responsibility activities (CSR) (see E17a_csr_ban)
E16_csr_promo_self Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities
E17_csr_promo_others Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility� activities of the tobacco companies
E17a_csr_ban Ban on Corporate Social Responsibility activities (CSR)
E17b_csr_promo_self Ban on tobacco companies/the tobacco industry publicizing their CSR activities
E17c_csr_promo_others Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry
E18_csr_anti_tobacco_media Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth
E19_indirect_ad_fines Law requires fines for violations of indirect advertising bans,2018
E19_movies_anti_tob_ads Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images (see E14b_movies_anti_tob_ads)
E2_intl_tv_radio Ban on advertising on international television and radio
E20_subnational_exists Subnational laws or regulations exist banning some or all types of tobacco advertising, promotion and sponsorship
E21_vending_machines Complete ban on tobacco vending machines
E21a_direct_ad_fines Law requires fines for violations of advertising bans
E21b_indirect_ad_fines Law requires fines for violations of promotion and sponsorship bans
E22_subnational_authority_exists Subnational bans on tobacco advertising, promotion and sponsorship authority exists
E22_subnational_exists Subnational bans on tobacco advertising, promotion and sponsorship
E23_subnat_complete_bans_exist Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place
E23_vending_machines Ban on tobacco vending machines
E24_internet_sales_ban Ban on internet sales of tobacco products
E25_ban_display_pt_of_sale Ban on display of tobacco products at points of sale
E26_direct_ad_fines Law requires fines for violations of direct advertising bans, 2015
E27_indirect_ad_fines Law requires fines for violations of indirect advertising bans,2015
E3_compliance Compliance of ban on advertising on local magazines and newspapers
E3_nat_print Ban on advertising in local magazines and newspapers
E4_intl_print Ban on advertising in international magazines and newspapers
E5_billboards Ban on billboard and outdoor advertising
E5_compliance Compliance of ban on advertising on billboards and outdoor advertising
E6_compliance Compliance of ban on advertising at point of sale
E6_pt_of_sale Ban on advertising: Point of sale
E6a_pt_of_sale Ban on advertising at point of sale
E6b_ban_display_pt_of_sale Ban on product display at point of sale
E7_internet Ban on advertising on the internet
E8_direct_ad_fines Law requires fines for violations of direct advertising bans, 2018
E9_compliance Compliance of ban on free distribution of tobacco products in the mail or through other means
E9_free_distrib Ban on free distribution in mail or through other means
ebreast (see bfearly)
ebreast5 (see bfearly)
EC_direct_compliance Compliance with bans on direct advertising
EC_indirect_compliance Compliance with bans on promotion and sponsorship
EMFLIMITELECTRIC Electric field (kV/m)
EMFLIMITELECTRIC1800 Electric field limit at 1800 MHz (V/m)
EMFLIMITELECTRIC900 Electric field limit at 900 MHz (V/m)
EMFLIMITELECTRICLF Electric field (kV/m) low frequency
EMFLIMITELECTRICRF Electric field (V/m)
EMFLIMITMAGNETIC Magnetic flux density (microT)
EMFLIMITPOWERDENSITY Power density (W/m^2)
EMFLIMITPOWERDENSITY1800 Power density limit at 1800 MHz (W/m^2)
EMFLIMITPOWERDENSITY900 Power density limit at 900 MHz (W/m^2)
EMFPOWERFREQUENCY Power frequency (Hz)
EMFSAR Specific absorption rate (SAR) (W/kg)
EMFSTANDARD Existence of standards
EMFSTATUS Legislative status
EQ_CONDOMUSE People who identify the use of condoms as a way to avoid AIDS (%)
EQ_OVERWEIGHTADULT Prevalence of overweight and obesity
FAMILYPLANNINGUNPDUHC Women of reproductive age (15−49 years) who are married or in-union who have their need for family planning satisfied with modern methods (%), UNPD
FINPROTECTION_CATA_CTPFHU_40_HH Households with out-of-pocket payments greater than 40% of capacity to pay for health care (food, housing and utilities approach - developed by WHO/Europe) (%, national)
FINPROTECTION_CATA_ESTIMATE_AVAILABLE Availability of estimates on large health expenditures as a share of total expenditure or income
FINPROTECTION_CATA_TOT_10_LEVEL_MILLION Total population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (millions, global, regional)
FINPROTECTION_CATA_TOT_10_LEVEL_SH Total population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (%, regional, global)
FINPROTECTION_CATA_TOT_10_POP Population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (%, national, rural, urban)
FINPROTECTION_CATA_TOT_25_LEVEL_MILLION Total population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (millions, regional, global)
FINPROTECTION_CATA_TOT_25_LEVEL_SH Total population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (%, regional, global)
FINPROTECTION_CATA_TOT_25_POP Population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (%, national, rural, urban)
FINPROTECTION_IMP_BNLFHU_FURIMP_HH Households impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities - developed by WHO/Europe) (%, national)
FINPROTECTION_IMP_BNLFHU_P_HH Households further impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities - developed by WHO/Europe) (%, national)
FINPROTECTION_IMP_BNLFHU_TOT_HH Households pushed below or further below a relative poverty line (reflecting basic needs: food, housing, utilities - developed by WHO/Europe) by out-of-pocket payments (%, national)
FINPROTECTION_IMP_NP_190_LEVEL_MILLION Total population pushed below the $1.90 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_NP_190_LEVEL_SH Total population pushed below the $1.90 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_NP_215_LEVEL_MILLION Total population pushed below the $2.15 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_NP_215_LEVEL_SH Total population pushed below the $2.15 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_NP_310_LEVEL_MILLION Total population pushed below the $3.20 a day poverty line by household health expenditures (millions)
FINPROTECTION_IMP_NP_310_LEVEL_SH Total population pushed below the $3.20 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_NP_365_LEVEL_MILLION Total population pushed below the $3.65 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_NP_365_LEVEL_SH Total population pushed below the $3.65 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_NP_REL_LEVEL_MILLION Total population pushed below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (millions, regional, global)
FINPROTECTION_IMP_NP_REL_LEVEL_SH Total population pushed below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (%, regional, global)
FINPROTECTION_IMP_NP190_POP Population pushed below the $1.90 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_NP215_POP Population pushed below the $2.15 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_NP310_POP Population pushed below the $3.20 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_NP365_POP Population pushed below the $3.65 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_NPRELPL_POP Population pushed below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (%, national, rural, urban)
FINPROTECTION_IMP_P_215_LEVEL_MILLION Total population pushed further below the $2.15 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_P_215_LEVEL_SH Total population pushed further below the $2.15 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_P_365_LEVEL_MILLION Total population pushed further below the $3.65 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_P_365_LEVEL_SH Total population pushed further below the $3.65 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_P190_LEVEL_MILLION Total population pushed further below the $1.90 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_P190_LEVEL_SH Total population pushed further below the $1.90 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_P190_POP Population pushed further below the $1.90 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_P215_POP Population pushed further below the $2.15 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_P310_LEVEL_MILLION Total population pushed further below the $3.20 a day poverty line by household health expenditures (millions, regional, global)
FINPROTECTION_IMP_P310_LEVEL_SH Total population pushed further below the $3.20 a day poverty line by household health expenditures (%, regional, global)
FINPROTECTION_IMP_P310_POP Population pushed further below the $3.20 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_P365_POP Population pushed further below the $3.65 a day poverty line by household health expenditures (%, national, rural, urban)
FINPROTECTION_IMP_PG_190 Increase in poverty gap due to household health expenditures at the $1.90 a day poverty line, in cents of international dollars
FINPROTECTION_IMP_PG_190_STD Increase in poverty gap due to household health expenditures, expressed as a proportion of the $1.90 a-day poverty line (%, national, rural, urban)
FINPROTECTION_IMP_PG_215_STD Increase in poverty gap due to household health expenditures, expressed as a proportion of the $2.15 a-day poverty line (%, national, rural, urban)
FINPROTECTION_IMP_PG_310 Increase in poverty gap due to household health expenditures at the $3.20 a day poverty line, in cents of international dollars
FINPROTECTION_IMP_PG_310_STD Increase in poverty gap due to household health expenditures, expressed as a proportion of the $3.20 a-day poverty line (%, national, rural, urban)
FINPROTECTION_IMP_PG_365_STD Increase in poverty gap due to household health expenditures, expressed as a proportion of the \(3.65 a-day poverty line (%, national, rural, urban) | |FINPROTECTION_IMP_PG_RELPL_STD |Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line - 60% of median daily per capita consumption or income (%, national, rural, urban) | |FINPROTECTION_IMP_PREL_LEVEL_MILLION |Total population pushed further below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (millions, regional, global) | |FINPROTECTION_IMP_PREL_LEVEL_SH |Total population pushed further below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (%, regional, global) | |FINPROTECTION_IMP_PRELPL_POP |Population pushed further below a relative poverty line by household health expenditures - 60% of median daily per capita consumption or income (%, national, rural, urban) | |FINPROTECTION_IMPOV_ESTIMATE_AVAILABLE |Availability of estimates on impoverishment due to out-of-pocket health expenditures | |FOODBORNE_DALY_100k_GE5 |Foodborne disability-adjusted life years per 100,000, aged 5 years and above | |FOODBORNE_DALY_100k_LT5 |Foodborne disability-adjusted life years per 100,000, aged less than 5 years | |FOODBORNE_DALY_100k_TOTAL |Foodborne disability-adjusted life years per 100,000, all ages | |FOODBORNE_DALY_CASE_GE5 |Foodborne disability-adjusted life years per case, aged 5 years and above | |FOODBORNE_DALY_CASE_LT5 |Foodborne disability-adjusted life years per case, aged less than 5 years | |FOODBORNE_DALY_CASE_TOTAL |Foodborne disability-adjusted life years per case, all ages | |FOODBORNE_DALY_GE5 |Foodborne disability-adjusted life years, aged 5 years and above | |FOODBORNE_DALY_LT5 |Foodborne disability-adjusted life years, aged less than 5 years | |FOODBORNE_DALY_TOTAL |Foodborne disability-adjusted life years, all ages | |FOODBORNE_DTH_100K_GE5 |Foodborne deaths per 100,000, aged 5 years and above | |FOODBORNE_DTH_100K_LT5 |Foodborne deaths per 100,000, aged less than 5 years | |FOODBORNE_DTH_100K_TOTAL |Foodborne deaths per 100,000, all ages | |FOODBORNE_DTH_GE5 |Foodborne deaths, aged 5 years and above | |FOODBORNE_DTH_LT5 |Foodborne deaths, aged less than 5 years | |FOODBORNE_DTH_TOTAL |Foodborne deaths, all ages | |FOODBORNE_ILL_100K_GE5 |Foodborne illnesses per 100,000, aged 5 years and above | |FOODBORNE_ILL_100K_LT5 |Foodborne illnesses per 100,000, aged less than 5 years | |FOODBORNE_ILL_100K_TOTAL |Foodborne illnesses per 100,000, all ages | |FOODBORNE_ILL_GE5 |Foodborne illnesses, aged 5 years and above | |FOODBORNE_ILL_LT5 |Foodborne illnesses, aged less than 5 years | |FOODBORNE_ILL_TOTAL |Foodborne illnesses, all ages | |FOODBORNE_YLD_100K_GE5 |Foodborne years lived with disability per 100,000, aged 5 years and above | |FOODBORNE_YLD_100K_LT5 |Foodborne years lived with disability per 100,000, aged less than 5 years | |FOODBORNE_YLD_100K_TOTAL |Foodborne years lived with disability per 100,000, all ages | |FOODBORNE_YLD_CASE_GE5 |Foodborne years lived with disability per case, aged 5 years and above | |FOODBORNE_YLD_CASE_LT5 |Foodborne years lived with disability per case, aged less than 5 years | |FOODBORNE_YLD_CASE_TOTAL |Foodborne years lived with disability per case, all ages | |FOODBORNE_YLD_GE5 |Foodborne years lived with disability, aged 5 years and above | |FOODBORNE_YLD_LT5 |Foodborne years lived with disability, aged less than 5 years | |FOODBORNE_YLD_TOTAL |Foodborne years lived with disability, all ages | |FOODBORNE_YLL_100K_GE5 |Foodborne years of life lost per 100,000, aged 5 years and above | |FOODBORNE_YLL_100K_LT5 |Foodborne years of life lost per 100,000, aged less than 5 years | |FOODBORNE_YLL_100K_TOTAL |Foodborne years of life lost per 100,000, all ages | |FOODBORNE_YLL_CASE_GE5 |Foodborne years of life lost per case, aged 5 years and above | |FOODBORNE_YLL_CASE_LT5 |Foodborne years of life lost per case, aged less than 5 years | |FOODBORNE_YLL_CASE_TOTAL |Foodborne years of life lost per case, all ages | |FOODBORNE_YLL_GE5 |Foodborne years of life lost, aged 5 years and above | |FOODBORNE_YLL_LT5 |Foodborne years of life lost, aged less than 5 years | |FOODBORNE_YLL_TOTAL |Foodborne years of life lost, all ages | |fps |Demand for family planning satisfied - use of modern and traditional methods (%) | |fpsmo |Demand for family planning satisfied - modern methods (%) | |fpsmowho |Demand for family planning satisfied - use of modern methods (%) | |fullv |Full immunization coverage among one-year-olds (%) (see vfull) | |GASPRP |Reporting countries | |GASPRSAZM |Proportion of isolates with resistance to azithromycin reported to WHO-GASP | |GASPRSCFM |Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefixime reported to WHO-GASP | |GASPRSCIP |Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP | |GASPRSCRO |Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP | |GASPRSESC |Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP | |GASPTIAZM |Number of isolates tested for azithromycin | |GASPTICFM |Number of isolates tested for cefixime | |GASPTICIP |Number of isolates tested for ciprofloxacin | |GASPTICRO |Number of isolates tested for ceftriaxone | |GASPTIESC |Number of isolates tested for extended-spectrum cephalosporins | |GB_XPD_RSDV |Research and development (R&amp;D) expenditure as a proportion of GDP | |GBD_DALYRTAGE |Age-standardized DALYs (per 100,000) | |GDO_q10x1 |National regulator approval of anti-dementia medication | |GDO_q10x1x1 |Availability of generic anti-dementia medication | |GDO_q10x1x2 |Availability of at least one anti-dementia medication approved for on-label use reimbursement | |GDO_q10x2_1AVAIL |Availability of atleast one adult hygiene products for people with dementia | |GDO_q10x2_HOSUE |Availability of atleast one housing adjustment for people with dementia | |GDO_q10x2_TECH |Availability of atleast one assistive technology for people with dementia | |GDO_q11x1 |Existence of dementia national nongovernmental organization | |GDO_q11x2x1 |Dementia nongovernmental organization equipped with office | |GDO_q11x2x2_1 |Dementia nongovernmental organization office branches (Sub-national) | |GDO_q11x2x2_2 |Dementia nongovernmental organization office branches (Local) | |GDO_q11x2x2_3 |Dementia nongovernmental organization office branches (National only) | |GDO_q11x2x3 |Dementia nongovernmental organization staff primarily salaried/volunteer | |GDO_q11x2x5 |Provision of governmental funding to dementia nongovernmental organization for activities/services | |GDO_q11x2x6 |Dementia nongovernmental organization's involvement in policy development | |GDO_q12x1 |Existence of dementia carer support services | |GDO_q12x1x1 |Implementation level [national/subnational] of dementia carer support services | |GDO_q12x1x2 |Existence of dedicated resources for dementia carer support services | |GDO_q12x1x3 |Existence of implementation plan for dementia carer support services | |GDO_q12x2_2 |Existence of psycho-social supports for dementia carers | |GDO_q12x2_3 |Existence of respite care for dementia carers | |GDO_q12x2_4 |Existence of information on legal rights for dementia carers | |GDO_q12x2_5 |Existence of financial benefits/social protection for dementia carers | |GDO_q12x2x1x1_1 |Accessibility of dementia carer training and education [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q12x2x1x1_1NGO |Majority provider of dementia carer training and education (NGO) | |GDO_q12x2x1x1_1PRV |Majority provider of dementia carer training and education (Private sector) | |GDO_q12x2x1x1_1PUB |Majority provider of dementia carer training and education (Public sector) | |GDO_q12x2x1x1_2 |Accessibility of psycho-social supports for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q12x2x1x1_2NGO |Majority provider of psycho-social supports for dementia carers (NGO) | |GDO_q12x2x1x1_2PRV |Majority provider of psycho-social supports for dementia carers (Private sector) | |GDO_q12x2x1x1_2PUB |Majority provider of psycho-social supports for dementia carers (Public sector) | |GDO_q12x2x1x1_3 |Accessibility of respite care for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q12x2x1x1_3NGO |Majority provider of respite care for dementia carers (NGO) | |GDO_q12x2x1x1_3PRV |Majority provider of respite care for dementia carers (Private sector) | |GDO_q12x2x1x1_3PUB |Majority provider of respite care for dementia carers (Public sector) | |GDO_q12x2x1x1_4 |Accessibility of information on legal rights for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q12x2x1x1_4NGO |Majority provider of information on legal rights for dementia carers (NGO) | |GDO_q12x2x1x1_4PRV |Majority provider of information on legal rights for dementia carers (Private sector) | |GDO_q12x2x1x1_4PUB |Majority provider of information on legal rights for dementia carers (Public sector) | |GDO_q12x2x1x1_5 |Accessibility of financial benefits/social protection for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q12x2x1x1_5NGO |Majority provider of information on financial benefits/social protection for dementia carers (NGO) | |GDO_q12x2x1x1_5PRV |Majority provider of information on financial benefits/social protection for dementia carers (Private sector) | |GDO_q12x2x1x1_5PUB |Majority provider of information on financial benefits/social protection for dementia carers (Public sector) | |GDO_q12x2x1x3 |Estimated number of dementia carers receiving training and education | |GDO_q12x2x2x3 |Estimated number of dementia carers receiving psycho-social supports | |GDO_q12x2x3x3 |Estimated number of dementia carers receiving respite care | |GDO_q12x2x4x3 |Estimated number of dementia carers receiving information on legal rights | |GDO_q12x2x5x3 |Estimated number of dementia carers receiving financial benefits/social protection | |GDO_q13x1 |Existence of at least one functioning dementia awareness campaign | |GDO_q13x1x1 |Implementation level [national/subnational] of dementia awareness campaign | |GDO_q13x3 |Existence of at least one functioning risk reduction campaign | |GDO_q13x3x1 |Implementation level [national/subnational] of dementia risk reduction campaign | |GDO_q14x1 |Availability of dementia-friendly initiatives that improve accessibility | |GDO_q14x2_1 |Existence of dementia-friendly initiative to improve accessibility of public spaces | |GDO_q14x2_2 |Existence of dementia-friendly initiative to improve accessibility of public transportation | |GDO_q14x2_3 |Existence of dementia-friendly initiative for assistance with home modification | |GDO_q14x2_4 |Existence of dementia-friendly initiative with assistive technology for loss of capacity | |GDO_q14x2_5 |Existence of dementia-friendly initiative supporting community places for older people | |GDO_q14x2_6 |Existence of dementia-friendly initiative supporting social opportunities | |GDO_q15x1 |Inclusion of dementia training and education for non-health workers | |GDO_q15x2_1 |Existence of dementia training for volunteers | |GDO_q15x2_2 |Existence of dementia training for police and fire services | |GDO_q15x2_3 |Existence of dementia training for first responders | |GDO_q15x2_4 |Existence of dementia training for legal professionals | |GDO_q15x2_5 |Existence of dementia training for community workers | |GDO_q15x2_6 |Existence of dementia training for school children | |GDO_q15x2_7 |Existence of dementia training for financial service staff | |GDO_q15x2_8 |Existence of dementia training for retail and hospitality staff | |GDO_q16x1 |Routine monitoring of people with dementia | |GDO_q16x1x1_1 |Data sources used to routinely monitor people with dementia (Clinical records) | |GDO_q16x1x1_2 |Data sources used to routinely monitor people with dementia (Household surveys) | |GDO_q16x1x1_3 |Data sources used to routinely monitor people with dementia (Administrative data) | |GDO_q16x1x1_4 |Data sources used to routinely monitor people with dementia (Facility survey or records) | |GDO_q16x1x1_other |Data sources used to routinely monitor people with dementia (Other) | |GDO_q16x1x2_1 |Electronic availability of data sources used to routinely monitor people with dementia | |GDO_q16x1x2_2 |Data used to routinely monitor people with dementia can be disaggregated | |GDO_q16x2_1 |Availability of routine hospital admissions records for people with dementia for monitoring purposes | |GDO_q16x2_2 |Availability of routine outpatient visit records for people with dementia for monitoring purposes | |GDO_q16x2_3 |Availability of routine outpatient intervention and treatment records for people with dementia for monitoring purposes | |GDO_q16x2_4 |Availability of routine pharmaceutical records for people with dementia for monitoring purposes | |GDO_q16x2_5 |Availability of routine antipsychotic prescription records for people with dementia for monitoring purposes | |GDO_q16x3 |Availability and status of dementia reporting in the past two years | |GDO_q17x1 |Existence of a current dementia research plan/programme | |GDO_q17x1x1 |Implementation level [national/subnational] of dementia research plan/programme | |GDO_q17x2 |Dementia integrated into other national research plan/programme | |GDO_q17x2x1_1 |Identification of other research plans in which dementia is integrated (Mental health) | |GDO_q17x2x1_2 |Identification of other research plans in which dementia is integrated (Ageing) | |GDO_q17x2x1_3 |Identification of other research plans in which dementia is integrated (Neuro or neurodegenerative disease) | |GDO_q17x2x1_4 |Identification of other research plans in which dementia is integrated (NCD) | |GDO_q17x2x2 |Implementation level [national/subnational] of research plan in which dementia is integrated | |GDO_q18x2 |Availability of funding for dementia-specific research plan/programme | |GDO_q18x2x1_1 |Total expenditure on dementia research (local currency, self-report) | |GDO_q18x2x3_1 |Total expenditure on dementia basic research (local currency, self-report) | |GDO_q18x2x3_2 |Total expenditure on dementia clinical/translational research (local currency, self-report) | |GDO_q18x2x3_3 |Total expenditure on dementia implementation research (local currency, self-report) | |GDO_q19x2 |Number of people with dementia involved in research routinely monitored | |GDO_q19x3 |Availability of investigational pharmaceutical trials for dementia | |GDO_q19x3x1_1 |Number of investigational pharmaceutical trials for dementia | |GDO_q1x1 |Inclusion of dementia in ministry portfolio | |GDO_q1x1x1 |Inclusion of dementia in a branch of government [health, ageing, social services, mental health, noncommunicable disease] | |GDO_q1x2 |Existence of dementia representative in ministry | |GDO_q20 |Total number of published dementia research output | |GDO_q2x1 |Existence of dementia national plan | |GDO_q2x1x2 |Availability of funding for dementia national plan | |GDO_q2x1x3 |Targets for monitoring implementation of dementia national plan | |GDO_q2x2 |Dementia integrated into other national plan | |GDO_Q2x2x1_AGE |Identification of other plans in which dementia is integrated (Ageing) | |GDO_Q2x2x1_DISAB |Identification of other plans in which dementia is integrated (Disability) | |GDO_Q2x2x1_MENTAL |Identification of other plans in which dementia is integrated (Mental health) | |GDO_Q2x2x1_NCD |Identification of other plans in which dementia is integrated (NCD) | |GDO_q2x2x1_other |Identification of other plans in which dementia is integrated (Other) | |GDO_q2x3 |Existence of dementia sub-national plan(s) | |GDO_q2x3x1_1 |Percentage of sub-national regions covered by dementia plan | |GDO_q2x4_1 |Inclusion of human rights as a guiding principle of the dementia plan | |GDO_q2x4_2 |Inclusion of equity as a guiding principle of the dementia plan | |GDO_q2x4_3 |Inclusion of empowerment as a guiding principle of the dementia plan | |GDO_q2x4_4 |Inclusion of multisectoral collaboration as a guiding principles of the dementia plan | |GDO_q2x4_5 |Inclusion of universal health coverage as a guiding principle of the dementia plan | |GDO_q2x5_1 |Inclusion of dementia-friendly communities as a specific action of the dementia plan | |GDO_q2x5_2 |Inclusion of dementia risk reduction as a specific action of the dementia plan | |GDO_q2x5_3 |Inclusion of dementia diagnosis, care and support as a specific action of the dementia plan | |GDO_q2x5_4 |Inclusion of dementia workforce training as a specific action of the dementia plan | |GDO_q2x5_5 |Inclusion of support for dementia carers and families as a specific action of the dementia plan | |GDO_q2x5_6 |Inclusion of improved information system as a specific action of the dementia plan | |GDO_q2x5_7 |Inclusion of research and innovation as a specific action of the dementia plan | |GDO_q35 |Estimated population-based prevalence of depression | |GDO_q3x1 |Existence of dementia legislation | |GDO_q3x1x1_1 |Implementation level [national/subnational] of dementia legislation | |GDO_q3x2 |Existence of other laws that apply to the rights of people with dementia | |GDO_q3x3a_1 |Existence of legislation for supported decision making for people with dementia | |GDO_q3x3a_2 |Existence of legislation to file appeals protecting the rights of people with dementia | |GDO_q3x3a_3 |Existence of legislation to promote community-based services for people with dementia | |GDO_q3x3a_4 |Existence of legislation to promote monitoring of human rights conditions of people with dementia in facilities where they reside | |GDO_q3x3b_1 |Existence of legislation to end coercieve practices for people with dementia | |GDO_q3x4_1 |Existence of legislation for advanced care directives for people with dementia | |GDO_q3x4_2 |Existence of legislation to end discrimination against people with dementia | |GDO_q3x4_3 |Existence of legislation to end discrimination against carers of people with dementia | |GDO_q4x1 |Existence of dementia standards/ guidelines/ protocols | |GDO_q4x1x1_SQ001 |Implementation level of dementia standards/ guidelines/ protocols (National) | |GDO_q4x1x1_SQ002 |Implementation level of dementia standards/ guidelines/ protocols (Sub-national) | |GDO_q4x1x2 |Existence of approved government dementia standards/ guidelines/ protocols | |GDO_q4x2_1 |Existence of standards/ guidelines/ protocols for prevention and risk reduction of dementia | |GDO_q4x2_2 |Existence of standards/ guidelines/ protocols for diagnosis of dementia | |GDO_q4x2_3 |Existence of standards/ guidelines/ protocols for management of dementia | |GDO_q4x2_4 |Existence of standards/ guidelines/ protocols for other post-diagnostic supports of people with dementia | |GDO_q4x2_5 |Existence of standards/ guidelines/ protocols for treatment and support of carers and families of people with dementia | |GDO_q4x3x4_1 |Existence of standards/ guidelines/ protocols for advance care directives, power of attorney or guardianship for people with dementia | |GDO_q4x3x4_2 |Existence of standards/ guidelines/ protocols for palliative and end-of-life care for people with dementia | |GDO_q4x3x4_3 |Existence of standards/ guidelines/ protocols of care in nursing & residential care facilities for people with dementia | |GDO_q4x3x4_4 |Existence of standards/ guidelines/ protocols of care in hospital for people with dementia | |GDO_q5x1 |Availability of mechanisms to coordinate dementia care across sectors | |GDO_q5x1x1_1 |Identification of different sectors in dementia care coordination (Health) | |GDO_q5x1x1_2 |Identification of different sectors in dementia care coordination (Social) | |GDO_q5x1x1_3 |Identification of different sectors in dementia care coordination (Education) | |GDO_q5x1x1_4 |Identification of different sectors in dementia care coordination (Employment) | |GDO_q5x1x1_5 |Identification of different sectors in dementia care coordination (Justice) | |GDO_q5x1x1_6 |Identification of different sectors in dementia care coordination (Housing) | |GDO_q5x1x1_7 |Identification of different sectors in dementia care coordination (Civil society) | |GDO_q5x1x1_8 |Identification of different sectors in dementia care coordination (Private sector) | |GDO_q5x1x1_other |Identification of different sectors in dementia care coordination (Other) | |GDO_q5x1x2 |Implementation level [national/subnational] of dementia care coordination | |GDO_q5x1x3 |Presence of formal agreement/joint plan for dementia care coordination | |GDO_q5x2 |Availability of dementia care coordination standards/ guidelines/ protocols | |GDO_q6x1_2 |Number of neurologists (per 100,000) | |GDO_q6x1_3 |Number of geriatricians or psychogeriatricians (per 100,000) | |GDO_q6x2_1 |Inclusion of basic dementia competencies in training of physicians | |GDO_q6x2_2 |Inclusion of basic dementia competencies in training of specialists | |GDO_q6x2_3 |Inclusion of basic dementia competencies in training of nurses | |GDO_q6x2_4 |Inclusion of basic dementia competencies in training of pharmaceutical personnel | |GDO_q6x2_5 |Inclusion of basic dementia competencies in training of social workers | |GDO_q6x2_6 |Inclusion of basic dementia competencies in training of personal support workers | |GDO_q7x1_AVAIL |Availability of dementia diagnostic rate | |GDO_q8x1 |Existence of community-based health or social care services for dementia | |GDO_q8x2_1 |Availability of diagnostic services in community for dementia | |GDO_q8x2_2 |Availability of behaviour and psychological management in community for dementia | |GDO_q8x2_3 |Availability of psychosocial and rehabilitation services in community for dementia | |GDO_q8x2_4 |Availability of activities of daily living suppport services in community for dementia | |GDO_q8x2_5 |Availability of palliative and end-of-life care services in community for dementia | |GDO_q8x2_6 |Availability of social and financial protection for dementia | |GDO_q8x3_1 |Accessibility of diagnostic services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x3_2 |Accessibility of behaviour and psychological management in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x3_3 |Accessibility of psychosocial and rehabilitation services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x3_4 |Accessibility of activities of daily living support services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x3_5 |Accessibility of palliative and end-of-life care services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x3_6 |Accessibility of social and financial protection for dementia [Capital/capital and main cities/capital, main cities, rural areas] | |GDO_q8x4_1 |Majority provider of diagnostic services in community for dementia [public, private] | |GDO_q8x4_2 |Majority provider of behaviour and psychological management in community for dementia [public, private] | |GDO_q8x4_3 |Majority provider of psychosocial and rehabilitation services in community for dementia [public, private] | |GDO_q8x4_4 |Majority provider of activities of daily living support services in community for dementia [public, private] | |GDO_q8x4_5 |Majority provider of palliative and end-of-life care services in community for dementia [public, private] | |GDO_q8x4_6 |Majority provider of social and financial protection for dementia [public, private] | |GDO_q8x5_2 |Estimated number of people receiving behaviour and psychological management services in community for dementia | |GDO_q8x5_3 |Estimated number of people receiving psychosocial and rehabilitation services in community for dementia | |GDO_q8x5_4 |Estimated number of people receiving activities of daily living support services in community for dementia | |GDO_q8x5_5 |Estimated number of people receiving palliative and end-of-life care services in community for dementia | |GDO_q8x5_6 |Estimated number of people with dementia receiving social and financial protection for dementia | |GDO_q9_1 |Dementia care facilities [hospitals] | |GDO_q9_2 |Care facilities [long-term care] | |GDO_q9_3 |Care facilities [hospice centres] | |GDO_q9_4 |Adult day centres | |GDO_q9_5 |Outpatient health centres | |GDO_q9_6 |Outpatient social centres | |GDO_q9x1_3 |Dementia-specific hospital beds (per 10,000 population) | |GDO_q9x1_4 |Geriatric-specific hospital beds (per 10,000 population) | |GDO_q9x1_5 |Total dementia hospital admissions (per 100,000) | |GDO_q9x1_7 |Estimated percentage of hospitals following national dementia standards | |GDO_q9x2_1 |Density of residential long-term care facilities (per 100,000 population) | |GDO_q9x2_2 |Residential long-term care beds (per 10 000 population) | |GDO_q9x2_3 |Dementia-specific residential long-term care beds (per 10,000 population) | |GDO_q9x2_4 |Estimated number of people with dementia living in residential long-term care | |GDO_q9x2_5 |Estimated percentage of residential long-term care facilities following national dementia standards | |GDO_q9x3_1 |Density of hospice centres (per 100,000 population) | |GDO_q9x3_2 |Hospice centre beds (per 10 000 population) | |GDO_q9x3_3 |Dementia-specific hospice care beds (per 10,000 population) | |GDO_q9x4_1 |Density of adult day centres (per 100,000 population) | |GDO_q9x4_2 |Adult day centre places (per 10,000 population) | |GDO_q9x4_3 |Dementia-specific adult day centre places (per 10,000 population) | |GDO_q9x5_1 |Density of outpatient health centres (per 100,000 population) | |GDO_q9x5_2 |Estimated number of people with dementia receiving services at outpatient health centre | |GDO_q9x6_1 |Density of outpatient social centres (per 100,000 population) | |GDO_q9x6_2 |Estimated number of people with dementia receiving services at outpatient social centre | |GHE_DALY_NUMERIC |Disability-adjusted life years (DALYs) | |GHE_DALYNUM |Disability-adjusted life years (DALYs) | |GHE_DALYRATE |Disability-adjusted life years (DALYs) (per 100 000 population) | |GHE_DEATHS_NUMERIC |GHE Deaths | |GHE_YLD_NUMERIC |Years of healthy life lost due to disability (YLDs) | |GHE_YLDNUM |Years of healthy life lost due to disability (YLDs) | |GHE_YLDRATE |Years of healthy life lost due to disability (YLDs) (per 100 000 population) | |GHE_YLL_NUMERIC |Years of life lost from mortality (YLLs) | |GHE_YLLNUM |Years of life lost from mortality (YLLs) | |GHE_YLLRATE |Years of life lost from mortality (YLLs) (per 100 000 population) | |GHED_CHE_pc_PPP_SHA2011 |Current health expenditure (CHE) per capita in PPP int\)
GHED_CHE_pc_US_SHA2011 Current health expenditure (CHE) per capita in US$
GHED_CHEGDP_SHA2011 Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%)
GHED_EXT_pc_PPP_SHA2011 External health expenditure (EXT) per capita in PPP int$
GHED_EXT_pc_US_SHA2011 External health expenditure (EXT) per capita in US$
GHED_EXTCHE_SHA2011 External health expenditure (EXT) as percentage of current health expenditure (CHE) (%)
GHED_GGHE-D_pc_PPP_SHA2011 Domestic general government health expenditure (GGHE-D) per capita in PPP int$
GHED_GGHE-D_pc_US_SHA2011 Domestic general government health expenditure (GGHE-D) per capita in US$
GHED_GGHE-DCHE_SHA2011 Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%)
GHED_GGHE-DGDP_SHA2011 Domestic general government health expenditure (GGHE-D) as percentage of gross domestic product (GDP) (%)
GHED_GGHE-DGGE_SHA2011 Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%)
GHED_OOP_pc_PPP_SHA2011 Out-of-pocket expenditure (OOP) per capita in PPP int$
GHED_OOP_pc_US_SHA2011 Out-of-pocket expenditure (OOP) per capita in US$
GHED_OOPSCHE_SHA2011 Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%)
GHED_PVT-D_pc_PPP_SHA2011 Domestic private health expenditure (PVT-D) per capita in PPP int$
GHED_PVT-D_pc_US_SHA2011 Domestic private health expenditure (PVT-D) per capita in US$
GHED_PVT-DCHE_SHA2011 Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%)
GLASSAMC_AWARE Pattern of antibiotic consumption at national level (relative consumption by AWaRe classification)
GLASSAMC_GPW13_T4B Target ≥60% of total antibiotic consumption being Access group antibiotics (GPW13 target 4b)
GLASSAMC_TC Total consumption of antibacterials expressed as DDD per 1000 inhabitants per day
GOE_Q001 National universal health coverage strategy
GOE_Q002 strategy refers to the use of ICT to support UHC
GOE_Q003 National eHealth strategy
GOE_Q004 National eHealth strategy refers to objectives of UHC
GOE_Q006 National health information system (HIS) policy or strategy
GOE_Q007 Public funding for eHealth
GOE_Q008 Private funding for eHealth
GOE_Q009 Donor/ non-public development funding for eHealth
GOE_Q010 Public-private partnerships for eHealth
GOE_Q011 Strategy implementation funding available for eHealth
GOE_Q012 Proportion of public funding
GOE_Q013 Proportion of private funding
GOE_Q014 Proportion of donor/non public development funding
GOE_Q015 Proportion ofpublic private partnerships funding
GOE_Q017 Government-supported health internet sites provide information in multiple languages
GOE_Q018 Tertiary institutions provide students of health sciences with training on eHealth
GOE_Q022 Institutions offer in-service training to health professionals on ICT for health
GOE_Q028 mHealth programmes are sponsored by government
GOE_Q030_1 Regulating mobile devices and software
GOE_Q030_2 Promoting standards and interoperability
GOE_Q030_3 Providing guidance on privacy and security
GOE_Q030_4 Providing oversight and enforcement of data ownership
GOE_Q030_5 Promoting the development and adoption of mHealth
GOE_Q031 Regulatory oversight of mobile apps for quality, safety and reliability
GOE_Q032 Providing incentives and guidance for innovation research and evaluation of health
GOE_Q047 Government-sponsored mHealth programmes are being evaluated
GOE_Q057 Capacity
GOE_Q058 Infrastructure
GOE_Q059 Funding
GOE_Q060 Effectiveness
GOE_Q061 Cost-effectiveness
GOE_Q062 Demand
GOE_Q063 Legal
GOE_Q064 Policy
GOE_Q065 Priorities
GOE_Q069 Country has telehealth policy or strategy
GOE_Q070 Strategy includes objectives as to how telehealth contributes to UHC
GOE_Q081 Evaluation of any government-sponsored telehealth programmes
GOE_Q103 eLearning is used in pre-service education to teach health sciences students
GOE_Q104_1 Reducing cost of delivering content (pre-service)
GOE_Q104_2 Improving access to content and experts (pre-service)
GOE_Q104_3 Enabling access to education where learning facilities are limited (pre-service)
GOE_Q109 Pre-service eLearning programmes have been evaluated
GOE_Q118 eLearning used for in-service training of health professionals
GOE_Q119_1 Reducing cost of delivering content (in-service)
GOE_Q119_2 Improving access to content and experts (in-service)
GOE_Q119_3 Enabling access to education where learning facilities are limited (in-service)
GOE_Q120 eLearning courses accredited by continuing medical education or professional licensing bodies
GOE_Q122 eLearning programmes for in-service training of health professionals have been evaluated
GOE_Q131 Lack of capacity
GOE_Q132 Lack of infrastructure
GOE_Q133 Lack of funding
GOE_Q134 Not possible to gain a health sciences degree entirely through eLearning
GOE_Q135 Lack of evidence that eLearning is effective
GOE_Q136 Lack of evidence over cost-effectiveness
GOE_Q137 Lack of demand for eLearning programmes
GOE_Q138 Lack of suitable courses available
GOE_Q139 Insitutional educational policy does not include eLearning as an approach to teaching health sciences
GOE_Q140 Competing educational priorities
GOE_Q144 Country has national EHR
GOE_Q146 Country has specific legislation governing the use of national EHR system
GOE_Q153 Lack of capacity (for EHR)
GOE_Q154 Lack of infrastructure (for EHR)
GOE_Q155 Lack of funding (for EHR)
GOE_Q156 lack of evidence showing effectiveness of EHR
GOE_Q157 Lack of evidence showing cost-effectiveness or EHR
GOE_Q158 Lack of demand by health professionals and patients
GOE_Q159 Lack of legislation or regulations covering use of EHR
GOE_Q160 National strategy does not promote the adoption of EHR
GOE_Q161 Lack of national or international standards for interoperability of EHR
GOE_Q162 Competing health system priorities
GOE_Q168 to define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth
GOE_Q169 to address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria
GOE_Q170 to protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format
GOE_Q171 to protect the privacy of individuals’ health-related data held in electronic format as an EHR
GOE_Q172 which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR
GOE_Q173 which governs the sharing of digital data between health professionals in health services in other countries through the use of an EHR
GOE_Q174 which allows for the sharing of personal and health data between research entities
GOE_Q175 which allows individuals electronic access to their own health-related data when held in an EHR
GOE_Q176 which allows individuals to demand that their own data be corrected when held in an EHR if it is known to be inaccurate
GOE_Q177 which allows individuals to demand the deletion of health-related data from their EHR
GOE_Q178 Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice
GOE_Q181 Country has national policy or strategy on the use of social media by government organizations
GOE_Q182 Policy or strategy makes specific reference tothe use of social media in the health domain
GOE_Q196 Country has national policy or strategy regulating the use of big data in the health sector
GOE_Q197 Country has national policy or strategy regulating the use of big data by private companies
GOE_Q198 Effective standards and best practices for data capture not fully established
GOE_Q199 Insufficient incentives for data sharing
GOE_Q200 Capacity building required for new skills
GOE_Q201 Privacy and security laws need to be in place
GOE_Q202 Research into new analytical methods needs occur to meet the challenges of working with big data
GOE_Q203 Lack of integration between various health services
HAZARD_DALY_GE5 Disability-adjusted life years caused by hazards, aged 5 years and above
HAZARD_DALY_LT5 Disability-adjusted life years caused by hazards, aged less than 5 years
HAZARD_DALY_TOTAL Disability-adjusted life years caused by hazards, all ages
HAZARD_DTH_GE5 Deaths caused by hazards, aged 5 years and above
HAZARD_DTH_LT5 Deaths caused by hazards, aged less than 5 years
HAZARD_DTH_TOTAL Deaths caused by hazards, all ages
HAZARD_ILL_GE5 Illnesses caused by hazards, aged 5 years and above
HAZARD_ILL_LT5 Illnesses caused by hazards, aged less than 5 years
HAZARD_ILL_TOTAL Illnesses caused by hazards, all ages
HAZARD_YLD_GE5 Years lived with disability caused by hazards, aged 5 years and above
HAZARD_YLD_LT5 Years lived with disability caused by hazards, aged less than 5 years
HAZARD_YLD_TOTAL Years lived with disability caused by hazards, all ages
HAZARD_YLL_GE5 Years of life lost caused by hazards, aged 5 years and above
HAZARD_YLL_LT5 Years of life lost caused by hazards, aged less than 5 years
HAZARD_YLL_TOTAL Years of life lost caused by hazards, all ages
HCF_NO_ELECTRICITY Percentage of health-care facilities with no access to any electricity supply (%)
HCF_REL_ELECTRICITY Percentage of health-care facilities with reliable electricity supply (%)
HCF_UNREL_ELECTRICITY Percentage of health-care facilities with unreliable electricity supply (%)
HEMOGLOBINLEVEL_CHILDREN_MEAN Mean hemoglobin level of children aged 6-59 months
HEMOGLOBINLEVEL_NONPREGNANT_MEAN Mean hemoglobin level of non-pregnant women (aged 15-49 years)
HEMOGLOBINLEVEL_PREGNANT_MEAN Mean hemoglobin level of pregnant women (aged 15-49 years)
HEMOGLOBINLEVEL_REPRODUCTIVEAGE_MEAN Mean hemoglobin level of women of reproductive age (aged 15-49 years)
HEPB_HBSAG_CARRIER Hepatitis B surface antigen (HBsAG) carriers (per 100 000 population)
HIV_0000000001 Number of people (all ages) living with HIV
HIV_0000000006 Number of people dying of HIV-related causes
HIV_0000000007 Testing and counselling facilities, reported number
HIV_0000000008 Testing and counselling facilities, estimated number per 100 000 adult population
HIV_0000000009 Reported number of people receiving antiretroviral therapy
HIV_0000000011 Reported number of children receiving antiretroviral therapy
HIV_0000000012 Reported number of children receiving antiretroviral therapy, month and year of report
HIV_0000000015 Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission
HIV_0000000016 Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, reporting period
HIV_0000000020 Estimated number of pregnant women living with HIV
HIV_0000000021 Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission
HIV_0000000022 Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines
HIV_0000000023 Estimated number of children needing antiretroviral therapy based on WHO methods
HIV_0000000024 Estimated antiretroviral therapy coverage among children
HIV_0000000025 Testing and counselling facilities, reporting period
HIV_0000000026 Number of new HIV infections
HIV_0000000027 Reported number of tests performed where results were received by a person (testing volume)
HIV_0000000028 Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population
HIV_0000000029 Reported number of tests performed where results were received by a person (testing volume), reporting period
HIV_ARTCOVERAGE Estimated antiretroviral therapy coverage among people living with HIV (%)
HRH_01 Number of nursing personnel
HRH_02 Number of physicians
HRH_03 Number of midwifery personnel
HRH_04 Number of pharmacists
HRH_05 Number of pharmaceutical technicians/assistants
HRH_06 Number of community health workers, 2018
HRH_07 Number of traditional birth attendants
HRH_08 Number of radiographers
HRH_09 Number of other health workers, 2013
HRH_10 Number of dental technicians/assistants
HRH_11 Number of health management & support workers
HRH_12 Number of environment and public health workers (see HWF_0017) (void HRH)
HRH_13 Number of laboratory scientists
HRH_14 Number of laboratory technicians/assistants
HRH_15 Number of dentists
HRH_16 Number of traditional medicine practitioners
HRH_17 Number of medical assistants
HRH_18 Number of personal care workers
HRH_19 Number of pharmaceutical personnel (see HWF_0015) (void HRH)
HRH_20 Number of laboratory health workers
HRH_21 Number of dentistry personnel (see HWF_0011) (void HRH_21)
HRH_22 Number of community and traditional health workers
HRH_23 Number of other health workers, 2018
HRH_24 Number of nursing and midwifery personnel (see HWF_0007) (void HRH)
HRH_25 Pharmaceutical personnel density (per 1000 population)
HRH_26 Physicians density (per 1000 population)
HRH_27 Laboratory health workers density (per 1000 population)
HRH_28 Dentistry personnel density (per 1000 population)
HRH_29 Community and traditional health workers density (per 1000 population)
HRH_30 Other health workers density (per 1000 population)
HRH_31 Environmental and public health workers density (per 1000 population)
HRH_32 Health management & support workers density (per 1000 population)
HRH_33 Nursing and midwifery personnel density (per 1000 population)
HRH_40 Biomedical engineers density (per 10 000 population)
HRH_41 Number of licensed qualified surgeons actively working
HRH_42 Number of licensed qualified obstetricians actively working
HRH_43 Number of licensed qualified anaesthesiologists actively working
HRH_44 Number of biomedical engineers
HRH_45 Biomedical technicians density (per 10 000 population)
HRH_46 Number of biomedical technicians
HSS_COMPREHENSIVEHEALTHPOLICY Countries that have a comprehensive national health sector policy/ strategy/ plan with goals and targets updated within the last 5 years
HSS_MONITORPROGRESS Countries that have monitored the progress of their national health policy/strategy/plan regularly
HSS_UHCLEGISLATION Countries that have passed legislation on Universal Health Coverage (UHC)
HWF_0001 Medical doctors (per 10 000 population)
HWF_0002 Medical doctors (number)
HWF_0003 Generalist medical practitioners (number)
HWF_0004 Specialist medical practitioners (number)
HWF_0005 Medical doctors not further defined (number)
HWF_0006 Nursing and midwifery personnel (per 10 000 population)
HWF_0007 Nursing and midwifery personnel (number)
HWF_0008 Nursing personnel (number)
HWF_0009 Midwifery personnel (number)
HWF_0010 Dentists (per 10 000 population)
HWF_0011 Dentists (number)
HWF_0012 Dental Assistants and Therapists (number)
HWF_0013 Dental Prosthetic Technicians (number)
HWF_0014 Pharmacists (per 10 000 population)
HWF_0015 Pharmacists (number)
HWF_0016 Pharmaceutical Technicians and Assistants (number)
HWF_0017 Environmental and Occupational Health and Hygiene Professionals (number)
HWF_0018 Environmental and Occupational Health Inspectors and Associates (number)
HWF_0019 Medical and Pathology Laboratory scientists (number)
HWF_0020 Medical and Pathology Laboratory Technicians (number)
HWF_0021 Physiotherapists (number)
HWF_0022 Physiotherapy Technicians and Assistants (number)
HWF_0023 Traditional and Complementary Medicine Professionals (number)
HWF_0024 Community Health Workers (number)
HWF_0025 Medical doctors (%)
HWF_0026 Nursing personnel (%)
HWWS_1 Handwashing with soap after using the toilet (%)
HWWS_2 Handwashing with soap after cleaning child’s stool (%)
ICD11_IMPL_LVL ICD-11 implementation progress level
IHR01 Legislation
IHR02 Coordination
IHR03 Surveillance
IHR04 Response
IHR05 Preparedness
IHR06 Risk communication
IHR07 Human resources
IHR08 Laboratory
IHR09 Points of entry
IHR10 Zoonosis
IHR11 Food safety
IHR12 Chemical
IHR13 Radionuclear
IHRSPAR_CAPACITY01 Legislation and Financing
IHRSPAR_CAPACITY02 IHR Coordination and National IHR Focal Point Functions
IHRSPAR_CAPACITY03 Zoonotic Events and the Human-animal Interface
IHRSPAR_CAPACITY04 Food Safety (SPAR)
IHRSPAR_CAPACITY05 Laboratory (SPAR)
IHRSPAR_CAPACITY06 Surveillance (SPAR)
IHRSPAR_CAPACITY07 Human Resources (SPAR)
IHRSPAR_CAPACITY08 National Health Emergency Framework
IHRSPAR_CAPACITY09 Health Service Provision
IHRSPAR_CAPACITY10 Risk Communication (SPAR)
IHRSPAR_CAPACITY11 Points of Entry (SPAR)
IHRSPAR_CAPACITY12 Chemical Events
IHRSPAR_CAPACITY13 Radiation Emergencies
IMMUNIZATION_VACCINATIONCARDSSEEN Proportion of vaccination cards seen (%)
imr Infant mortality rate (deaths per 1000 live births)
IR_CARBAMATE_EXTENT Percentage of sites for which carbamate resistance was reported
IR_CARBAMATE_PRESENCE Carbamate resistance reported for at least one site
IR_INSECTICIDERESISTANCE_PREV Number of insecticide classes to which resistance was reported
IR_ORGANOCHLORINE_EXTENT Percentage of sites for which organochlorine resistance was reported
IR_ORGANOCHLORINE_PRESENCE Organochlorine resistance reported for at least one site
IR_ORGANOPHOSPHATE_EXTENT Percentage of sites for which organophosphate resistance was reported
IR_ORGANOPHOSPHATE_PRESENCE Organophosphate resistance reported for at least one site
IR_PYRETHROID_EXTENT Percentage of sites for which pyrethroid resistance was reported
IR_PYRETHROID_PRESENCE Pyrethroid resistance reported for at least one site
itnch Children aged < 5 years sleeping under insecticide-treated nets (%)
itnwm Pregnant women sleeping under insecticide-treated nets (%)
ITU_ICT_1 Percentage of individuals using the Internet
ITU_ICT_2 Mobile-cellular telephone subscriptions per 100 inhabitants
ITU_IDI ICT Development Index (IDI)
ITU_IDI_RANK ICT Development Index (IDI) rank
LBW_NUMBER Low birth weight number (in thousands)
LBW_PREVALENCE Low birth weight prevalence (%)
LEAD_1 Percentage of the children under 15 years with blood lead levels above 5ug/dl
LEAD_10 Lead attributable DALYs per 100’000 children under 5 years
LEAD_2 Percentage of the children under 15 years with blood lead levels above 10ug/dl
LEAD_3 Percentage of the adults (15+ years) with blood lead levels above 5ug/dl
LEAD_4 Percentage of the adults (15+ years) with blood lead levels above 10ug/dl
LEAD_5 Lead attributable deaths
LEAD_6 Lead attributable DALYs (’000)
LEAD_7 Lead attributable deaths per 100’000 capita
LEAD_8 Lead attributable DALYs per 100’000 capita
LEAD_9 Lead attributable DALYs (’000) in children under 5 years
LEADCONTROL Legally-binding controls on lead paint
LEPTO_DALY Disability-adjusted life years (DALYs) due to leptospirosis
LEPTO_DALY100K Disability-adjusted life years (DALYs) (per 100 000 population) due to leptospirosis
LEPTO_MORBIDITY Estimated leptospirosis incidence (per 100 000 population)
LEPTO_MORTALITY Estimated leptospirosis deaths (per 100 000 population)
LEPTO_YLD Years of healthy life lost to disability (YLDs) due to leptospirosis
LEPTO_YLD100K Years of healthy life lost to disability (YLDs) (per 100 000 population) due to leptospirosis
LEPTO_YLL Years of life lost (YLLs) due to leptospirosis
LEPTO_YLL100K Years of life lost (YLLs) (per 100 000 population) due to leptospirosis
LIFE_0000000029 nMx - age-specific death rate between ages x and x+n
LIFE_0000000030 nqx - probability of dying between ages x and x+n
LIFE_0000000031 lx - number of people left alive at age x
LIFE_0000000032 ndx - number of people dying between ages x and x+n
LIFE_0000000033 nLx - person-years lived between ages x and x+n
LIFE_0000000034 Tx - person-years lived above age x
LIFE_0000000035 ex - expectation of life at age x
M_def_1_prev_adult Adult indicator 1 rate
M_def_1_prev_youth Youth indicator 1 rate
M_def_1_text_adult Adult indicator 1 definition
M_def_1_text_youth Youth indicator 1 definition
M_def_2_prev_adult Adult indicator 2 rate
M_def_2_prev_youth Youth indicator 2 rate
M_def_2_text_adult Adult indicator 2 definition
M_def_2_text_youth Youth indicator 2 definition
M_Est_cig_curr Estimate of current cigarette smoking prevalence (%)
M_Est_cig_curr_crude Current cigarette smoking, crude adjusted
M_Est_cig_curr_std Estimate of current cigarette smoking prevalence (%) (age-standardized rate)
M_Est_cig_daily Estimate of daily cigarette smoking prevalence (%)
M_Est_cig_daily_crude Daily cigarette smoking, crude adjusted
M_Est_cig_daily_std Estimate of daily cigarette smoking prevalence (%) (age-standardized rate)
M_Est_smk_curr Estimate of current tobacco smoking prevalence (%)
M_Est_smk_curr_std Estimate of current tobacco smoking prevalence (%) (age-standardized rate)
M_Est_smk_daily Estimate of daily tobacco smoking prevalence (%)
M_Est_smk_daily_std Estimate of daily tobacco smoking prevalence (%) (age-standardized rate)
M_Est_tob_curr Estimate of current tobacco use prevalence (%)
M_Est_tob_curr_crude Current tobacco smoking, crude adjusted
M_Est_tob_curr_std Estimate of current tobacco use prevalence (%) (age-standardized rate)
M_Est_tob_daily Estimate of daily tobacco use prevalence (%)
M_Est_tob_daily_crude Daily tobacco smoking, crude adjusted
M_Est_tob_daily_std Estimate of daily tobacco use prevalence (%) (age-standardized rate)
M_Group Monitor
M_smkless_age_range_adult Adult survey age range - smokeless
M_smkless_age_range_youth Youth survey age range - smokeless
M_smkless_def_text_adult Adult smokeless tobacco use indicator definition
M_smkless_def_text_youth Youth smokeless tobacco use indicator definition
M_smkless_prev_adult Adult smokeless tobacco use indicator rate
M_smkless_prev_youth Youth smokeless tobacco use indicator rate
M_smkless_survey_title_adult Name of survey of adults - smokeless
M_smkless_survey_title_youth Name of survey of youth - smokeless
M_smkless_svy_national_adult Representativeness of survey of adults - smokeless
M_smkless_svy_national_youth Representativeness of survey of youth - smokeless
M_smkless_svy_yr_adult Year of survey of adults - smokeless
M_smkless_svy_yr_youth Year of survey of youth - smokeless
M_survey_title_adult Name of survey of adults
M_survey_title_youth Name of survey of youth
M_svy_age_adult Adult survey age range
M_svy_age_youth Youth survey age range
M_svy_national_adult Representativeness of survey of adults
M_svy_national_youth Representativeness of youth survey
M_svy_yr_adult Year of latest adult prevalence survey
M_svy_yr_youth Year of youth survey
M1_adult_recent Most recent survey among adults was recent (in the past 5 years)
M2_adult_representative Most recent survey among adults was representative of the national population
M3_adult_periodic Survey previous to the most recent survey among adults was within the 5 years prior
M4_youth_recent Most recent school-based survey among adolescents was recent (in the past 5 years)
M5_youth_representative Most recent school-based survey among adolescents was representative of the national population
M6_youth_periodic Survey previous to the most recent school-based survey among adolescents was within the 5 years prior
MALARIA_1STLINE_TREATED Number of malaria cases treated with any first  line tx courses (including artemisinin-based combination therapies (ACTs))
MALARIA_ACT_TREATED Number of malaria cases treated with artemisinin-based combination therapies (ACTs)
MALARIA_CONF_CASES Number of confirmed malaria cases
MALARIA_EST_CASES Estimated number of malaria cases
MALARIA_EST_DEATHS Estimated number of malaria deaths
MALARIA_EST_INCIDENCE Estimated malaria incidence (per 1000 population at risk)
MALARIA_EST_MORTALITY Estimated malaria mortality rate (per 100 000 population)
MALARIA_IMPORTED Number of imported malaria cases
MALARIA_INDIG Number of indigenous malaria cases
MALARIA_INDIG_STATUS Status of indigenous malaria cases
MALARIA_IPTP3_COVERAGE Pregnant women attending antenatal care  at least once and receiving at least 3 doses of Intermittent Preventive Treatment of Malaria for Pregnant Women (IPTp3) (%)
MALARIA_IRS_COVERAGE Number of people protected from malaria by indoor residual spraying (IRS)
MALARIA_ITN_COVERAGE Population with access to an insecticide-treated bed net (ITN) for malaria protection (%), modelled
MALARIA_MICR_POS Number of malaria positive cases by microscopy
MALARIA_MICR_TEST Number of malaria suspects examined by microscopy
MALARIA_PF_INDIG Number of indigenous P. falciparum malaria cases
MALARIA_PRES_CASES Number of presumed malaria cases
MALARIA_PV_INDIG Number of indigenous P. vivax malaria cases
MALARIA_RDT_POS Number of malaria positive cases by rapid diagnostic test (RDT)
MALARIA_RDT_TEST Number of malaria suspects examined by rapid diagnostic test (RDT)
MALARIA_SUSPECTS Number of suspected malaria cases
MALARIA_TOTAL_CASES Total number of  malaria cases (presumed + confirmed cases)
MALARIA001 Malaria - number of reported deaths
MALARIA002 Estimated number of malaria cases (see MALARIA_EST_CASES)
MALARIA003 Estimated number of malaria deaths (see MALARIA_EST_DEATHS)
MALARIA004 Number of under-five deaths from malaria
MALARIA005 Malaria incidence per 100 000 population
MCV2 Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%)
MDG_0000000001 Infant mortality rate (between birth and 11 months per 1000 live births)
MDG_0000000003 Adolescent birth rate (per 1000 women)
MDG_0000000005 Contraceptive prevalence (%)
MDG_0000000005_AGE1519 Contraceptive prevalence, among girls aged 15-19 (%)
MDG_0000000006_AGE1519 Unmet need for family planning, among girls aged 15-19 (%)
MDG_0000000007 Under-five mortality rate (per 1000 live births) (SDG 3.2.1)
MDG_0000000010 Median availability of selected generic medicines (%) - Public
MDG_0000000011 Median consumer price ratio of selected generic medicines - Public
MDG_0000000013 Children aged <5 years sleeping under insecticide-treated nets (%)
MDG_0000000014 Children aged <5 years with fever who received treatment with any antimalarial (%)
MDG_0000000015 Prevalence of condom use by adults during higher-risk sex (15-49) (%)
MDG_0000000016 Deaths due to malaria (per 100 000 population) (see MALARIA_EST_MORTALITY) ( void MDG_0000000016)
MDG_0000000017 Deaths due to tuberculosis among HIV-negative people (per 100 000 population)
MDG_0000000018 Deaths due to tuberculosis among HIV-positive people (per 100 000 population)
MDG_0000000019 Prevalence of HIV among adults aged >=15 years (per 100 000 population)
MDG_0000000020 Incidence of tuberculosis (per 100 000 population per year)
MDG_0000000021 Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%)
MDG_0000000022 Tuberculosis detection rate under DOTS (%)
MDG_0000000023 Prevalence of tuberculosis (per 100 000 population)
MDG_0000000024 Tuberculosis treatment success under DOTS (%)
MDG_0000000025 Births attended by skilled health personnel (%)
MDG_0000000025_AGE1519 Births attended by skilled health personnel, among girls aged 15-19 (%)
MDG_0000000026 Maternal mortality ratio (per 100 000 live births)
MDG_0000000027 xxxxx for deletion: (child stunting, see NUTSTUNTINGPREV)
MDG_0000000029 Prevalence of HIV among adults aged 15 to 49 (%)
MDG_0000000030 Smear-positive tuberculosis case-detection rate (%)
MDG_0000000031 Smear-positive tuberculosis treatment-success rate (%)
MDG_0000000032 Maternal mortality ratio (per 100 000 live births) - Country reported estimates
MDG_0000000033 Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%)
MDG_0000000034 Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines
MENING_1 Number of suspected meningitis deaths reported
MENING_2 Number of suspected meningitis cases reported
MENING_3 Number of meningitis epidemic districts
MH_1 Mental health policy
MH_10 Mental health outpatient facilities (per 100 000 population)
MH_11 Mental health day treatment facilities (per 100 000 population)
MH_12 Age-standardized suicide rates (per 100 000 population)
MH_13 Beds for mental health in general hospitals (per 100 000 population)
MH_14 Community residential facilities (per 100 000 population)
MH_15 Beds in community residential facilities (per 100 000 population)
MH_16 Beds in mental hospitals (per 100 000 population)
MH_17 Mental hospitals (per 100 000 population)
MH_18 Mental health units in general hospitals (per 100 000 population)
MH_19 Mental hospital admissions (per 100 000 population)
MH_2 Mental health plan
MH_20 Outpatient visits (per 100 000 population)
MH_21 Total workforce in mental health sector (per 100 000 population)
MH_22 Occupational therapists in mental health sector (per 100 000 population)
MH_23 Other non-specialized doctors in mental health sector (per 100 000 population)
MH_24 Mental health units in general hospitals admissions (per 100 000 population)
MH_25 Stand-alone policy or plan for mental health
MH_26 Year the law was enacted (latest revision)
MH_27 Publication year of the policy or plan (latest revision)
MH_3 Stand-alone law for mental health
MH_4 Government expenditures on mental health as a percentage of total government expenditures on health (%)
MH_5 Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%)
MH_6 Psychiatrists working in mental health sector (per 100 000 population)
MH_7 Nurses working in mental health sector (per 100 000 population)
MH_8 Social workers working in mental health sector (per 100 000 population)
MH_9 Psychologists working in mental health sector (per 100 000 population)
MORT_100 Deaths in children aged <5 years, by cause
MORT_200 Deaths in children aged <5 years, by cause (per 1 000 live births)
MORT_300 Distribution of causes of death among children aged < 5 years (%)
MORT_400 Deaths per 100 000 population
MORT_500 Number of deaths (see MORT_100)
MORT_600 Projection of number of deaths
MORT_700 Projection of deaths per 100 000 population
MORT_MATERNALNUM Number of maternal deaths
MORTADO Adolescent mortality rate (per 100 000 population)
mslv (see vmsl)
NCD_BMI_18A Prevalence of underweight among adults, BMI < 18.5 (age-standardized estimate) (%)
NCD_BMI_18C Prevalence of underweight among adults, BMI < 18.5 (crude estimate) (%)
NCD_BMI_25A Prevalence of overweight among adults, BMI ≥ 25 (age-standardized estimate) (%)
NCD_BMI_25C Prevalence of overweight among adults, BMI ≥ 25 (crude estimate) (%)
NCD_BMI_30A Prevalence of obesity among adults, BMI ≥ 30 (age-standardized estimate) (%)
NCD_BMI_30C Prevalence of obesity among adults, BMI ≥ 30 (crude estimate) (%)
NCD_BMI_MEAN Mean BMI (kg/m²) (age-standardized estimate)
NCD_BMI_MEANC Mean BMI (kg/m²) (crude estimate)
NCD_BMI_MINUS2A Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (age-standardized estimate) (%)
NCD_BMI_MINUS2C Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%)
NCD_BMI_PLUS1A Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (age-standardized estimate) (%)
NCD_BMI_PLUS1C Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%)
NCD_BMI_PLUS2A Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (age-standardized estimate) (%)
NCD_BMI_PLUS2C Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%)
NCD_CCS_ACE General availability of ACE inhibitors in the public health sector
NCD_CCS_ALC_MGMT_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of alcohol use disorders
NCD_CCS_ALC_SVY Has conducted a recent, national adult risk factor survey covering harmful alcohol use
NCD_CCS_ALC_TARGET Existence of a national target on alcohol
NCD_CCS_AlcPlan Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol
NCD_CCS_alteplase General availability of alteplase for acute stroke management in the public health system
NCD_CCS_ARB General availability of Angiotensin II receptor blockers (ARBs) in the public health sector
NCD_CCS_Aspirin General availability of aspirin (100 mg) in the public health sector
NCD_CCS_betablockers General availability of beta blockers in the public health sector
NCD_CCS_bone_marrow General availability of bone marrow transplantation in the public health system
NCD_CCS_BowelCancer General availability of colon cancer screening at the primary health care level
NCD_CCS_BP_SVY Has conducted a recent, national adult risk factor survey covering raised blood pressure/hypertension
NCD_CCS_BP_TARGET Existence of a national target on blood pressure / hypertension
NCD_CCS_BPmsmt General availability of blood pressure measurement at the primary health care level
NCD_CCS_BreastCancer General availability of breast cancer screening (by palpation or mammogram) at the primary health care level
NCD_CCS_breastcancerscreening Existence of national screening program for breast cancer
NCD_CCS_Bronchodilators General availability of bronchodilators in the public health sector
NCD_CCS_CANCER_DEPT General availability of cancer centres or cancer departments at tertiary level in the public sector
NCD_CCS_CANCER_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of cancer
NCD_CCS_cancer_surgery General availability of cancer surgery in the public sector
NCD_CCS_CancerPlan Existence of operational policy/strategy/action plan for cancer
NCD_CCS_CancerRegNational Existence of population-based cancer registry
NCD_CCS_CCBlkrs General availability of CC blockers in the public health sector
NCD_CCS_CervCy General availability of cervical cytology at the primary health care level
NCD_CCS_cervicalcancermethod Most widely used screening method in national cervical cancer screening program
NCD_CCS_cervicalcancerpgmcvg Coverage of national cervical cancer screening program (%)
NCD_CCS_cervicalcancerpgmtype Type of national cervical cancer screening program
NCD_CCS_cervicalcancerscreening Existence of national screening program for cervical cancer
NCD_CCS_chemo General availability of chemotherapy in the public sector
NCD_CCS_CHOL_SVY Has conducted a recent, national adult risk factor survey covering raised total cholesterol
NCD_CCS_CholMsmt General availability of total cholesterol measurement at the primary health care level
NCD_CCS_ComboInhaler General availability of combination budesonide formoterol inhaler in the public health sector
NCD_CCS_coronary General availability of coronary bypass or stenting in the public health system
NCD_CCS_CRD_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of chronic respiratory diseases
NCD_CCS_CRDPlan Existence of operational policy/strategy/action plan for chronic respiratory diseases
NCD_CCS_CVD_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of cardiovascular diseases
NCD_CCS_CVDPlan Existence of operational policy/strategy/action plan for cardiovascular diseases
NCD_CCS_DIAB_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of diabetes
NCD_CCS_diab_retin General availability of diabetic retinopathy screening in the public health system
NCD_CCS_DIAB_SVY Has conducted a recent, national adult risk factor survey covering raised blood glucose/diabetes
NCD_CCS_DIAB_TARGET Existence of a national target on diabetes
NCD_CCS_DiabetesReg Existence of a diabetes registry
NCD_CCS_DiabetesTest General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level
NCD_CCS_DiabPlan Existence of operational policy/strategy/action plan for diabetes
NCD_CCS_diabtest General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level
NCD_CCS_dialysis General availability of dialysis in the public health system
NCD_CCS_DIET_AWARE Implementation of a nutrition public awareness program
NCD_CCS_DIET_SVY Has conducted a recent, national adult risk factor survey covering unhealthy diet
NCD_CCS_dietpaaware Implementation of diet and/or physical activity public awareness program
NCD_CCS_DietPlan Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs
NCD_CCS_dilated_fundus General availability of dilated fundus examination at the primary health care level
NCD_CCS_DRUG_THERAPY_TARGET Existence of a national target on drug therapy and counselling
NCD_CCS_ESS_MEDS_TECH_TARGET Existence of a national target on essential medicines and technologies
NCD_CCS_EyePlan Existence of operational policy/strategy/action plan for eye health
NCD_CCS_FOOD_TAX Existence of tax on foods high in fat, sugars or salt
NCD_CCS_foot_vibr General availability of foot vibration perception by tuning fork at the primary health care level
NCD_CCS_HbA1c General availability of diabetes testing (by HbA1c) at the primary health care level
NCD_CCS_HearingPlan Existence of operational policy/strategy/action plan for hearing health
NCD_CCS_hpv Existence of national HPV vaccination programme
NCD_CCS_Insulin General availability of insulin in the public health sector
NCD_CCS_integNCDplan Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors
NCD_CCS_LIS_AML_COMBO General availability of Fixed dose combination avail (lisinopril + amlodipine) in the public health sector
NCD_CCS_LIS_HYDRO_COMBO General availability of Fixed dose combination avail (lisinopril + hydrochlorothiazide) in the public health sector
NCD_CCS_Metformin General availability of metformin in the public health sector
NCD_CCS_Mkting Existence of any policies on marketing of foods to children
NCD_CCS_MORT_TARGET Existence of a national target on NCD mortality
NCD_CCS_MultisecComm Existence of a national multisectoral commission, agency or mechanism for NCDs
NCD_CCS_NCDGuide Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach
NCD_CCS_NCDIndicators Existence of a set of national NCD indicators and has set time-bound national targets for these indicators
NCD_CCS_NCDUnit_Operational Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs
NCD_CCS_Nicotine General availability of nicotine replacement therapy in the public health sector
NCD_CCS_OBES_MGMT_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of overweight/obesity
NCD_CCS_OBES_TARGET Existence of a national target on obesity
NCD_CCS_oralhealthplan Existence of operational policy/strategy/action plan for oral health
NCD_CCS_OralMorph General availability of oral morphine in the public health sector
NCD_CCS_OVWT_SVY Has conducted a recent, national adult risk factor survey covering overweight and obesity
NCD_CCS_OvwtPlan Existence of operational policy/strategy/action plan to reduce overweight/obesity
NCD_CCS_PA_GUIDELINES Existence of national guidelines for physical activity
NCD_CCS_PA_GUIDELINES_5to19 Existence of national guidelines for physical activity for children and adolescents aged 5-19
NCD_CCS_PA_GUIDELINES_ADULTS Existence of national guidelines for physical activity for adults
NCD_CCS_PA_GUIDELINES_OLDADULTS Existence of national guidelines for physical activity for older adults
NCD_CCS_PA_GUIDELINES_UNDER5 Existence of national guidelines for physical activity for children under 5
NCD_CCS_PA_MASS_PART Implementation of a recent mass participation event
NCD_CCS_PA_MGMT_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of physical inactivity
NCD_CCS_PA_POL_AGEING Existence of policy promoting physical activity: active ageing
NCD_CCS_PA_POL_CHILDCARE Existence of policy promoting physical activity: childcare settings
NCD_CCS_PA_POL_COMM_BASED Existence of policy promoting physical activity: community-based and sports initiatives
NCD_CCS_PA_POL_PUBLIC Existence of policy promoting physical activity: public open spaces
NCD_CCS_PA_POL_WALKBIKE Existence of policy promoting physical activity: walking and cycling
NCD_CCS_PA_POL_WORK Existence of policy promoting physical activity: workplace initiatives
NCD_CCS_PA_SVY Has conducted a recent, national adult risk factor survey covering physical inactivity
NCD_CCS_PA_TARGET Existence of a national target on physical inactivity
NCD_CCS_PA_TAX Existence of tax incentives to promote physical activity
NCD_CCS_paaware Implementation of physical activity public awareness program
NCD_CCS_palliative_home General availability of palliative care in community or home-based care in the public health system
NCD_CCS_palliative_prim General availability of palliative care in primary health care in the public health system
NCD_CCS_PAPlan Existence of operational policy/strategy/action plan to reduce physical inactivity
NCD_CCS_path_lab General availability of pathology services (laboratories) in the public sector
NCD_CCS_PBCR Existence of population-based cancer registry
NCD_CCS_PeakFlow General availability of peak flow measurement at the primary health care level
NCD_CCS_photocoag General availability of retinal photocoagulation in the public health system
NCD_CCS_PM3_Surv Has a STEPS survey or a comprehensive health examination survey every 5 years
NCD_CCS_PRICE_SUBS Existence of price subsidies for healthy foods
NCD_CCS_radio General availability of radiotherapy in the public sector
NCD_CCS_renaltrans General availability of renal replacement by transplantation in the public health system
NCD_CCS_rheum Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities
NCD_CCS_rheumfollowup Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease
NCD_CCS_rheumreg Existence of a register of patients who had rheumatic fever and rheumatic heart disease
NCD_CCS_riskstrat Availability of cardiovascular risk stratification in 50% or more primary health care facilities
NCD_CCS_SALT_SVY Has conducted a recent, national adult risk factor survey covering salt/sodium intake
NCD_CCS_SALT_TARGET Existence of a national target on salt
NCD_CCS_SaltPol Existence of any policies to reduce population salt consumption
NCD_CCS_SatFat Existence of national policies on saturated fatty acids
NCD_CCS_SatTransFat Existence of national policies on saturated fatty acids / trans-fats
NCD_CCS_Spirom General availability of spirometry at the primary health care level
NCD_CCS_SSBTAX Existence of tax on sugar-sweetened beverages
NCD_CCS_Statins General availability of statins in the public health sector
NCD_CCS_Steroid General availability of steroid inhalers in the public health sector
NCD_CCS_stroke Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities
NCD_CCS_sulphonylurea General availability of sulphonylurea(s) in the public health sector
NCD_CCS_SurvMonRep9NCD Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets
NCD_CCS_targets Existence of a set of time-bound national targets based on WHO guidance
NCD_CCS_TEL_AML_COMBO General availability of Fixed dose combination avail (telmisartan + amlodipine) in the public health sector
NCD_CCS_TEL_HYDRO_COMBO General availability of Fixed dose combination avail (telmisartan + hydrochlorothiazide) in the public health sector
NCD_CCS_Thiazide General availability of thiazide diuretics in the public health sector
NCD_CCS_thrombolytic General availability of thrombolytic therapy in the public health system
NCD_CCS_TOB_MGMT_GUIDE Existence of evidence-based national guidelines/protocols/standards for the management of tobacco dependence
NCD_CCS_TOB_SVY Has conducted a recent, national adult risk factor survey covering tobacco use
NCD_CCS_TOB_TARGET Existence of a national target on tobacco
NCD_CCS_TobPlan Existence of operational policy/strategy/action plan to decrease tobacco use
NCD_CCS_TransFat Existence of national policies on trans-fatty acid elimination
NCD_CCS_urine_strips_gluc_ketone General availability of urine strips for glucose and ketone measurement at the primary health care level
NCD_CCS_UrineAlbumin General availability of urine testing for albumin
NCD_CHOL_MEANHDL_A Mean HDL cholesterol, age-standardized
NCD_CHOL_MEANHDL_C Mean HDL cholesterol, crude
NCD_CHOL_MEANNONHDL_A Mean Non-HDL cholesterol, age-standardized
NCD_CHOL_MEANNONHDL_C Mean Non-HDL cholesterol, crude
NCD_CHOL_MEANTOTALCHOL_A Mean total cholesterol, age-standardized
NCD_CHOL_MEANTOTALCHOL_C Mean total cholesterol, crude
NCD_CXCA_SCREENED_WITHIN_TIMEPERIOD Prevalence of cervical cancer screening among women aged 30-49 years (%)
NCD_DTH_TOT Total NCD Deaths (in thousands)
NCD_GLUC_01 Mean fasting blood glucose (mmol/l) (age-standardized estimate)
NCD_GLUC_02 Mean fasting blood glucose (mmol/l) (crude estimate)
NCD_GLUC_03 Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate)
NCD_GLUC_04 Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate)
NCD_HYP_CONTROL_A Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized
NCD_HYP_CONTROL_C Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude
NCD_HYP_DIAGNOSIS_A Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, age-standardized
NCD_HYP_DIAGNOSIS_C Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, crude
NCD_HYP_PREVALENCE_A Prevalence of hypertension among adults aged 30-79 years, age-standardized
NCD_HYP_PREVALENCE_C Prevalence of hypertension among adults aged 30-79 years, crude
NCD_HYP_TREATMENT_A Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, age-standardized
NCD_HYP_TREATMENT_C Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, crude
NCD_PAA Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)
NCD_PAC Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)
NCD_PAC_ADO Prevalence of insufficient physical activity among school going adolescents aged 11-17 (crude estimate)
NCD_UNDER70 Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths (%)
NCDMORT3070 Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease
NHABASIS Basis for NHA estimate
NHAGGHEGDP General government expenditure on health as percentage of gross domestic product
NHAOOPSTHE Out-of-Pocket expenditure on health as percentage of total health expenditure??
NHAPREPAIDTHE Prepaid plans as percentage of total health expenditure?
NLIS_NU_CA_003 NLIS: Early initiation of breastfeeding within 1 hour of birth (%)
NLIS_NU_CA_010 Median urinary iodine concentration in children 6-12 years (μg/L)
NLIS_NU_CA_017 NLIS: Population using improved drinking-water sources (%)
NLIS_NU_CA_018 NLIS: Population using improved sanitation facility (%)
NLIS_NU_CA_023 Nutrition Governance score
NLIS_NU_CA_041 NLIS: Children with diarrhoea <5 y receiving oral rehydration therapy (ORT) and continued feeding (%)
NLIS_NU_CA_044 International Code on Marketing of Breast-milk Substitutes: Legal status of the Code
NLIS_NU_CA_046 GDP per capita annual growth rate (%)
NLIS_NU_CA_048 Any antenatal iron supplementation (%)
NLIS_NU_CA_049 NLIS: Children with diarrhoea receiving zinc and ORS (%)
NLIS_NU_CA_053 NLIS: Introduction to solid, semisolid or soft foods in infants 6-8 months (%)
NLIS_NU_CA_060 NLIS: Children aged 6-59 months receiving vitamin A supplements (dose 1) (%)
NLIS_NU_CA_061 NLIS: Children aged 6-59 months receiving vitamin A supplements (dose 2) (%)
NLIS_NU_CA_078 Subclinical vitamin A deficiency in preschool-age children (serum/plasma retinol <0.70 μmol/L) (%)
NLIS_NU_CA_079 Clinical vitamin A deficiency in women (history of night blindness during most recent pregnancy) (%)
NLIS_NU_CA_084 Population below the international poverty line (%)
NLIS_NU_CA_095 NLIS: Minimum acceptable diet (MAD) in children 6-23 months (%)
NLIS_NU_CA_106 Births in baby-friendly facilities (%)
NLIS_NU_CA_108 Maternity protection: Compliance with international labour standards
NLIS_NU_CA_114 NLIS: Continued breastfeeding at 1 year in infants 12-15 months (%)
NLIS_NU_CA_115 NLIS: Continued breastfeeding at 2 years in infants 20-23 months (%)
NLIS_NU_CA_116 NLIS: Minimum dietary diversity (MDD) in children 6-23 months (%)
nmr Neonatal mortality rate (deaths per 1000 live births)
NTCP_agcy National agency for tobacco control exists
NTCP_budget_year Budget year
NTCP_curr National tobacco control budget - currency reported
NTCP_FTE Number of full-time equivalent staff in national agency
NTCP_govt_exp Annual budget for tobacco control in currency reported
NTCP_govt_obj Government objectives on tobacco control exist
NTD_1 Number of new reported cases of Buruli ulcer
NTD_2 Dracunculiasis certification status of countries at the beginning of the year
NTD_3 Annual incidence of dracunculiasis cases
NTD_4 Number of new reported cases of human African trypanosomiasis (T.b. gambiense)
NTD_5 Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense)
NTD_6 Status of elimination of trachoma as a public health problem
NTD_7 Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem
NTD_8 Number of people who received treatment with antibiotics for trachoma
NTD_BEJELSTATUS Status of bejel endemicity
NTD_BU_END Status of endemicity of buruli ulcer
NTD_DRACASES Dracunculiasis cases
NTD_LEISHCEND Status of endemicity of cutaneous leishmaniasis
NTD_LEISHCNUM Number of cases of cutaneous leishmaniasis reported
NTD_LEISHCNUM_IM Number of imported cases of cutaneous leishmaniasis reported
NTD_LEISHVEND Status of endemicity of visceral leishmaniasis
NTD_LEISHVNUM Number of cases of visceral leishmaniasis reported
NTD_LEISHVNUM_IM Number of imported cases of visceral leishmaniasis reported
NTD_LEPR11 Number of new leprosy cases among females
NTD_LEPR13 New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population
NTD_LEPR2 New leprosy case detection rate per 1 000 000 population
NTD_LEPR3 Number of leprosy cases registered for treatment (prevalence)
NTD_LEPR4 Leprosy registered prevalence rate per 1 000 000 population
NTD_LEPR5 Number of new leprosy cases with G2D
NTD_LEPR7 New leprosy cases with G2D rate per 1 000 000 population
NTD_LEPR8 Number of new leprosy cases among children (less than 15 years of age)
NTD_LEPR9 Number of new leprosy cases with G2D among children (less than 15 years of age)
NTD_ONCHEMO Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis
NTD_ONCHSTATUS Status of endemicity of onchocerciasis
NTD_ONCTREAT Reported number of individuals treated for onchocerciasis
NTD_PINTASTATUS Status of pinta endemicity
NTD_RAB2 Reported number of human rabies deaths
NTD_TRA5 Number of people operated for trachomatous trichiasis
NTD_TSOL1 Status of endemicity of Taenia solium
NTD_TSOL2 Presence of porcine cysticercosis
NTD_TSOL3 Number of pigs in the country
NTD_TSOL4 Presence of roaming backyard pigs
NTD_YAWSEND Status of yaws endemicity
NTD_YAWSNUM Number of cases of yaws reported
NTD_YAWSNUM_CONF Number of confirmed yaws cases reported
NTD_YAWSNUM_SUSP Number of suspected yaws cases reported
NUT_BF_CBF Continued breastfeeding 12-23 months
NUT_BF_EBF Exclusive breastfeeding under six months
NUT_BF_EBF_NUMTH Exclusive breastfeeding under six months (in thousands)
NUT_BF_EBF2D Exclusively breastfed for the first two days after birth
NUT_BF_EIBF Early Initiation of Breastfeeding, Children born in the last 24 months
NUT_BF_EVBF Ever breastfed
NUT_CF_EFF Egg and/or Flesh Food Consumption 6-23 months
NUT_CF_ISSSF Introduction of solid, semi-solid or soft foods 6-8 months
NUT_CF_MAD Minimum Acceptable Diet 6-23 months
NUT_CF_MDD Minimum dietary diversity 6-23 months
NUT_CF_MMF Minimum Meal Frequency 6-23 months
NUT_CF_ZVF Zero vegetable or fruit consumption, 6-23 months
NUTOVERWEIGHTNUM Overweight numbers among children under 5 years of age (millions), model-based estimates
NUTOVERWEIGHTPREV Overweight prevalence among children under 5 years of age (% weight-for-height >+2 SD), model-based estimates
NUTRITION_2005 Proportion of children aged 6-23 months who receive a minimum acceptable diet
NUTRITION_564 Children aged <5 years wasted for age (%)
NUTRITION_570 Early initiation of breastfeeding (%)
NUTRITION_579 Exclusive breastfeeding under 6 months (%)
NUTRITION_ANAEMIA_CHILDREN_NUM Number of children aged 6-59 months with anaemia (thousands)
NUTRITION_ANAEMIA_CHILDREN_PREV Prevalence of anaemia in children aged 6-59 months (%)
NUTRITION_ANAEMIA_NONPREGNANT_NUM Number of non-pregnant women (aged 15-49 years) with anaemia (thousands)
NUTRITION_ANAEMIA_NONPREGNANT_PREV Prevalence of anaemia in non-pregnant women (aged 15-49) (%)
NUTRITION_ANAEMIA_PREGNANT_NUM Number of pregnant women (aged 15-49 years) with anaemia (thousands)
NUTRITION_ANAEMIA_PREGNANT_PREV Prevalence of anaemia in pregnant women (aged 15-49) (%)
NUTRITION_ANAEMIA_REPRODUCTIVEAGE_NUM Number of women of reproductive age (aged 15-49 years) with anaemia (thousands)
NUTRITION_ANAEMIA_REPRODUCTIVEAGE_PREV Prevalence of anaemia in women of reproductive age (aged 15-49) (%)
NUTRITION_ANT_HAZ_NE2 Stunting prevalence among children under 5 years of age (% height-for-age <-2 SD), survey-based estimates
NUTRITION_ANT_WHZ_NE2 Overweight prevalence among children under 5 years of age (% weight-for-height >+2 SD), survey-based estimates
NUTRITION_WA_2 Underweight prevalence among children under 5 years of age (% weight-for-age <-2 SD), survey-based estimates
NUTRITION_WH_2 Wasting among children under 5 years of age (weight-for-height <-2 SD), prevalence (%), survey-based estimates
NUTRITION_WH_2_NUM Wasting among children under 5 years of age (weight-for-height <-2 SD), number (in thousands), survey-based estimates
NUTRITION_WH_3 Severe wasting prevalence among children under 5 years of age (% weight-for-height <-3 SD), survey-based estimates
NUTSEVWASTINGNUM Severe wasted numbers among children under 5 years of age (millions), model-based estimates
NUTSEVWASTINGPREV Severe wasting prevalence among children under 5 years of age (%), model-based estimates
NUTSTUNTINGNUM Stunting numbers among children under 5 years of age (millions), model-based estimates
NUTSTUNTINGPREV Stunting prevalence among children under 5 years of age (% height-for-age <-2 SD), model-based estimates
NUTUNDERWEIGHTNUM Underweight numbers among children under 5 years of age (millions), model-based estimates
NUTUNDERWEIGHTPREV Underweight prevalence among children under 5 years of age (%), model-based estimates
NUTWASTINGNUM Wasting numbers among children under 5 years of age (millions), model-based estimates
NUTWASTINGPREV Wasting prevalence among children under 5 years of age (%), model-based estimates
O_Avail_community Smoking cessation support is available in the community
O_Avail_hlth_clin Smoking cessation support is available in health clinics or other primary care facilities
O_Avail_hlthSPACEclin Treatment for tobacco dependence available in health clinics or other primary care facilities
O_Avail_hosp Smoking cessation support is available in hospitals
O_Avail_off_hlth_prof Smoking cessation support is available in offices of health professionals
O_Avail_other Smoking cessation support is available in other settings
O_Bup_ins Bupropion - cost covered
O_Bup_sold Bupropion - legally sold
O_Bup_where Bupropion - place available
O_Cytisine_ins Cytisine - cost covered
O_Cytisine_sold Cytisine - legally sold
O_Cytisine_where Cytisine - place available
O_Group Offer help to quit tobacco use
O_Ins_community Smoking cessation support is cost-covered in the community
O_Ins_hlth_clin Smoking cessation support is cost-covered in health clinics or other primary care facilities
O_Ins_hosp Smoking cessation support is cost-covered in hospitals
O_Ins_off_hlth_prof Smoking cessation support is cost-covered in offices of health professionals
O_Ins_other Smoking cessation support is cost-covered in other settings
O_mCessation Provision of a mobile cessation service
O_NRT_EML Nicotine replacement therapy - on the Essential Medicines List
O_NRT_ins Nicotine replacement therapy - cost covered
O_NRT_sold Nicotine replacement therapy - legally sold
O_NRT_where Nicotine replacement therapy - place available
O_Quitline Access to a toll-free quit line
O_Varen_ins Varenicline - cost covered
O_Varen_sold Varenicline - legally sold
O_Varen_where Varenicline - place available
OA_DMFT Decayed, missing, or filled teeth
obesewm (see bmi30wm)
OCC_1 Occupational risk factors attributable deaths
OCC_10 Occupational carcinogens attributable DALYs (’000)
OCC_11 Occupational carcinogens attributable deaths per 100’000 capita
OCC_12 Occupational carcinogens attributable DALYs per 100’000 capita
OCC_13 Occupational noise attributable DALYs (’000)
OCC_14 Occupational noise attributable DALYs per 100’000 capita
OCC_15 Occupational ergonomic stressors attributable deaths
OCC_16 Occupational ergonomic stressors attributable DALYs (’000)
OCC_17 Occupational ergonomic stressors attributable deaths per 100’000 capita
OCC_18 Occupational ergonomic stressors attributable DALYs per 100’000 capita
OCC_19 Occupational injuries attributable deaths
OCC_2 Occupational risk factors attributable DALYs (’000)
OCC_20 Occupational injuries attributable DALYs (’000)
OCC_21 Occupational injuries attributable deaths per 100’000 capita
OCC_22 Occupational injuries attributable DALYs per 100’000 capita
OCC_3 Occupational risk factors attributable deaths per 100’000 capita
OCC_4 Occupational risk factors attributable DALYs per 100’000 capita
OCC_5 Occupational airborne particulates attributable deaths
OCC_6 Occupational airborne particulates attributable DALYs (’000)
OCC_7 Occupational airborne particulates attributable deaths per 100’000 capita
OCC_8 Occupational airborne particulates attributable DALYs per 100’000 capita
OCC_9 Occupational carcinogens attributable deaths
ODA_1 Donor commitments (Million, constant 2009 US\() | |ODA_2 |Commitments to recipient countries (Million, constant 2009 US\))
ODA_3 Donor disbursements (Million, constant 2009 US\() | |ODA_4 |Disbursements to recipient countries (Million, constant 2009 US\))
OHS_POLICYSTATUS Existence of national policy instruments for occupational health and safety for health workers
ORAL_HEALTH_CANCER_LIPORALCAVITY_100K Incidence rate of lip and oral cavity cancer (per 100 000 population)
ORAL_HEALTH_CANCER_LIPORALCAVITY_NEWCASE_NUMBER Number of new cases of lip and oral cavity cancer
ORALHEALTH_AFFORDABILITY_FLUORIDETOOTHPASTE Affordability of fluoride toothpaste
ORALHEALTH_AVAILABILITY_RESTORATIVE Oral health: Basic restorative dental procedures to treat existing dental decay
ORALHEALTH_AVAILABILITY_SCREENING Oral health screening for early detection of oral diseases
ORALHEALTH_AVAILABILITY_URGENTCARE Oral health: Urgent treatment for providing emergency oral care and pain relief
ORALHEALTH_DENOMINATOR_CHEPPP Per capita current health expenditure in PPP (oral health)
ORALHEALTH_DENOMINATOR_TTLPOP Total population in thousands (oral health)
ORALHEALTH_DENTALHEALTHCARE_EXP_PERCAP Per capita expenditure on dental healthcare (US\() | |ORALHEALTH_DENTALHEALTHCARE_EXP_TOTAL |Total expenditure on dental healthcare in million (US\))
ORALHEALTH_EDENTULISM_PREVALENCE Prevalence of edentulism in people 20+ years (%)
ORALHEALTH_FLUORIDETOOTHPHASTE_LABOURDAYS Number of labour days needed to buy annual supply of fluoride toothpaste per person
ORALHEALTH_HWF_DENTALPROSTHETICTECH_10K Dental prosthetic technicians (per 10 000 population)
ORALHEALTH_NCD_STAFF Presence of dedicated staff for oral health working on NCDs at the MoH
ORALHEALTH_NOMA Oral health: Noma recognized as a national public health problem
ORALHEALTH_PRODLOSS_ORALDISEASES Total productivity losses due to 5 oral diseases in million (US\() | |ORALHEALTH_SEVEREPERIODONTALDISEASE |Prevalence of severe periodontal disease in people 15+ year (%) | |ORALHEALTH_SUGAR_AVAILABILITY |Per capita availability of refined sugar (g/day) | |ORALHEALTH_UHC_ADVANCE_CURATIVE |Oral health interventions as part of health benefit packages: Advanced curative oral health care | |ORALHEALTH_UHC_ESSENTIAL_CURATIVE |Oral health interventions as part of health benefit packages: Essential curative oral health care | |ORALHEALTH_UHC_GOVSCHEME |Oral health interventions as part of health benefit packages: Coverage of the largest government health financing scheme (%) | |ORALHEALTH_UHC_PREVENTIVE |Oral health interventions as part of health benefit packages: Routine and preventive oral health care | |ORALHEALTH_UHC_REHABILITATION |Oral health interventions as part of health benefit packages: Rehabilitatative oral health care | |ORALHEALTH_UNTREATEDCARIESDECIDUOUS |Prevalence of untreated caries of deciduous teeth in children 1-9 years (%) | |ORALHEALTH_UNTREATEDCARIESPERMANENT |Prevalence of untreated caries of permanent teeth in people 5+ years (%) | |ORGANKIDNEYNUM |Kidney transplants (absolute number) | |ORGANKIDNEYRATE |Kidney transplants (per million) | |ORGANLIVERNUM |Liver transplants (absolute number) | |ORGANLIVERRATE |Liver transplants (per million) | |ORGANPOP |Population (millions) | |ORGANTOTALDECNUM |Total actual deceased donors (absolute number) | |ORGANTOTALDECRATE |Total actual deceased donors (per million) | |ORGANTOTALNUM |Total organs transplanted (absolute number) | |ORGANTOTALRATE |Total organs transplanted (per million) | |ors |Children aged < 5 years with diarrhoea receiving oral rehydration salts (%) | |ort |Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%) | |overwgt3 |xxxxx for deletion: (child overweight, see overwgt5) | |overwgt5 |Overweight prevalence in children aged < 5 years (%) (Health inequality monitor) | |P_compl_all_sfe |Overall compliance with regulations on smoke-free environments (score) | |P_compl_p1 |Compliance with smoke-free health-care facilities law (score) | |P_compl_p2 |Compliance with smoke-free education facilities except universities law (score) | |P_compl_p3 |Compliance with smoke-free universities law (score) | |P_compl_p4 |Compliance with smoke-free government facilities law (score) | |P_compl_p5 |Compliance with smoke-free indoor offices law (score) | |P_compl_p6 |Compliance with smoke-free restaurants law (score) | |P_compl_p7 |Compliance with smoke-free pubs and bars law (score) | |P_compl_p8 |Compliance with smoke-free public transport law (score) | |P_comprehensive_subnat |Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place | |P_count_places_sf |Number of places smoke-free (national legislation) | |P_Group |Protect from tobacco smoke | |P1_compliance |Compliance of ban on smoking in HEALTH-CARE FACILITIES | |P1_healthcare |Smoke-free health-care facilities (national legislation) | |P10_subnat_auth_exists |Subnational smoke-free legislation authority exists | |P11_fines_any |Fines for violations of smoke-free laws | |P12_fines_establishment |Fines on the establishment for violations of smoke-free laws | |P13_fines_smoker |Fines on the patrons of establishments for violations of smoke-free laws | |P14_funds_for_enforce |Dedicated funds for enforcement of smoke-free laws | |P15_complaints |Citizen complaints and investigations of violations of smoke-free laws | |P16_subnat_complete_bans_exist |Comprehensive bans in place subnationally | |P2_compliance |Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES | |P2_education |Smoke-free education facilities except universities (national legislation) | |P3_compliance |Compliance of ban on smoking in UNIVERSITIES | |P3_universities |Smoke-free universities (national legislation) | |P4_compliance |Compliance of ban on smoking in GOVERNMENT FACILITIES | |P4_govt |Smoke-free government facilities (national legislation) | |P5_compliance |Compliance of ban on smoking in INDOOR OFFICES | |P5_indoor_off |Smoke-free indoor offices (national legislation) | |P6_compliance |Compliance of ban on smoking in RESTAURANTS | |P6_restaurants |Smoke-free restaurants (national legislation) | |P7_compliance |Compliance of ban on smoking in PUBS AND BARS | |P7_pubs |Smoke-free pubs, bars and cafés (national legislation) | |P8_compliance |Compliance of ban on smoking in PUBLIC TRANSPORT | |P8_pub_transp |Smoke-free public transport (national legislation) | |P9_all_other |Smoke-free other indoor public places (national legislation) | |PC_sfe_compliance |Compliance with regulations on smoke-free environments (national legislation) | |PCV3 |Pneumococcal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%) | |PercposANC |Antenatal care attendees who were positive for syphilis (%), reported | |PercposMSM |Men who have sex with men (MSM) with active syphilis (%) | |PercposSW |Sex workers with active syphilis (%) | |PerctestedANC |Women accessing antenatal care (ANC) services who were tested for syphilis (%), reported | |PerctreatedANC |Antenatal care attendees positive for syphilis who received treatment (%), reported | |PHE_HHAIR_POP_CATEGORY_FUELS |Population with primary reliance on fuels and technologies for cooking, by fuel type (in millions) | |PHE_HHAIR_POP_CLEAN_FUELS |Population with primary reliance on clean fuels and technologies for cooking (in millions) | |PHE_HHAIR_POP_POLLUTING_FUELS |Population with primary reliance on polluting fuels and technologies for cooking (in millions) | |PHE_HHAIR_PROP_POP_CATEGORY_FUELS |Proportion of population with primary reliance on fuels and technologies for cooking, by fuel type (%) | |PHE_HHAIR_PROP_POP_CLEAN_FUELS |Proportion of population with primary reliance on clean fuels and technologies for cooking (%) | |PHE_HHAIR_PROP_POP_POLLUTING_FUELS |Proportion of population with primary reliance on polluting fuels and technologies for cooking (%) | |pncall |Postnatal care visit within two days of birth (in the x years preceding the survey) (%) | |pncall3 |Postnatal care visit within two days of birth (in the three years preceding the survey) (%) | |pncall5 |Postnatal care visit within two days of birth (in the five years preceding the survey) (%) | |pnchome |Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%) | |pnchome3 |Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%) | |pnchome5 |Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%) | |poliov |Polio immunization coverage among one-year-olds (%) (see vpolio) | |PRETERMBIRTH_NUMBER |Preterm birth (number) | |PRETERMBIRTH_RATE |Preterm birth rate (per 100 live births) | |PRISON_A1_CAPACITY |Official prison capacity (count) | |PRISON_A2_PRISIONERS_N |Number of prisoners | |PRISON_A2_PRISIONERS_PER100KPOP |Number of prisoners (per 100 000 inhabitants) | |PRISON_A4_NEWPRISONERS_PER100KPOP |Number of people newly-admitted to prison (per 100 000 inhabitants) | |PRISON_B11_VACPREV_DTP |In-prison vaccination for DTP | |PRISON_B11_VACPREV_FLU |In-prison vaccination for seasonal flu | |PRISON_B11_VACPREV_HEPA |In-prison vaccination for Hepatitis A | |PRISON_B11_VACPREV_HEPB |In-prison vaccination for Hepatitis B | |PRISON_B11_VACPREV_HPV |In-prison vaccination for HPV | |PRISON_B11_VACPREV_MMR |In-prison vaccination for MMR | |PRISON_B13_ASSESSMENTS |In-prison regular assessments of essential medicines | |PRISON_B14_ERRORS |In-prison standardized process for medication errors | |PRISON_B15_REPDRUGEVENTS |In-prison standardized process for adverse drug events | |PRISON_B16_SUICIDERISK |In-prison standardized protocol for suicide | |PRISON_B17_INVOLVEMENT |In-prison patient involvement in healthcare planning and reform | |PRISON_B20_CLINICALREP |In-prison clinical health records | |PRISON_B3_DELIVHEALTHCARE |Agencies responsible for delivering prison healthcare | |PRISON_B9_1_DENTISTS_RATIO |Dentists in prisons (FTEs per 1000 prisoners) | |PRISON_B9_1_NURSES_RATIO |Nurses in prisons (FTEs per 1000 prisoners) | |PRISON_B9_1_PHYCHIATRISTS_RATIO |Psychiatrists in prisons (FTEs per 1000 prisoners) | |PRISON_B9_1_PHYSICIANS_RATIO |Physicians in prisons (FTEs per 1000 prisoners) | |PRISON_B9_STAFF_RATIO |Healthcare staff in prisons (FTEs per 1000 prisoners) | |PRISON_C16_LABTESTS |In-prison laboratory tests | |PRISON_C8_CONDOMS |In-prison condoms free of charge | |PRISON_C8_NEEDLES |In-prison needles free of charge | |PRISON_D3_DEATHS_COVID_MRATE |In-prison COVID-19 mortality rate (per 100 000 incarcerated persons per year) | |PRISON_D3_DEATHS_DRUG_MRATE |In-prison drug overdose mortality rate (per 100 000 incarcerated persons per year) | |PRISON_D3_DEATHS_SUICIDE_MRATE |In-prison suicide mortality rate (per 100 000 incarcerated persons per year) | |PRISON_D3_DEATHS_TOT |In-prison total deaths | |PRISON_D4_CANCER_DIAG_TOT |In-prison cancer diagnosis (number of diagnoses) | |PRISON_D4_CARDIOVASC_DIAG_TOT |In-prison cardiovascular disease diagnosis (number of diagnoses) | |PRISON_D4_COVID_TOT |In-prison COVID-19 diagnosis (number of diagnoses) | |PRISON_D4_DIABETES_DIAG_TOT |In-prison diabetes mellitus diagnosis (number of diagnoses) | |PRISON_D4_HEPB_DIAG_TOT |In-prison Hepatitis B diagnosis (number of diagnoses) | |PRISON_D4_HEPC_DIAG_TOT |In-prison Hepatitis C diagnosis (number of diagnoses) | |PRISON_D4_HIV_DIAG_TOT |In-prison HIV diagnosis (number of diagnoses) | |PRISON_D4_MDRTB_DIAG_TOT |In-prison MDR-TB diagnosis (number of diagnoses) | |PRISON_D4_MH_DIAG_TOT |In-prison mental disorder diagnosis (number of diagnoses) | |PRISON_D4_STI_DIAG_TOT |In-prison STIs diagnosis (number of diagnoses) | |PRISON_D4_SUD_DIAG_TOT |In-prison active drug use diagnosis (number of diagnoses) | |PRISON_D4_TB_DIAG_TOT |In-prison TB diagnosis (number of diagnoses) | |PRISON_F1_ALCOHOL_TOT |In-prison people who drink/drank alcohol (number of prisoners, in the last 12 months) | |PRISON_F1_BMI25_TOT |In-prison people who have BMI >= 25 (number of prisoners who are overweight) | |PRISON_F1_BMI30_TOT |In-prison people who have BMI >= 30 (number of prisoners who are obese) | |PRISON_F1_DRUGUSERS_TOT |In-prison people who use/have used drugs (number of prisoners, in the last 12 months) | |PRISON_F1_EXERCISE_TOT |In-prison people who regularly exercise for a minimum of 150 minutes/week (number of prisoners) | |PRISON_F1_INJECTDRUGUSERS_TOT |In-prison people who inject/have injected drugs (number of prisoners, over the last 12 months) | |PRISON_F1_TOBACCO_TOT |In-prison people who currently use tobacco (number of prisoners) | |R_Ad_val |Taxes as a % of price - ad valorem excise | |R_Ad_val_average |Average - taxes as a % of cigarette price - ad valorem excise | |R_Ad_val_estimate |Most sold brand of cigarettes - taxes as a % of price - ad valorem excise | |R_admin_covert_marking |Tax administration - Marking is covert | |R_admin_duty_free_allowance |Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks) | |R_admin_duty_free_banned |Ban on sale of duty-free or excise-free cigarettes | |R_admin_duty_free_limited |Tax administration: Bans or limits on duty free imports by travellers | |R_admin_identifier_track_and_trace |Tax administration - Marking/unique identifier contains data for track and tracing purposes | |R_admin_overt_marking |Tax administration - Marking is overt | |R_admin_tax_stamps |Tax administration: Tax stamps applied on tobacco products | |R_admin_tax_stamps_cig |Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes | |R_admin_tax_stamps_other |Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products | |R_admin_unique_identifier |Tax administration - Unique identifier | |R_afford_cat |Affordability – category of change 2010-2020 (Yes (less affordable), No (more affordable), No change). | |R_afford_cat_2 |Affordability - category of change over past 2 years | |R_afford_gdp |Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand | |R_afford_inflation_adjusted_price_lcu |Price in local currency adjusted by year on year changes in average consumer prices in each country | |R_afford_inflation_adjusted_price_ppp |Prices in purchasing power parity adjusted by year on year changes in average consumer prices in the United States of America | |R_afford_price_dispersion |Price dispersion: Share of cheapest brand price in premium brand price (%) (the higher the % the smaller the gap) | |R_afford_price_gap_decreased |Price gap decreased over the last two years | |R_afford_tax_auto_adjust |Specific tax component automatically adjusted for inflation (or other) | |R_afford_trend_growth_rate |Affordability - trend growth rate | |R_contains_nicotine |Cheapest brand of e-liquid of contains nicotine or not | |R_Curr_lowest_cost |Cheapest brand of cigarettes - currency reported | |R_Curr_mp |Most sold brand of cigarettes - currency reported | |R_Curr_premium_cost |Premium brand of cigarettes - currency reported | |R_earmarking |Reported use of earmarked tobacco taxes | |R_excise_incr |Tobacco excises increased over the survey period | |R_excise_min_specific |Minimum specific tax applied in ad valorem or mixed excise regime | |R_excise_proportion |Excise tax as a proportion of price | |R_excise_retail_price_base |Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT) | |R_excise_specific_reliance |Greater reliance on specific tax in mixed excise regime | |R_excise_type |Type of excise tax applied. | |R_excise_uniform_varied |Uniform excise tax applied Yes (Uniform), No (Tiered/varying rates) | |R_Group |Raise taxes on tobacco | |R_Imp_duty |Taxes as a % of price - import duties | |R_imp_duty_average |Average - taxes as a % of cigarette price - import duties | |R_imp_duty_estimate |Most sold brand of cigarettes - taxes as a % of price - import duties | |R_min_price_policy |A minimum price policy is implemented | |R_Other_average |Average - taxes as a % of cigarette price - other taxes | |R_Other_estimate |Most sold brand of cigarettes - taxes as a % of price - other taxes | |R_Price_lowest_cost_estimate |Cheapest brand of cigarettes - price in currency reported | |R_Price_lowest_cost_ppp |Cheapest brand of cigarettes - price in PPP\)
R_Price_lowest_cost_usd Cheapest brand of cigarettes - price in US$ at official exchange rates
R_Price_mp_estimate Most sold brand of cigarettes - price in currency reported
R_Price_mp_estimate_ppp Most sold brand of cigarettes - price in PPP$
R_Price_mp_estimate_usd Most sold brand of cigarettes - price in US$ at official exchange rates
R_Price_premium_estimate Premium brand of cigarettes - price in currency reported
R_Price_premium_ppp Premium brand of cigarettes - price in PPP$
R_Price_premium_usd Premium brand of cigarettes - price in US$ at official exchange rates
R_Sp_excise Taxes as a % of price - specific excise
R_Sp_excise_average Average - taxes as a % of cigarette price - specific excise
R_Sp_excise_estimate Most sold brand of cigarettes - taxes as a % of price - specific excise
R_tax_other Taxes as a % of price - other taxes
R_Total_tax Taxes as a % of price - total tax
R_total_tax_average Average - taxes as a % of cigarette price - total tax
R_total_tax_estimate Most sold brand of cigarettes - taxes as a % of price - total tax
R_type_variant Most sold brand of other tobacco type
R_VAT Taxes as a % of price - value added tax
R_VAT_average Average - taxes as a % of cigarette price - value added tax
R_VAT_estimate Most sold brand of cigarettes - taxes as a % of price - value added tax
RADON_Q201 Existence of any national radon activity
RADON_Q202 Existence of any subnational radon activity
RADON_Q301 Existence of national radon survey(s)
RADON_Q302 National radon concentration levels
RADON_Q303 Existence of national radon database
RADON_Q304 Data in national radon database
RADON_Q305 Existence of national radon map
RADON_Q401 Existence of national radon action plan
RADON_Q401_1 Existence of national radon action plan - Years covered
RADON_Q402 Existence of national radon regulations
RADON_Q403 Radon in building regulations for new buildings
RADON_Q404 Radon in building regulations for existing buildings i.e. renovation/remodeling/major alteration
RADON_Q405 Radon in national drinking-water regulations
RADON_Q501 Existence of national reference level for dwellings
RADON_Q501_1 Reference level for dwellings (Bq/m3)
RADON_Q502 Existence of national reference level for buildings with high public occupancy
RADON_Q502_1 Reference level for buildings with high public occupancy (Bq/m3)
RADON_Q503 Existence of national reference level for workplaces
RADON_Q503_1 Reference level for workplaces (Bq/m3)
RADON_Q601 Existence of official protocols for radon measurements
RADON_Q602 Radon concentration measurements for new buildings
RADON_Q603 Radon concentration measurements for existing buildings
RADON_Q604 Radon concentration measurements for workplaces
RADON_Q605 Authorization/accreditation required for official radon measurement providers
RADON_Q701 Mandatory preventive measures (new buildings)
RADON_Q702 Mandatory mitigation measures if legal value is exceeded (existing buildings)
RADON_Q703 Financial support provided for mitigation (existing dwellings)
RADON_Q704 Authorization required for prevention/mitigation service providers
RADON_Q705 Official standards/guidelines for prevention/mitigation
RADON_Q706 Existence of training for mitigation providers
RADON_Q707 Inclusion of radon education for building professionals
RADON_Q801 Existence of national radon risk communication strategy
RADON_Q802 Inclusion of radon measurements in property transactions
RADON_Q803 Inclusion of radon in different national strategies
RateCS Congenital syphilis rate per 100 000 live births, reported
Rev_curr Tobacco tax revenues - currency reported
Rev_excise Tobacco tax revenues - total excise (specific and ad valorem)
Rev_govt_total Tobacco tax revenues - total revenues
Rev_imp_other Tobacco tax revenues - import duties and all other taxes
Rev_import Tobacco tax revenues - import duties
Rev_other Tobacco tax revenues - other
Rev_type Tobacco tax revenues - tobacco product types included
Rev_VAT Tobacco tax revenues - valued added tax (VAT) and other sales taxes
Rev_year Tobacco tax revenues - year reported
RHR_IPV Intimate partner violence prevalence among ever partnered women (%)
RHR_NPSV Non-partner sexual violence prevalence (%)
ROTAC Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%)
RS_1845 Population
RS_193 Income level
RS_194 Number of registered vehicles
RS_196 Estimated number of road traffic deaths
RS_198 Estimated road traffic death rate (per 100 000 population)
RS_204 Existence of a national drink-driving law
RS_205 Definition of drink-driving by BAC
RS_207 Blood Alcohol Concentration (BAC) limit for drivers
RS_208 Attribution of road traffic deaths to alcohol (%)
RS_209 Existence of a national seat-belt law
RS_210 Applicability of seat-belt law to all occupants
RS_212 Seat-belt wearing rate (%)
RS_213 Existence of a national child-restraint law
RS_214 Existence of national speed limits
RS_217 Maximum speed limits
RS_219 Applicability of national motorcycle helmet law to all occupants
RS_223_BIS Law requires helmet to be fastened
RS_225 Existence of a road safety lead agency
RS_228 Existence of a national road safety strategy
RS_229 Availability of funding for national road safety strategy
RS_237 Existence of a formal pre-hospital care system
RS_238 Existence of a universal access telephone number for pre-hospital care
RS_242 Vehicle standards
RS_246 Distribution of road traffic deaths by type of road user (%)
RS_576 Gross national income per capita (Atlas method)
RSUD_1 Point prevalence (%), alcohol use disorders, 15+ years
RSUD_10 National survey on substance use among children and adolescents
RSUD_100 Government unit/official responsible for prevention for substance use
RSUD_11 Data on substance use disorders disseminated in national annual reports
RSUD_110 Ministry/office that takes primary responsibility for prevention for substance use
RSUD_12 Substance use policy at the national level
RSUD_120 Five years change in international cooperation for prevention for substance use
RSUD_13 Substance use policy at the national level, level of integration
RSUD_130 Government unit/official responsible for treatment of substance use disorders
RSUD_14 Policy documents on the pharmacological treatment of substance use disorders
RSUD_140 Ministry/office that takes primary responsibility for treatment of substance use disorders
RSUD_15 Guidelines on the pharmacological treatment of substance use disorders
RSUD_150 Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders
RSUD_16 Legislative provision for treatment and rehabilitation of substance use disorders
RSUD_160 Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders
RSUD_17 Legislative provision for compulsory treatment
RSUD_170 Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs
RSUD_18 Drug courts
RSUD_180 Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs
RSUD_19 Programmes diverting clients from the justice system towards treatment
RSUD_190 Five years change in international cooperation for treatment of substance use disorders
RSUD_2 Point prevalence (%), drug use disorders, 15+ years
RSUD_20 Confidentiality of health records on substance use disorders protected by law
RSUD_200 Confidentiality of people in treatment for substance use disorders
RSUD_21 Government unit for substance use disorder treatment
RSUD_210 Voluntary treatment for people with alcohol use disorders in the criminal justice system
RSUD_22 Budget line for substance use disorder treatment
RSUD_220 Voluntary treatment for people with drug use disorders in the criminal justice system
RSUD_23 Financing method for substance use disorder treatment
RSUD_230 Compulsory treatment for people with alcohol use disorders in the criminal justice system
RSUD_240 Compulsory treatment for people with drug use disorders in the criminal justice system
RSUD_250 Five-year change in government resources for prevention for substance use
RSUD_26 Governement benefits for persons with substance use disorders
RSUD_260 Five-year change in government resources for treatment of substance use disorders
RSUD_27 Government benefits for alcohol use disorders, subsidy or disability pension
RSUD_270 Financing methods for treatment for alcohol use disorders
RSUD_28 Government benefits for drug use disorders, subsidy or disability pension
RSUD_280 Financing methods for treatment for drug use disorders
RSUD_29 Sector for inpatient detoxification of alcohol use disorders
RSUD_290 Hypothecated taxes to be spent on prevention and treatment for substance use disorders
RSUD_3 Age-standardized death rates, alcohol and drug use disorders, per 100 000
RSUD_30 Sector for inpatient treatment of alcohol dependence
RSUD_300 Government benefits for people with alcohol use disorders
RSUD_31 Sector for outpatient treatment of alcohol dependence
RSUD_310 Government benefits for people with drug use disorders
RSUD_32 Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions
RSUD_320 Main sector for treatment for alcohol use disorders
RSUD_33 Sector for residential long-term rehabilitation of alcohol use disorders
RSUD_330 Main sector for treatment for drug use disorders
RSUD_34 Sector for inpatient detoxification of drug use disorders
RSUD_340 Treatment programmes for children and adolescents with alcohol use disorders (treatment)
RSUD_35 Sector for inpatient treatment of drug dependence
RSUD_350 Treatment programmes for children and adolescents with drug use disorders (treatment)
RSUD_36 Sector for outpatient treatment of drug dependence
RSUD_360 Specialized treatment facilities for substance use disorders
RSUD_37 Sector for substitution maintenance therapy of opioid dependence
RSUD_370 Specialized treatment facilities for alcohol use disorders
RSUD_38 Sector for residential long-term rehabilitation of drug use disorders
RSUD_380 Specialized treatment facilities for drug use disorders
RSUD_39 Treatment system for substance use disorders
RSUD_390 Self-help groups
RSUD_40 Treatment setting for substance use disorders, most common
RSUD_400 Main substance at treatment entry
RSUD_41 Specialized treatment services for drug use disoders and HIV/AIDS
RSUD_410 Reported treatment coverage for substance dependence
RSUD_42 Specialized treatment services for substance use disorders and TB
RSUD_420 Guidelines on pharmacological treatment for substance use disorders
RSUD_43 Open access services for substance use disorders
RSUD_430 Pharmacotherapy with methadone
RSUD_44 Treatment slots for alcohol and drug use disorders, outpatient, per 10 000
RSUD_440 Pharmacotherapy with buprenorphine
RSUD_45 Beds for the treatment of substance use disorders, per 100 000
RSUD_450 Pharmacotherapy with buprenorphine/naloxone
RSUD_46 Length of stay for inpatient detoxification, days
RSUD_460 Access restrictions to maintenance treatment
RSUD_47 Length of stay for inpatient short-term treatment, days
RSUD_470 Timeframe for maintenance treatment of opioid dependence
RSUD_48 Length of stay for inpatient long-term residential treatment, days
RSUD_480 Registration of medications for alcohol dependence and withdrawal
RSUD_49 Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance)
RSUD_490 Registration of medications for opioid dependence
RSUD_5 Age-standardized DALYs, alcohol and drug use disorders, per 100 000
RSUD_50 Timeframe of opioid agonist treatment
RSUD_500 Registration of medications for opioid withdrawal
RSUD_51 Methadone used for the treatment of opioid dependence
RSUD_510 Registration of naloxone for injection for opioid overdose
RSUD_52 Methadone used for detoxification or maintenance
RSUD_520 Availability of naloxone
RSUD_53 Methadone formulation used for the treatment of opiod dependence
RSUD_530 Screening and brief intervention for substance use in primary health care
RSUD_54 Buprenorphine used for the treatment of opioid dependence
RSUD_540 Screening and brief intervention for substance use in antenatal services
RSUD_55 Buprenorphine used for detoxification or maintenance
RSUD_550 Recommendations for screening and brief interventions for substance use in primary health care
RSUD_56 Buprenorphine/naloxone used for the treatment of opioid dependence
RSUD_560 Recommendations for screening and brief interventions for substance use in antenatal services
RSUD_57 Buprenorphine/naloxone used for detoxification or maintenance
RSUD_570 Groups and agencies involved in prevention programs
RSUD_58 Methadone provision in clinical and community-based settings
RSUD_580 Prevention programmes for alcohol
RSUD_59 Buprenorphine provision in clinical and community-based settings
RSUD_590 Prevention programmes for specific populations for alcohol
RSUD_60 Buprenorphine/naloxone provision in clinical and community-based settings
RSUD_600 Prevention programmes for drugs
RSUD_61 Supervision requirements for methadone administration
RSUD_610 Prevention programmes for specific populations for drugs
RSUD_62 Supervision requirements for buprenorphine administration
RSUD_620 HIV, Hepatitis counselling and treatment availability in specialized facilities and services
RSUD_63 Supervision requirements for buprenorphine/naloxone administration
RSUD_630 Programmes readily available
RSUD_64 Prescription requirements for methadone
RSUD_640 Standards of treatment and care for public specialized treatment facilities
RSUD_65 Prescription requirements for buprenorphine
RSUD_650 Special treatment programmes for gambling disorder
RSUD_66 Prescription requirements for buprenorphine/naloxone
RSUD_660 Treatment programmes for women with alcohol use disorders
RSUD_67 Commencement of treatment with opioid agonists
RSUD_670 Treatment programmes for women with drug use disorders
RSUD_68 Pharmacotherapy used for the management of alcohol withdrawal
RSUD_680 Special housing services for alcohol use disorders
RSUD_69 Pharmacotherapy used for the management of benzodiazepine withdrawal
RSUD_690 Special housing services for drug use disorders
RSUD_7 Psychoactive substance causing entry into treatment
RSUD_70 Pharmacotherapy used for the management of cannabis withdrawal
RSUD_700 Employment services for alcohol use disorders
RSUD_71 Essential list of medicines
RSUD_710 Employment services for drug use disorders
RSUD_72 Essential list of medicines, pharmacotherapy for substance use disorders
RSUD_720 Open access interventions for alcohol
RSUD_73 Government unit for substance use disorder prevention
RSUD_730 Open access interventions for drugs
RSUD_74 Budget line for substance use disorder prevention
RSUD_740 Health professionals providing treatment for alcohol and drug use disorders
RSUD_75 Funding method for substance use disorder prevention
RSUD_750 Standards of care for professionals providing treatment for alcohol and drug use disorders
RSUD_76 Prevention activities for substance use disorders, main focus
RSUD_760 Educational attainment in prevention
RSUD_77 Programmes for the prevention of substance use disorders for special populations
RSUD_770 Postgraduate training programme in prevention
RSUD_78 Screening and brief interventions for substance use and substance use disorders
RSUD_780 Continuing professional development in prevention
RSUD_79 Harm reduction programmes for IDUs
RSUD_790 Educational attainment in treatment
RSUD_8 Epidemiological data collection system for substance use disorders
RSUD_80 Health professionals mostly involved in treatment of substance use disorders
RSUD_800 Postgraduate training programme in treatment
RSUD_81 Clinical supervision of health care staff
RSUD_810 Continuing professional development in treatment
RSUD_82 Standards of care for health professionals
RSUD_820 Epidemiological data collection for substance use
RSUD_83 Standards of care for health professionals, maintenance
RSUD_830 Service delivery data collection for substance use
RSUD_84 Standards of care for health professionals, human rights
RSUD_840 Regular reports on epidemiological and service delivery data for substance use
RSUD_85 NGOs for alcohol use disorders
RSUD_850 System of monitoring alcohol involvement in forensic pathology
RSUD_86 NGOs for drug use disorders
RSUD_860 System of monitoring drugs involvement in forensic pathology
RSUD_87 Self-help groups for substance use disorders
RSUD_870 Epidemiological data collection system for substance use among children and adolescents (see RSUD_880)
RSUD_88 Groups and agencies for the prevention of substance use disorders
RSUD_880 Epidemiological data collection system for substance use among children and adolescents
RSUD_89 Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance)
RSUD_890 Treatment programmes for children and adolescents with alcohol use disorders (youth)
RSUD_9 Service delivery data collection system for substance use disorders
RSUD_900 Treatment programmes for children and adolescents with drug use disorders (youth)
SA_0000001398 Alcohol, consumption of pure alcohol by type of beverage (%)
SA_0000001398_ARCHIVED Alcohol, consumption of pure alcohol by type of beverage (%) (archived)
SA_0000001400 Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol)
SA_0000001400_ARCHIVED Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol) (archived)
SA_0000001401 Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average
SA_0000001401_ARCHIVED Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average (archived)
SA_0000001402 Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010
SA_0000001402_ARCHIVED Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010 (archived)
SA_0000001403 Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)
SA_0000001403_ARCHIVED Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) (archived)
SA_0000001404 Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol
SA_0000001404_ARCHIVED Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol (archived)
SA_0000001405 Alcohol, tourist consumption (in litres of pure alcohol)
SA_0000001405_ARCHIVED Alcohol, tourist consumption (in litres of pure alcohol) (archived)
SA_0000001406 Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol)
SA_0000001406_ARCHIVED Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) (archived)
SA_0000001409 Alcohol, abstainers lifetime (%)
SA_0000001409_ARCHIVED Alcohol, abstainers lifetime (%) (archived)
SA_0000001410 Abstainers (15-19 years), lifetime (%)
SA_0000001411 Alcohol, abstainers past 12 months (%)
SA_0000001411_ARCHIVED Alcohol, abstainers past 12 months (%) (archived)
SA_0000001412 Abstainers (15-19 years), past 12 months (%)
SA_0000001413 Alcohol, consumers past 12 months (%)
SA_0000001413_ARCHIVED Alcohol, consumers past 12 months (%) (archived)
SA_0000001414 Alcohol, former drinkers (%)
SA_0000001414_ARCHIVED Alcohol, former drinkers (%) (archived)
SA_0000001415_ARCHIVED Alcohol, heavy episodic drinking (population) past 30 days (%)
SA_0000001416 Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)
SA_0000001416_ARCHIVED Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%) (archived)
SA_0000001417 Alcohol, patterns of drinking score
SA_0000001417_ARCHIVED Alcohol, patterns of drinking score (archived)
SA_0000001418 Age-standardized DALYs, alcohol use disorders, per 100,000
SA_0000001419 Age-standardized DALYs, breast cancer, per 100,000
SA_0000001420 Age-standardized DALYs, colon and rectum cancers, per 100,000
SA_0000001421 Age-standardized DALYs, diabetes mellitus, per 100,000
SA_0000001422 Age-standardized DALYs, drownings, per 100,000
SA_0000001423 Age-standardized DALYs, falls, per 100,000
SA_0000001424 Age-standardized DALYs, fires, per 100,000
SA_0000001425 Age-standardized DALYs, ischaemic heart disease, per 100,000
SA_0000001426 Age-standardized DALYs, liver cancer, per 100,000
SA_0000001427 Age-standardized DALYs, liver cirrhosis, per 100,000
SA_0000001429 Age-standardized DALYs, mouth and oropharynx cancer, per 100,000
SA_0000001430 Age-standardized DALYs, oesophagus cancer, per 100,000
SA_0000001431 Age-standardized DALYs, poisoning, per 100,000
SA_0000001432 Age-standardized DALYs, prematurity and low birth rate, per 100,000
SA_0000001433 Age-standardized DALYs, road traffic accidents, per 100,000
SA_0000001434 Age-standardized DALYs, self-inflicted injury, per 100,000
SA_0000001435 Age-standardized DALYs, other unintentional injuries, per 100,000
SA_0000001436 Age-standardized DALYs, violence, per 100,000
SA_0000001437 Age-standardized death rates, alcohol use disorders, per 100,000
SA_0000001438 Age-standardized death rates, breast cancer, per 100,000
SA_0000001439 Age-standardized death rates, colon and rectum cancers, per 100,000
SA_0000001440 Age-standardized death rates, diabetes mellitus, per 100,000
SA_0000001441 Age-standardized death rates, drownings, per 100,000
SA_0000001442 Age-standardized death rates, falls, per 100,000
SA_0000001443 Age-standardized death rates, fires, per 100,000
SA_0000001444 Age-standardized death rates, ischaemic heart disease, per 100,000
SA_0000001445 Age-standardized death rates, liver cancer, per 100,000
SA_0000001446 Age-standardized death rates, liver cirrhosis, per 100,000
SA_0000001448 Age-standardized death rates, mouth and oropharynx cancer, per 100,000
SA_0000001449 Age-standardized death rates, oesophagus cancer, per 100,000
SA_0000001450 Age-standardized death rates, poisoning, per 100,000
SA_0000001451 Age-standardized death rates, prematurity and low birth rate, per 100,000
SA_0000001452 Age-standardized death rates, road traffic accidents, per 100,000
SA_0000001453 Age-standardized death rates, self-inflicted injury, per 100,000
SA_0000001454 Age-standardized death rates, other unintentional injuries, per 100,000
SA_0000001455 Age-standardized death rates, violence, per 100,000
SA_0000001456 Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000
SA_0000001457 Liver cirrhosis, age-standardized death rates (15+), per 100,000 population
SA_0000001457_ARCHIVED Liver cirrhosis, age-standardized death rates (15+), per 100,000 population (archived)
SA_0000001458 Age-standardized death rates (15+ years), poisoning, per 100,000
SA_0000001459 Road traffic injuries, age-standardized death rates (15+), per 100,000 population
SA_0000001459_ARCHIVED Road traffic injuries, age-standardized death rates (15+), per 100,000 population (archived)
SA_0000001460 Age-standardized death rates (15+ years), violence, per 100,000
SA_0000001461 Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI
SA_0000001461_ARCHIVED Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI (archived)
SA_0000001462 Alcohol use disorders (15+), 12 month prevalence (%) with 95%
SA_0000001462_ARCHIVED Alcohol use disorders (15+), 12 month prevalence (%) with 95% (archived)
SA_0000001463 Alcoholic psychosis, incidence, per 100,000
SA_0000001463_ARCHIVED Alcoholic psychosis, incidence, per 100,000 (archived)
SA_0000001464 Cautions and arrests for drink-driving, per 100,000 population
SA_0000001464_ARCHIVED Cautions and arrests for drink-driving, per 100,000 population (archived)
SA_0000001465 Hospital discharges, alcohol-related injuries and poisoning, per 100,000
SA_0000001466 Hospital discharges, alcoholic liver disease, per 100,000
SA_0000001467 Perceived trend in alcohol-related harm and consequences
SA_0000001468 Treatment admissions (inpatient), alcohol dependence, per 100,000
SA_0000001469 Treatment admissions (inpatient), alcoholic psychosis, per 100,000
SA_0000001470 Alcohol-related road traffic crashes, per 100,000 population
SA_0000001470_ARCHIVED Alcohol-related road traffic crashes, per 100,000 population (archived)
SA_0000001471 Alcohol-related road traffic crashes (% of all traffic crashes)
SA_0000001471_ARCHIVED Alcohol-related road traffic crashes (% of all traffic crashes) (archived)
SA_0000001472 Alcohol-related injury mortality, per 1,000
SA_0000001473 Alcohol-related disease mortality, per 100,000 (15+ years)
SA_0000001474 Alcoholic excise tax revenue as a per cent of government revenue
SA_0000001474_ARCHIVED Alcoholic excise tax revenue as a per cent of government revenue (archived)
SA_0000001475 Annual revenues from alcohol excise tax in millions US$
SA_0000001475_ARCHIVED Annual revenues from alcohol excise tax in millions US$ (archived)
SA_0000001476 Alcohol expenditure as a per cent of total household expenditure
SA_0000001476_ARCHIVED Alcohol expenditure as a per cent of total household expenditure (archived)
SA_0000001477 Social costs of alcohol use in millions US$
SA_0000001477_ARCHIVED Social costs of alcohol use in millions US$ (archived)
SA_0000001502 Adopted written national policy on alcohol
SA_0000001502_ARCHIVED Adopted written national policy on alcohol (archived)
SA_0000001503 Alcoholic beverage legally defined
SA_0000001503_ARCHIVED Alcoholic beverage legally defined (archived)
SA_0000001504 Alcohol use is banned
SA_0000001504_ARCHIVED Alcohol use is banned (archived)
SA_0000001506 National legislation to prevent illegal alcohol
SA_0000001506_ARCHIVED National legislation to prevent illegal alcohol (archived)
SA_0000001507 Advertising restrictions on national television
SA_0000001507_ARCHIVED Advertising restrictions on national television (archived)
SA_0000001508 Advertising restrictions on cable television
SA_0000001508_ARCHIVED Advertising restrictions on cable television (archived)
SA_0000001509 Advertising restrictions on national radio
SA_0000001509_ARCHIVED Advertising restrictions on national radio (archived)
SA_0000001510 Advertising restrictions on local radio
SA_0000001510_ARCHIVED Advertising restrictions on local radio (archived)
SA_0000001511 Advertising restrictions in print media
SA_0000001511_ARCHIVED Advertising restrictions in print media (archived)
SA_0000001512 Advertising restrictions at cinemas
SA_0000001512_ARCHIVED Advertising restrictions at cinemas (archived)
SA_0000001513 Advertising restrictions on billboards
SA_0000001513_ARCHIVED Advertising restrictions on billboards (archived)
SA_0000001514 Advertising restrictions at point-of-sale
SA_0000001514_ARCHIVED Advertising restrictions at point-of-sale (archived)
SA_0000001515 Advertising restrictions on the internet
SA_0000001515_ARCHIVED Advertising restrictions on the internet (archived)
SA_0000001516 Restrictions on product placement on national television
SA_0000001516_ARCHIVED Restrictions on product placement on national television (archived)
SA_0000001517 Restrictions on product placement on cable television
SA_0000001517_ARCHIVED Restrictions on product placement on cable television (archived)
SA_0000001518 Age limits on-premise service
SA_0000001518_ARCHIVED Age limits on-premise service (archived)
SA_0000001519 Minimum legal drinking age
SA_0000001520 Legal blood alcohol concentration (BAC) limits
SA_0000001520_ARCHIVED Legal blood alcohol concentration (BAC) limits (archived)
SA_0000001521 Random breath testing (RBT) use
SA_0000001521_ARCHIVED Random breath testing (RBT) use (archived)
SA_0000001523 Prices for alcoholic beverages (average, US\() | |SA_0000001523_ARCHIVED |Prices for alcoholic beverages (average, US\)) (archived)
SA_0000001525 Off-premise sales restrictions on days
SA_0000001525_ARCHIVED Off-premise sales restrictions on days (archived)
SA_0000001526 Off-premise sales restrictions on hours
SA_0000001526_ARCHIVED Off-premise sales restrictions on hours (archived)
SA_0000001527 Off-premise sales restrictions on places
SA_0000001527_ARCHIVED Off-premise sales restrictions on places (archived)
SA_0000001528 Off-premise sales restrictions on outlet density
SA_0000001528_ARCHIVED Off-premise sales restrictions on outlet density (archived)
SA_0000001529 Off-premise sales restrictions at specific events
SA_0000001529_ARCHIVED Off-premise sales restrictions at specific events (archived)
SA_0000001530 Off-premise sales restrictions at petrol stations
SA_0000001530_ARCHIVED Off-premise sales restrictions at petrol stations (archived)
SA_0000001531 On-premise sales restrictions on days
SA_0000001531_ARCHIVED On-premise sales restrictions on days (archived)
SA_0000001532 On-premise sales restrictions on hours
SA_0000001532_ARCHIVED On-premise sales restrictions on hours (archived)
SA_0000001533 On-premise sales restrictions on places
SA_0000001533_ARCHIVED On-premise sales restrictions on places (archived)
SA_0000001534 On-premise sales restrictions on outlet density
SA_0000001534_ARCHIVED On-premise sales restrictions on outlet density (archived)
SA_0000001535 On-premise sales restrictions at specific events
SA_0000001535_ARCHIVED On-premise sales restrictions at specific events (archived)
SA_0000001536 On-premise sales restrictions to intoxicated persons (archived)
SA_0000001536_ARCHIVED On-premise sales restrictions to intoxicated persons
SA_0000001537 Restrictions on sponsorship of sporting events
SA_0000001537_ARCHIVED Restrictions on sponsorship of sporting events (archived)
SA_0000001538 Restrictions on sponsorship of youth events
SA_0000001538_ARCHIVED Restrictions on sponsorship of youth events (archived)
SA_0000001539 Restrictions on sales promotion from producers (parties, events)
SA_0000001539_ARCHIVED Restrictions on sales promotion from producers (parties, events) (archived)
SA_0000001540 Restrictions on sales promotion from retailers (sales below cost)
SA_0000001540_ARCHIVED Restrictions on sales promotion from retailers (sales below cost) (archived)
SA_0000001541 Restrictions on sales promotion from owners of pubs and bars (alcohol for free)
SA_0000001541_ARCHIVED Restrictions on sales promotion from owners of pubs and bars (alcohol for free) (archived)
SA_0000001542 Government monopoly on production
SA_0000001542_ARCHIVED Government monopoly on production (archived)
SA_0000001543 Government monopoly on retail sales
SA_0000001543_ARCHIVED Government monopoly on retail sales (archived)
SA_0000001544 Licence required for production
SA_0000001544_ARCHIVED Licence required for production (archived)
SA_0000001545 Licence required for retail sales
SA_0000001545_ARCHIVED Licence required for retail sales (archived)
SA_0000001546 Excise tax as a per cent of the retail price of alcoholic beverages
SA_0000001546_ARCHIVED Excise tax as a per cent of the retail price of alcoholic beverages (archived)
SA_0000001547 Excise duty (average) per hectolitre in Euros
SA_0000001547_ARCHIVED Excise duty (average) per hectolitre in Euros (archived)
SA_0000001548 Excise tax as a per cent of the total retail price for 1 litre of pure alcohol
SA_0000001548_ARCHIVED Excise tax as a per cent of the total retail price for 1 litre of pure alcohol (archived)
SA_0000001549 Duty paid or excise stamp on alcohol container
SA_0000001549_ARCHIVED Duty paid or excise stamp on alcohol container (archived)
SA_0000001550 Excise tax on alcoholic beverages
SA_0000001550_ARCHIVED Excise tax on alcoholic beverages (archived)
SA_0000001551 Value-added tax (VAT) on alcohol (%)
SA_0000001551_ARCHIVED Value-added tax (VAT) on alcohol (%) (archived)
SA_0000001553 Restrictions on alcohol use in public places
SA_0000001553_ARCHIVED Restrictions on alcohol use in public places (archived)
SA_0000001554 Health warning labels on alcohol advertising
SA_0000001554_ARCHIVED Health warning labels on alcohol advertising (archived)
SA_0000001555 Health warning labels on alcohol containers
SA_0000001555_ARCHIVED Health warning labels on alcohol containers (archived)
SA_0000001647 Awareness activities
SA_0000001647_ARCHIVED Awareness activities (archived)
SA_0000001648 Information, education, prevention
SA_0000001649 National drinking guidelines, 2010
SA_0000001650 Standard drink measures, in grams per unit
SA_0000001650_ARCHIVED Standard drink measures, in grams per unit (archived)
SA_0000001651 Monitoring
SA_0000001652 Interventions, projects, training
SA_0000001653 Treatment, services
SA_0000001654 Surveys, research
SA_0000001655 Counselling
SA_0000001676 Production in 1000s hectolitres
SA_0000001677 Imports in 1000s hectolitres
SA_0000001678 Sales of beer in 1000s hectolitres
SA_0000001679 Exports of beer (barley) in 1000s hectolitres
SA_0000001680 Perceived trend in production
SA_0000001681 Perceived trend in imports
SA_0000001682 Perceived trend in sales
SA_0000001683 Perceived trend in exports
SA_0000001684 Sales of wine in 1000s hectolitres
SA_0000001685 Sales of spirits in 1000s hectolitres
SA_0000001686 Exports of wine (grape) in 1000s hectolitres
SA_0000001687 Exports of spirits in 1000s hectolitres
SA_0000001688 Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2)
SA_0000001688_ARCHIVED Total (recorded+unrecorded) alcohol per capita (15+) consumption
SA_0000001689 Age-standardized DALYs, cerebrovascular disease, per 100,000
SA_0000001690 Age-standardized death rates, cerebrovascular disease, per 100,000
SA_0000001691 Central coordinating entity for alcohol policy implementation
SA_0000001691_ARCHIVED Central coordinating entity for alcohol policy implementation (archived)
SA_0000001692 Framework of national alcohol policy
SA_0000001692_ARCHIVED Framework of national alcohol policy (archived)
SA_0000001693 Level of adoption of national alcohol policy
SA_0000001693_ARCHIVED Level of adoption of national alcohol policy (archived)
SA_0000001694 Sectors represented in national alcohol policy
SA_0000001694_ARCHIVED Sectors represented in national alcohol policy (archived)
SA_0000001695 Cautions and arrests for public drunkenness, per 100,000 population
SA_0000001695_ARCHIVED Cautions and arrests for public drunkenness, per 100,000 population (archived)
SA_0000001696 Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities)
SA_0000001696_ARCHIVED Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities) (archived)
SA_0000001697 Adopted written national policy on alcohol, year adopted
SA_0000001697_ARCHIVED Adopted written national policy on alcohol, year adopted (archived)
SA_0000001698 Adopted written national policy on alcohol, year revised
SA_0000001698_ARCHIVED Adopted written national policy on alcohol, year revised (archived)
SA_0000001699 Age limits off-premise sales
SA_0000001699_ARCHIVED Age limits off-premise sales (archived)
SA_0000001700 Consumer information on alcohol and health at points of sale
SA_0000001701 Educational programmes involving target groups in school curriculum
SA_0000001702 Brief interventions as health promotion/disease prevention
SA_0000001703 Server training on a regular basis
SA_0000001704 Data collection on alcohol-related health indicators
SA_0000001705 System for monitoring alcohol-related harm
SA_0000001706 National treatment policy for alcohol use disorders
SA_0000001707 Persons with alcohol use disorders receiving treatment (%)
SA_0000001708 Designation of alcohol tax revenues to health services
SA_0000001709 National surveys on drink-driving
SA_0000001710 Public-funded alcohol research/monitoring programmes
SA_0000001711 Public funds designated for alcohol research/monitoring programmes, in Euros
SA_0000001712 Community-based interventions/projects involving stakeholders
SA_0000001713 Interventions/projects actively involving young people and civil society
SA_0000001714 Training in screening and brief interventions for alcohol problems
SA_0000001715 Counselling to children in families with alcohol problems
SA_0000001716 Counselling to pregnant women with alcohol problems
SA_0000001717 Prevention/counselling at workplaces for those with alcohol problems
SA_0000001719 Advertising restrictions on social media
SA_0000001719_ARCHIVED Advertising restrictions on social media (archived)
SA_0000001720 Restrictions on product placement in films/movies
SA_0000001720_ARCHIVED Restrictions on product placement in films/movies (archived)
SA_0000001721 Importance of measures for enhancing compliance with age limits
SA_0000001721_ARCHIVED Importance of measures for enhancing compliance with age limits (archived)
SA_0000001722 Government support for community action
SA_0000001722_ARCHIVED Government support for community action (archived)
SA_0000001723 Community-based interventions involving stakeholders
SA_0000001723_ARCHIVED Community-based interventions involving stakeholders (archived)
SA_0000001724 National guidelines for implementing effective community-based interventions
SA_0000001724_ARCHIVED National guidelines for implementing effective community-based interventions (archived)
SA_0000001725 National alcohol policy specifically involves young people activities
SA_0000001725_ARCHIVED National alcohol policy specifically involves young people activities (archived)
SA_0000001726 Penalties for drink driving
SA_0000001726_ARCHIVED Penalties for drink driving (archived)
SA_0000001727 Sobriety checkpoints
SA_0000001727_ARCHIVED Sobriety checkpoints (archived)
SA_0000001728 Detection of marketing infringements
SA_0000001728_ARCHIVED Detection of marketing infringements (archived)
SA_0000001729 Penalties for marketing infringements
SA_0000001729_ARCHIVED Penalties for marketing infringements (archived)
SA_0000001730 Price measures
SA_0000001730_ARCHIVED Price measures (archived)
SA_0000001731 Level of taxation adjusted for inflation
SA_0000001731_ARCHIVED Level of taxation adjusted for inflation (archived)
SA_0000001732 New types of alcoholic beverages emerging
SA_0000001732_ARCHIVED New types of alcoholic beverages emerging (archived)
SA_0000001733 Consumer information about calories, additives, etc on containers
SA_0000001733_ARCHIVED Consumer information about calories, additives, etc on containers (archived)
SA_0000001734 Number of standard alcoholic drinks displayed on containers
SA_0000001734_ARCHIVED Number of standard alcoholic drinks displayed on containers (archived)
SA_0000001735 Alcohol content displayed on containers
SA_0000001735_ARCHIVED Alcohol content displayed on containers (archived)
SA_0000001736 Action Plan for implementation of alcohol policy
SA_0000001736_ARCHIVED Action Plan for implementation of alcohol policy (archived)
SA_0000001737 Alcohol, regional per capita (15+) consumption (in litres of pure alcohol)
SA_0000001737_ARCHIVED Alcohol, regional per capita (15+) consumption (in litres of pure alcohol) (archived)
SA_0000001739 Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI
SA_0000001739_ARCHIVED Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI (archived)
SA_0000001740 Alcohol-attributable Years of Life Lost (YLL) score
SA_0000001740_ARCHIVED Alcohol-attributable Years of Life Lost (YLL) score (archived)
SA_0000001741 Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)
SA_0000001741_ARCHIVED Alcohol-attributable fractions (15+), liver cirrhosis deaths (%) (archived)
SA_0000001742 Alcohol-attributable fractions (15+), road traffic crash deaths (%)
SA_0000001742_ARCHIVED Alcohol-attributable fractions (15+), road traffic crash deaths (%) (archived)
SA_0000001743 Alcohol-attributable fractions, all-cause deaths (%)
SA_0000001743_ARCHIVED Alcohol-attributable fractions, all-cause deaths (%) (archived)
SA_0000001744 Alcohol, regional prevalence of alcohol dependence (%)
SA_0000001744_ARCHIVED Alcohol, regional prevalence of alcohol dependence (%) (archived)
SA_0000001745 Alcohol, regional prevalence of alcohol use disorders (%)
SA_0000001745_ARCHIVED Alcohol, regional prevalence of alcohol use disorders (%) (archived)
SA_0000001746 Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025
SA_0000001746_ARCHIVED Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025 (archived)
SA_0000001747_ARCHIVED Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI
SA_0000001748 Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI, 2010 ( already in archive)
SA_0000001748_ARCHIVED Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI, 2010 (archived)
SA_0000001749 Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI
SA_0000001749_ARCHIVED Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI (archived)
SA_0000001751 Alcohol, average daily intake in grams among drinkers with 95%CI
SA_0000001751_ARCHIVED Alcohol, average daily intake in grams among drinkers with 95%CI (archived)
SA_0000001752 Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016
SA_0000001752_ARCHIVED Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016 (archived)
SA_0000001753_ARCHIVED Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI
SA_0000001754 Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI
SA_0000001754_ARCHIVED Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI (archived)
SA_0000001755 15-19 years old heavy episodic drinkers (population), % with 95%CI
SA_0000001755_ARCHIVED 15-19 years old heavy episodic drinkers (population), % with 95%CI (archived)
SA_0000001756 15-19 years old heavy episodic drinkers (drinkers only), %
SA_0000001756_ARCHIVED 15-19 years old heavy episodic drinkers (drinkers only), % (archived)
SA_0000001757 15-19 years old abstainers, lifetime (%)
SA_0000001757_ARCHIVED 15-19 years old abstainers, lifetime (%) (archived)
SA_0000001758 15-19 years old former drinkers (%)
SA_0000001758_ARCHIVED 15-19 years old former drinkers (%) (archived)
SA_0000001759 15-19 years old, current drinkers (%)
SA_0000001759_ARCHIVED 15-19 years old, current drinkers (%) (archived)
SA_0000001760 15-19 years old total alcohol consumption in litres of pure alcohol
SA_0000001760_ARCHIVED 15-19 years old total alcohol consumption in litres of pure alcohol (archived)
SA_0000001761 National guidelines for the prevention and reduction of alcohol-related harm in schools
SA_0000001761_ARCHIVED National guidelines for the prevention and reduction of alcohol-related harm in schools (archived)
SA_0000001762 National guidelines for alcohol problem prevention and counselling at workplaces
SA_0000001762_ARCHIVED National guidelines for alcohol problem prevention and counselling at workplaces (archived)
SA_0000001763 Workplace representatives nationally involved to prevent and address alcohol-related harm
SA_0000001763_ARCHIVED Workplace representatives nationally involved to prevent and address alcohol-related harm (archived)
SA_0000001764 Server training
SA_0000001764_ARCHIVED Server training (archived)
SA_0000001765 Legal obligation for schools to include alcohol use prevention
SA_0000001765_ARCHIVED Legal obligation for schools to include alcohol use prevention (archived)
SA_0000001766 Legal obligation for schools to interact with parents regarding education and well-being
SA_0000001766_ARCHIVED Legal obligation for schools to interact with parents regarding education and well-being (archived)
SA_0000001767 Legislation on alcohol testing at workplaces
SA_0000001767_ARCHIVED Legislation on alcohol testing at workplaces (archived)
SA_0000001768 Standard drink defined
SA_0000001768_ARCHIVED Standard drink defined (archived)
SA_0000001769 National systems for monitoring alcohol consumption and harms
SA_0000001769_ARCHIVED National systems for monitoring alcohol consumption and harms (archived)
SA_0000001770 Regular reports from national monitoring systems
SA_0000001770_ARCHIVED Regular reports from national monitoring systems (archived)
SA_0000001771 Comprehensive and regular reporting of alcohol situation
SA_0000001771_ARCHIVED Comprehensive and regular reporting of alcohol situation (archived)
SA_0000001772 Clinical guidelines for brief interventions
SA_0000001772_ARCHIVED Clinical guidelines for brief interventions (archived)
SA_0000001773 National surveys on adult alcohol consumption
SA_0000001773_ARCHIVED National surveys on adult alcohol consumption (archived)
SA_0000001774 National surveys on youth alcohol consumption
SA_0000001774_ARCHIVED National surveys on youth alcohol consumption (archived)
SA_0000001775 National surveys on heavy espisodic drinking
SA_0000001775_ARCHIVED National surveys on heavy espisodic drinking (archived)
SA_0000001776 Data collection on Foetal Alcohol Syndome
SA_0000001776_ARCHIVED Data collection on Foetal Alcohol Syndome (archived)
SA_0000001777 Data collected on harm from alcohol at workplace
SA_0000001777_ARCHIVED Data collected on harm from alcohol at workplace (archived)
SA_0000001779 Level of enforcement of BAC limits
SA_0000001781 15-years old any alcoholic beverage consumed in past 12 months, (%)
SA_0000001781_ARCHIVED 15-years old any alcoholic beverage consumed in past 12 months, (%) (archived)
SA_0000001782 15-years old first drink at 13 years or younger, (%)
SA_0000001782_ARCHIVED 15-years old first drink at 13 years or younger, (%) (archived)
SA_0000001783 15-years old any alcoholic beverage consumed in past 30 days, (%)
SA_0000001783_ARCHIVED 15-years old any alcoholic beverage consumed in past 30 days, (%) (archived)
SA_0000001784 15-years old, any alcoholic beverage consumed at least once a week, (%)
SA_0000001784_ARCHIVED 15-years old, any alcoholic beverage consumed at least once a week, (%) (archived)
SA_0000001786 13-15-years old any alcoholic beverage consumed in past 30 days, (%)
SA_0000001786_ARCHIVED 13-15-years old any alcoholic beverage consumed in past 30 days, (%) (archived)
SA_0000001787 13-15-years old first drink before age 14, (%)
SA_0000001787_ARCHIVED 13-15-years old first drink before age 14, (%) (archived)
SA_0000001788 Alcohol-related road traffic crashes with fatalities, per 100,000 population
SA_0000001788_ARCHIVED Alcohol-related road traffic crashes with fatalities, per 100,000 population (archived)
SA_0000001789 Alcohol-related crimes (% of all crimes)
SA_0000001789_ARCHIVED Alcohol-related crimes (% of all crimes) (archived)
SA_0000001790 National drinking guidelines,2016
SA_0000001791 Graduated licensing
SA_0000001792 National legislation to prevent illegal alcohol sales
SA_0000001793 Penalties for drink driving, repeated offense
SA_0000001794 Licensing required for exports of alcoholic beverages
SA_0000001795 Licensing required for imports of alcoholic beverages
SA_0000001796 Licensing required for wholesale/distribution of alcoholic beverages
SA_0000001797 Licenses issued for production, change since 2010
SA_0000001798 Licenses issued for retail sale, change since 2010
SA_0000001799 Licenses issued for wholesale/distribution, change since 2010
SA_0000001800 Monopoly on exports of alcoholic beverages
SA_0000001801 Monopoly on imports of alcoholic beverages
SA_0000001802 Monopoly on wholesale /distribution of alcoholic beverages
SA_0000001803 Health warning labels on pregnancy
SA_0000001804 Health warning labels on under-age drinking
SA_0000001805 Health warning labels on drink-driving
SA_0000001806 Legal requirement for size of health warning labels
SA_0000001807 Cancer, age-standardized death rates (15+), per 100,000 population
SA_0000001808 Alcohol-attributable fractions (15+), cancer deaths
SA_0000001809 National system of epidemiological data collection for alcohol use
SA_0000001810 National system of data collection based on health service delivery
SA_0000001811 Report with epidemiological data on lcohol use and AUDs
SA_0000001812 Report with data from health services on alcohol use and AUDs
SA_0000001813 National organization for monitoring alcohol
SA_0000001814 Taxation of ethanol production
SA_0000001815 Ethanol tax deducted from excise tax
SA_0000001816 Tax incentives for production low/no alcohol content beer
SA_0000001817 Tax incentives for production of alcoholic beverages
SA_0000001818 Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2020 and 2025
SA_0000001819 Heavy episodic drinking (youth 15 -19 years) past 30 days (%)
SA_0000001820 Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)
SA_0000001821 Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI
SA_0000001821_ARCHIVED Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI (archived)
SA_0000001822 Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI
SA_0000001822_ARCHIVED Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI (archived)
SA_0000001823 Alcohol, tourist consumption (in litres of pure alcohol) (three-year average)
SA_0000001823_ARCHIVED Alcohol, tourist consumption (in litres of pure alcohol) (three-year average) (archived)
SA_0000001824 Alcohol, regional alcohol per capita (15+) consumption (in litres of pure alcohol)
SA_0000001825 Regional prevalence, AAFs (15+), liver cirrhosis deaths (%)
SA_0000001826 Regional prevalence, AAFs (15+), road traffic crash deaths (%)
SA_0000001827 Regional prevalence, AAFs (15+), cancer
SA_0000001828 Regional prevalence, AAFs ,all-cause deaths (%)
SA_0000001829 Average price 500 mls Beer in US$
SA_0000001830 Average price 750 mls Wine in US$
SA_0000001831 Average price 500 mls Spirits in US$
SA_0000001832 Alcohol-attributable all-cause deaths per 100,000, age standardized
SA_0000001833 Alcohol-attributable DALYs per 100,000 people (age standardized)
SA_0000001834 Percent of all DALYs attributable to alcohol
SA_0000001835 Alcohol-related road traffic deaths, per 100,000 population
SA_0000001836 Alcohol-related road traffic deaths (% of all road traffic deaths)
SA_0000001837 Alcohol poisoning deaths, per 100,000 population
SA_0000001838 Alcohol-related cardiomyopathy deaths (% of all cardiomyopathy deaths)
sba Births attended by skilled health personnel (in the two or three years preceding the survey) (%)
sba5 Births attended by skilled health personnel (in the five years preceding the survey) (%)
SDG_SH_DTH_RNCOM Number of deaths attributed to non-communicable diseases, by type of disease and sex
SDG_SH_STA_SCIDEN Number of suicide deaths
SDGAIRBOD Ambient and household air pollution attributable death rate (per 100 000 population)
SDGAIRBODA Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)
SDGCODCOMPLETENESS Completeness of cause-of-death data (%)
SDGCONFLICT Estimated direct deaths from major conflicts (per 100 000 population)
SDGDISASTER Average death rate due to natural disasters (per 100 000 population)
SDGFPALL Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%)
SDGHEALTHFACILITIESESSENTIALMEDS Proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis
SDGHEPHBSAGPRV Hepatitis B surface antigen (HBsAg) prevalence
SDGHIV New HIV infections (per 1000 uninfected population)
SDGHIV1524 New HIV infections among adults 15-24 years old (per 1000 uninfected population)
SDGHPVRECEIVED HPV immunization coverage estimates among primary target cohort (9-14 years old girls) (%)
SDGIHR Average of 13 International Health Regulations core capacity scores, 1st version of the questionnaire
SDGIHR2018 Average of 13 International Health Regulations core capacity scores, SPAR version, 1st edition
SDGIHR2021 Average of 15 International Health Regulations core capacity scores, SPAR version, 2nd edition
SDGIPV Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months
SDGIPV12M Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months
SDGIPVLT Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in their lifetime
SDGMALARIA Malaria incidence (per 1 000 population at risk)
SDGNTDTREATMENT Reported number of people requiring interventions against NTDs
SDGODA Total net official development assistance to medical research and basic health sectors per capita (constant 2014 US\(), by recipient | |SDGODA01 |Total net official development assistance to medical research and basic health sectors per capita (US\)), by recipient country
SDGODA02 Official development assistance for medical research and basic health sectors as a percentage of GNI (%), by donor country
SDGODAWS Amount of water- and sanitation-related official development assistance that is part of a government-coordinated spending plan (current US$ millions)
SDGOOP Out-of-pocket expenditure as a percentage of total expenditure on health (see GHED_OOPSCHE_SHA2011) (void SDGOOP)
SDGPM25 Concentrations of fine particulate matter (PM2.5)
SDGPOISON Mortality rate attributed to unintentional poisoning (per 100 000 population)
SDGROADAGE Age-standardized road traffic mortality (per 100 000 population)
SDGSHP Skilled health professionals density (per 10 000 population)
SDGSUICIDE Crude suicide rates (per 100 000 population)
SDGTOBACCO Prevalence of current tobacco use among persons aged 15 years and older (age-standardized rate)
SDGWSHBOD Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)
SE_DEV_ONTRK Children aged 36-59 months who are developmentally on track in at least three of the following domains: literacy-numeracy, physical development, social-emotional development and learning (%)
SE_G23_MATH Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%)
SE_G23_RDG Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%)
SE_LSC_MATH Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%)
SE_LSC_RDNG Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%)
SE_PRE_PARTN Participation rate in organized learning (one year before the official primary entry age) (%)
SE_PRM_MATH Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%)
SE_PRM_PRSL_ZS Persistence to last grade of primary (% of cohort)
SE_PRM_RDNG Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%)
sevwast5 Severe wasting prevalence in children aged < 5 years (%)
SG_DMK_SRCR_FN_ZS Proportion of women aged 15-49 years who make their own informed decisions regarding sexual relations, contraceptive use and reproductive health care (%)
SG_REG_BRTH Proportion of children under 5 years of age whose births have been registered with a civil authority
SG_REG_CENSUS Proportion of countries that have conducted at least one population and housing census in the last 10 years (%)
SG_REG_CENSUSN Number of countries that have conducted at least one population and housing census in the last 10 years
SH_STA_FGMS Proportion of girls and women aged 15-49 years who have undergone female genital mutilation/cutting (FMG/C) (%)
SHS_1 Percentage of children under 15 years exposed to second-hand smoke
SHS_10 Second-hand smoke attributable DALYs (’000) in children under 5 years
SHS_11 Second-hand smoke attributable DALYs per 100’000 children under 5 years
SHS_2 Percentage of women (15+ years) exposed to second-hand smoke
SHS_3 Percentage of men (15+ years) exposed to second-hand smoke
SHS_4 Second-hand smoke attributable deaths
SHS_5 Second-hand smoke attributable DALYs (’000)
SHS_6 Second-hand smoke attributable deaths per 100’000 capita
SHS_7 Second-hand smoke attributable DALYs per 100’000 capita
SHS_8 Second-hand smoke attributable deaths (’000) in children under 5 years
SHS_9 Second-hand smoke attributable deaths per 100’000 children under 5 years
SI_POV_DAY1 Proportion of population below the international poverty line of US$1.90 per day (%)
SI_POV_EMP1 Employed population below the international poverty line of US\(1.90 per day (the working poor) (%) | |SP_DYN_MRBF15 |Proportion of women aged 20-24 years who were married or in a union by age 15 (%) | |SP_DYN_MRBF18 |Proportion of women aged 20-24 years who were married or in a union by age 18 (%) | |SRH_ABORTION_RATE |Abortion rate (model-estimated) | |SRH_PREGNANCY_UNINTENDED_RATE |Unintended pregnancy rate (model-estimated) | |SRHINSTITUTIONALBIRTH |Institutional Births (birth taken place in a facility) (%) | |STI_CHLAMYDIA_INCIDENCE_PER1000 |Incident cases of chlamydia in individuals (per 1000) | |STI_CHLAMYDIA_INCIDENTCASES |Incident cases of chlamydia in individuals (in millions) | |STI_CHLAMYDIA_PREVALENCE_PER100 |Prevalence of chlamydia in individuals (%) | |STI_CHLAMYDIA_PREVALENTCASES |Prevalent cases of chlamydia in individuals (in millions) | |STI_GONORRHOEA_INCIDENCE_PER1000 |Incident cases of gonorrhoea in individuals (per 1000) | |STI_GONORRHOEA_INCIDENTCASES |Incident cases of gonorrhoea in individuals (in millions) | |STI_GONORRHOEA_PREVALENCE_PER100 |Prevalence of gonorrhoea in individuals (%) | |STI_GONORRHOEA_PREVALENTCASES |Prevalent cases of gonorrhoea in individuals (in millions) | |STI_SYPHILIS_INCIDENCE_PER1000 |Incident rate of active syphilis (per 1000) | |STI_SYPHILIS_INCIDENTCASES |Incident cases of syphilis in individuals (in millions) | |STI_SYPHILIS_PREVALENCE_PER100 |Prevalence of active syphilis in individuals (%) | |STI_SYPHILIS_PREVALENTCASES |Prevalent cases of active syphilis (in millions) | |STI_TRICHOMONIASIS_INCIDENCE_PER1000 |Incident cases of trichomoniasis in individuals (per 1000) | |STI_TRICHOMONIASIS_INCIDENTCASES |Incident cases of trichomoniasis in individuals (in millions) | |STI_TRICHOMONIASIS_PREVALENCE_PER100 |Prevalence of trichomoniasis in individuals (%) | |STI_TRICHOMONIASIS_PREVALENTCASES |Prevalent cases of trichomoniasis in individuals (in millions) | |stunt3 |Stunting prevalence in children aged < 3 years (%) (Health inequality monitor) | |stunt5 |Stunting prevalence in children aged < 5 years (%) (Health inequality monitor) | |SUNBEDEXIST |Existence of national regulation | |SUNBEDEXISTSUBNATIONAL |Existence of subnational regulation | |SUNBEDEXISTYEAR |Year of national implementation of regulation | |SUNBEDREG_ACCESS |Access restrictions | |SUNBEDREG_CONTROL |Restriction and inspection of facilities | |SUNBEDREG_INFO |Information requirements | |SUNBEDREG_SAFETY |Safety requirements | |SUNBEDREG_TRAINING |Training requirements | |TAXBEV_ABV |Alcohol content in beverage in percent of volume, (alcohol by volume) (ABV %) | |TAXBEV_ADVALOREMBASE |Base for ad valorem excise tax on beverage | |TAXBEV_ALCOHOLBASEDTIERED |If tiered on the beverage, the tiers are alcohol-based | |TAXBEV_ALCOHOLSALESTATUS |Status of alcohol sale | |TAXBEV_EARMARKEDEXCISETAX |Use of earmarked excise tax on beverages | |TAXBEV_EXCISE |Excise taxes on beverages (%) | |TAXBEV_EXCISE_APPLIED_YN |Excise taxes are applied on beverages | |TAXBEV_EXCISE_AUTOADJUST |Automatic adjustment of specific excise on beverage | |TAXBEV_EXCISE_TYPE |Type of excise tax applied on beverage | |TAXBEV_EXCISE_UNIFORMTIERED_ALCOHOLIC |Uniform or tiered excise tax system applied on alcoholic beverage | |TAXBEV_EXCISE_UNIFORMTIERED_NONALCOHOLIC |Uniform or tiered excise tax system applied on non-alcoholic beverage | |TAXBEV_IMPORTDUTIES |Import duties on beverages (%) | |TAXBEV_MOSTSOLDSPIRIT |Most sold type of spirit | |TAXBEV_OTHERTAXES |Other taxes on beverages (%) | |TAXBEV_PRICE |Beverage price | |TAXBEV_SUGARBASEDTIERED |If tiered on the beverage, the tiers are sugar-content-based | |TAXBEV_SUGARCONTENT |Sugar-content of beverage per 100ml | |TAXBEV_TOTALTAXES |Total taxes on beverages (%) | |TAXBEV_VATSALES |Value-added/sales tax on beverages (%) | |TB_1 |Tuberculosis treatment coverage | |TB_c_dst_rlt_new_pct |New cases tested for RR-/MDR-TB (%) | |TB_c_dst_rlt_ret_pct |Previously treated cases tested for RR-/MDR-TB (%) | |TB_c_lab_cul_5m |Laboratories providing tuberculosis diagnostic services using culture (per 5 million population) | |TB_c_lab_dst_5m |Laboratories providing drug susceptibility testing (DST) (per 5 million population) | |TB_c_lab_sm_100k |Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population) | |TB_c_mdr_tsr |Treatment success rate for patients treated for MDR-TB (%) | |TB_c_mdr_tx |Cases started on MDR-TB treatment | |TB_c_new_snep_tsr |Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases | |TB_c_new_tsr |Treatment success rate: new TB cases | |TB_c_newinc |Tuberculosis - new and relapse cases | |TB_c_notified |Total number of notified TB cases | |TB_c_ret_tsr |Treatment success rate: previously treated TB cases | |TB_c_tbhiv_tsr |Treatment success rate: HIV-positive TB cases | |TB_c_xdr_tsr |Treatment success rate: XDR-TB cases | |TB_cc_prct |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB. | |TB_cc_prct_DRTB |Percentage of TB-affected households facing costs >20% of household income or expenditure due to DR-TB. | |TB_cc_prct_DSTB |Percentage of TB-affected households facing costs >20% of household income or expenditure due to DS-TB. | |TB_cc_prct_Q1 |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB among Q1 (lowest) income or expenditure quantile. | |TB_cc_prct_Q2 |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB among Q2 income or expenditure quantile. | |TB_cc_prct_Q3 |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB among Q3 income or expenditure quantile. | |TB_cc_prct_Q4 |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB among Q4 income or expenditure quantile. | |TB_cc_prct_Q5 |Percentage of TB-affected households facing costs >20% of household income or expenditure due to TB among Q5 (highest) income or expenditure quantile. | |TB_conf_mdr_tx_pct |Confirmed cases of MDR-TB started treatment for MDR-TB (%) | |TB_drs_rr_prct |Prevalence of rifampicin resistance among pulmonary TB cases. | |TB_e_inc_num |Number of incident tuberculosis cases | |TB_e_inc_num_014 |Number of incident tuberculosis cases in children aged 0 - 14 | |TB_e_inc_rr_num |Estimated number of MDR/RR-TB incident cases | |TB_e_inc_tbhiv_100k |Incidence of tuberculosis (per 100 000 population) (HIV-positive cases) | |TB_e_inc_tbhiv_num |Number of incident tuberculosis cases, (HIV-positive cases) | |TB_e_mdr_num |Estimated MDR-TB cases among notified pulmonary TB cases | |TB_e_mort_exc_tbhiv_num |Number of deaths due to tuberculosis, excluding HIV | |TB_e_prev_num |Number of prevalent tuberculosis cases | |TB_effective_treatment_coverage |Tuberculosis effective treatment coverage (%) | |TB_hiv_art_pct |HIV-positive TB patients on ART (antiretroviral therapy) (%) | |TB_hiv_cpt_pct |HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%) | |TB_hivtest_pct |TB patients with known HIV status (%) | |TB_hivtest_pos_pct |Tested TB patients HIV-positive (%) | |TB_mdr |Confirmed cases of MDR-TB | |TB_new_clindx |New or unknown treatment history cases: Pulmonary, clinically diagnosed | |TB_new_ep |New cases: extrapulmonary | |TB_new_labconf |New or unknown treatment history cases: Pulmonary, bacteriologically confirmed | |TB_new_oth |New cases: other | |TB_new_sn |New cases: pulmonary smear-negative | |TB_new_snsuoth |New cases: Pulmonary, smear-negative/unknown/not done and other new cases | |TB_new_snuoth |TB_new_snuoth | |TB_new_sp |New cases: Pulmonary, smear-positive | |TB_new_su |New cases: pulmonary smear unknown/not done | |TB_newret_oth |Treatment history unknown | |TB_notif_num |Number of people notified with new episode of TB in a given year | |TB_notif_num_agesex |Number of people diagnosed with new episode TB who by age group and sex. | |TB_notif_num_labconf |Number of people diagnosed with new episode of pulmonary TB who are bacteriologically confirmed. | |TB_notif_num_newrel_clindx |Number of people diagnosed with new episode of pulmonary TB who are clinically diagnosed. | |TB_notif_num_newrel_ep |Number of people diagnosed with new episode of pulmonary TB who have extrapulmonary TB. | |TB_Notification_agesex_num |The number of new and relapse cases of tuberculosis detected in a given year by age and sex | |TB_ps_prev_bc_100k |Prevalence of bacteriologically-confirmed pulmonary TB among those aged ≥15 years, per 100,000 population | |TB_ps_prev_bc_100k_byagegroup |Prevalence of bacteriologically-confirmed pulmonary TB among those aged ≥15 years, per 100,000 population by age group | |TB_ps_prev_bc_100k_byagegroup_sp |Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive among those aged ≥15 years, per 100,000 population by age group | |TB_ps_prev_bc_100k_bysex |Prevalence of bacteriologically-confirmed pulmonary TB among those aged ≥15 years, per 100,000 population by sex. | |TB_ps_prev_bc_100k_bysex_sp |Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive among those aged ≥15 years, per 100,000 population by sex. | |TB_ps_prev_bc_100k_sp |Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive among those aged ≥15 years, per 100,000 population | |TB_rdst_num |The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients. | |TB_rdst_num_prct |The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage. | |TB_ret_nrel |Previously treated cases, excluding relapse | |TB_ret_oth |Retreatment cases: other | |TB_ret_rel |Relapse cases (pre-2013 definition) | |TB_ret_rel_clindx |Relapse cases: Pulmonary, clinically diagnosed | |TB_ret_rel_ep |Relapse cases: extrapulmonary | |TB_ret_rel_labconf |Relapse cases: Pulmonary, bacteriologically confirmed | |TB_ret_tad |Retreatment cases: treatment after default (pulmonary smear and/or culture positive) | |TB_ret_taf |Retreatment cases: treatment after failure (pulmonary smear and/or culture positive) | |TB_rr_mdr |Confirmed cases of RR-/MDR-TB | |TB_sb |Standards and benchmarks for TB and vital registration system surveillance | |TB_sldst_avail |Second-line drug susceptibility testing (DST) available | |TB_tot_newrel |Tuberculosis - new and relapse cases (TB_c_newinc) | |TB_treatment_coverage |xxx | |tfr |Total fertility rate (births per woman) | |TOB_R_PRICE |Retail price for tobacco and other nicotine products | |TOBACCO_0000000192 |Prevalence of smoking any tobacco product among persons aged >= 15 years | |TOBACCO_0000000209 |Fines for violations | |TOBACCO_0000000210 |Fines on the establishment | |TOBACCO_0000000211 |Fines on the patron | |TOBACCO_0000000212 |Dedicated funds for enforcement | |TOBACCO_0000000213 |Citizen complaints and investigations | |TOBACCO_0000000342 |Daily users of any smokeless tobacco product (crude rate) | |TOBACCO_0000000344 |Prevalence of current tobacco use among adolescents aged 13-15 years | |TOBACCO_0000000345 |Current smokers of cigarettes (youth rate) | |TOBACCO_0000000346 |Exposure to smoke at home | |TOBACCO_0000000347 |Exposure to smoke outside home | |TOBACCO_0000000361 |Access to a toll-free quit line (please see O_Quitline) | |TOBACCO_0000000362 |Smoking cessation support is available in hospitals (see O_Avail_hosp) | |TOBACCO_0000000363 |Smoking cessation support is available in health clinics or other primary care facilities (see O_Avail_hlth_clin) | |TOBACCO_0000000364 |Smoking cessation support is available in offices of health professionals (see O_Avail_off_hlth_prof) | |TOBACCO_0000000365 |Smoking cessation support is available in the community (see O_Avail_community) | |TOBACCO_0000000366 |Smoking cessation support is available in other settings (see O_Avail_other) | |TOBACCO_0000000367 |Nicotine replacement therapy - legally sold (see O_NRT_sold) | |TOBACCO_0000000368 |Nicotine replacement therapy - place available (see O_NRT_where) | |TOBACCO_0000000369 |Bupropion - legally sold (see O_Bup_sold) | |TOBACCO_0000000370 |Bupropion - place available (see O_Bup_where) | |TOBACCO_0000000371 |Varenicline - legally sold (see O_Varen_sold) | |TOBACCO_0000000372 |Varenicline - place available (see O_Varen_where) | |TOBACCO_0000000386 |Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging (see W2_pc_front_back_B) | |TOBACCO_0000000387 |Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging (see W3_pc_front_B) | |TOBACCO_0000000388 |Specific health warnings are mandated for other smoked tobacco packaging (see W15_specific_hw_B) | |TOBACCO_0000000389 |Number of health warnings approved by the law for other smoked tobacco packaging (see W16_number_hw_B) | |TOBACCO_0000000390 |Health warnings on other smoked tobacco packaging must be rotated (see W7_rotation_B) | |TOBACCO_0000000391 |Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging (see W4_pc_back_B) | |TOBACCO_0000000392 |Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale (see W11_outside_pack_B) | |TOBACCO_0000000393 |Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health (see W14_harm_effects_B) | |TOBACCO_0000000394 |Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging (see W6_font_B) | |TOBACCO_0000000395 |Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country (see W8_princ_langs_B) | |TOBACCO_0000000396 |Health warnings on other smoked tobacco packaging must include a photograph or graphic (see W10_graphic_B) | |TOBACCO_0000000505 |Year of survey of youth (M_svy_yr_youth) | |TOBACCO_0000000506 |Representativeness of youth survey (see M_svy_national_youth) | |TOBACCO_0000000507 |Repeating interval for survey of youth (years) | |TOTENV_1 |Deaths attributable to the environment | |TOTENV_10 |Total environment attributable DALYs per 100'000 children under 5 years | |TOTENV_11 |Deaths attributable to the environment in children under 5 years (%) | |TOTENV_12 |DALYs attributable to the environment in children under 5 years (%) | |TOTENV_2 |Age-standardized deaths attributable to the environment (per 100 000 population) | |TOTENV_3 |Disability-adjusted life years (DALYs) attributable to the environment | |TOTENV_4 |Age-standardized DALYs attributable to the environment (per 100 000 population) | |TOTENV_5 |Deaths attributable to the environment (%) | |TOTENV_6 |Disability-adjusted life years (DALYs) attributable to the environment (%) | |TOTENV_7 |Total environment attributable deaths ('000) in children under 5 years | |TOTENV_70 |Total environment attributable deaths in children under 5 years | |TOTENV_8 |Total environment attributable deaths per 100'000 children under 5 years | |TOTENV_9 |Total environment attributable DALYs ('000) in children under 5 years | |TOTENV_90 |Total environment attributable DALYs in children under 5 years | |u5mr |Under-five mortality rate (deaths per 1000 live births) | |UHC_AVAILABILITY_SCORE |Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%) | |UHC_DATA_AVAIL_CODE |Data availability for UHC index of service coverage (ranking) | |UHC_HRHSURGEONDENSITY |Surgeons (per 100 000) | |UHC_IHR |Compliance with international health regulations | |UHC_INDEX_ACTUAL |Index of Service Coverage (Actual) | |UHC_INDEX_REPORTED |UHC Service Coverage Index (SDG 3.8.1) | |UHC_NCD_FPG |Mean fasting plasma glucose | |UHC_NCD_NONELEVBP |Prevalence of non-elevated blood pressure (%) | |UHC_SCI_CAPACITY |UHC Service Coverage sub-index on service capacity and access | |UHC_SCI_INFECT |UHC Service Coverage sub-index on infectious diseases | |UHC_SCI_NCD |UHC Service Coverage sub-index on noncommunicable diseases | |UHC_SCI_RMNCH |UHC Service Coverage sub-index on reproductive, maternal, newborn and child health | |UHC_TB_DT |Tuberculosis detection and treatment | |UHC_TOBACCONO |Prevalence of non-use of tobacco | |UHCTRANSFATS |Best-practice policy implemented for industrially produced trans-fatty acids (TFA) (Y/N) | |UNICEF_ORS |Children aged <5 years with diarrhoea receiving ORS (%) | |UNICEF_PNCMOTHER |Women age 15-49 years who received a health check within 2 days after delivery of their most recent live birth in the last 2 years (%) | |UNICEF_PNCNEWBORN |Proportion of newborns who have postnatal contact with a health provider within 2 days of delivery (%) | |UV_1 |UV radiation | |UV_2 |UV radiation attributable deaths | |UV_3 |UV radiation attributable DALYs ('000) | |UV_4 |UV radiation attributable deaths per 100'000 capita | |UV_5 |UV radiation attributable DALYs per 100'000 capita | |uweight3 |xxxxx for deletion: (child underweight, see uwgt5) | |uweight5 |xxxxx for deletion: (child underweight, see uwgt5) | |uwgt5 |Underweight prevalence in children aged < 5 years (%) (Health inequality monitor) | |VACCINEPREVENTABLE_WILDPOLIO |Number of reported cases of poliomyelitis by wild poliovirus (WPV) | |vbcg |BCG immunization coverage among one-year-olds (%) | |vdpt |DTP3 immunization coverage among one-year-olds (%) | |vfull |Full immunization coverage among one-year-olds (%) | |VIOLENCE_BULLIED |Bullied, past 30 days (%) | |VIOLENCE_CHILD_EMOTIONAL |Lifetime prevalence of child emotional abuse (%) | |VIOLENCE_CHILD_NEGLECT |Lifetime prevalence of child physical neglect (%) | |VIOLENCE_CHILD_PHYSICAL |Lifetime prevalence of child physical abuse (%) | |VIOLENCE_CHILD_SEXUAL |Lifetime prevalence of child sexual abuse (%) | |VIOLENCE_EXTENTIMP_ALLTYPES |Extent of implementation of mental health services for victims of all types of violence | |VIOLENCE_EXTENTIMP_CHILDHOMEVISIT |Child maltreatment: Extent of implementation of home-visiting programmes | |VIOLENCE_EXTENTIMP_CHILDPROTECTION |Extent of implementation of child protection services | |VIOLENCE_EXTENTIMP_ELDERCAREGIVER |Elder abuse: Extent of implementation of caregiver-support programmes | |VIOLENCE_EXTENTIMP_PARTNERVIOLPREVENTION |Intimate partner violence: Extent of implementation of dating violence prevention programmes | |VIOLENCE_EXTENTIMP_VICTIMSMEDICOLEGAL |Extent of implementation of medico-legal services for victims of sexual violence | |VIOLENCE_EXTENTIMP_YOUTHLIFESKILLS |Youth violence: Extent of implementation of life-skills and social development programmes | |VIOLENCE_HOMICIDENUM |Estimates of number of homicides | |VIOLENCE_HOMICIDERATE |Estimates of rates of homicides per 100 000 population | |VIOLENCE_PHYSICAL_FIGHTING |Physical fighting, past 12 months (%) | |vita |Children aged 6-59 months who received vitamin A supplementation (%) | |vmsl |Measles immunization coverage among one-year-olds (%) | |vpolio |Polio immunization coverage among one-year-olds (%) | |vzdpt |One-year-old children who have not received any doses of the DTP vaccine (%) | |W_Group |Warn about the dangers of tobacco | |W1_HW_law_A |Law mandates that health warnings appear on cigarette packages | |W1_HW_law_B |Law mandates that health warnings appear on other smoked tobacco packages | |W1_HW_law_C |Law mandates that health warnings appear on smokeless tobacco packages | |W10_graphic_A |Health warnings on cigarette packaging must include a photograph or graphic | |W10_graphic_B |Health warnings on other smoked tobacco packaging must include a photograph or graphic | |W10_graphic_C |Health warnings on smokeless tobacco packaging must include a photograph or graphic | |W11_outside_pack_A |Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale | |W11_outside_pack_B |Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale | |W11_outside_pack_C |Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale | |W12_imports_dutyfree_A |Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale | |W12_imports_dutyfree_B |Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale | |W12_imports_dutyfree_C |Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale | |W13_ind_liability_A |Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry | |W13_ind_liability_B |Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry | |W13_ind_liability_C |Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry | |W14_harm_effects_A |Health warnings on cigarette packaging describe the harmful effects of tobacco use on health | |W14_harm_effects_B |Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health | |W14_harm_effects_C |Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health | |W15_specific_hw_A |Specific health warnings are mandated for cigarette packaging | |W15_specific_hw_B |Specific health warnings are mandated for other smoked tobacco packaging | |W15_specific_hw_C |Specific health warnings are mandated for smokeless tobacco packaging | |W16_number_hw_A |Number of health warnings approved by the law for cigarette packaging | |W16_number_hw_B |Number of health warnings approved by the law for other smoked tobacco packaging | |W16_number_hw_C |Number of health warnings approved by the law for smokeless tobacco packaging | |W17_fines_A |Health warnings on cigarette packaging law requires or establishes fines for violations | |W17_fines_B |Health warnings on other smoked tobacco packaging law requires or establishes fines for violations | |W17_fines_C |Health warnings on smokeless tobacco packaging law requires or establishes fines for violations | |W18_misleading_terms_A |Ban on deceitful terms on cigarette packaging | |W18_misleading_terms_B |Ban on deceitful terms on other smoked tobacco packaging | |W18_misleading_terms_C |Ban on deceitful terms on smokeless tobacco packaging | |W19_colours_numbers_A |Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | |W19_colours_numbers_B |Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | |W19_colours_numbers_C |Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | |W2_pc_front_back_A |Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging | |W2_pc_front_back_B |Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging | |W2_pc_front_back_C |Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging | |W20_flavours_A |Cigarette packaging and labelling must not use descriptors depicting flavours | |W20_flavours_B |Other smoked tobacco packaging and labelling must not use descriptors depicting flavours | |W20_flavours_C |Smokeless tobacco packaging and labelling must not use descriptors depicting flavours | |W21_emissions_A |Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark (see W21_emissions_quant_A) | |W21_emissions_B |Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) (see W21_emissions_quant_B) | |W21_emissions_quant_A |Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | |W21_emissions_quant_B |Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | |W21_emissions_quant_C |Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | |W22_emissions_qual_A |Cigarette packaging and labelling must display qualitative information on emission yields | |W22_emissions_qual_B |Other smoked tobacco packaging and labelling must display qualitative information on emission yields | |W22_emissions_qual_C |Smokeless tobacco packaging and labelling must display qualitative information on emission yields | |W23_emissions_front_back_A |Qualitative information on emission yields must be displayed on one or more principle display areas of cigarette packaging | |W23_emissions_front_back_B |Qualitative information on emission yields must be displayed on one or more principle display areas of other smoked tobacco packaging | |W23_emissions_front_back_C |Qualitative information on emission yields must be displayed on one or more principle display areas of smokeless tobacco packaging | |W24_exp_date_A |Display of expiry dates is prevented on cigarette packaging | |W24_exp_date_B |Display of expiry dates is prevented on other smoked tobacco packaging | |W24_exp_date_C |Display of expiry dates is prevented on smokeless tobacco packaging | |W25_quitline_number_A |The quit line number must appear on cigarette packaging or labelling | |W25_quitline_number_B |The quit line number must appear on other smoked tobacco packaging or labelling | |W25_quitline_number_C |The quit line number must appear on smokeless tobacco packaging or labelling | |W26_plain_packaging_A |Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) | |W26_plain_packaging_B |Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) | |W26_plain_packaging_C |Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) | |W26_plainSPACEpackaging_A |Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | |W27_smokeless_prod_ban |Ban on sale of smokeless tobacco products | |W3_pc_front_A |Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging | |W3_pc_front_B |Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging | |W3_pc_front_C |Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging | |W4_pc_back_A |Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging | |W4_pc_back_B |Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging | |W4_pc_back_C |Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging | |W5_top_side_A |Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package | |W5_top_side_B |Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package | |W5_top_side_C |Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package | |W6_font_A |Font style, font size and colour of health warnings are mandated for cigarette packaging | |W6_font_B |Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging | |W6_font_C |Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging | |W7_rotation_A |Health warnings on cigarette packaging must be rotated | |W7_rotation_B |Health warnings on other smoked tobacco packaging must be rotated | |W7_rotation_C |Health warnings on smokeless tobacco packaging must be rotated | |W8_princ_langs_A |Health warnings on cigarette packaging must be written in the principal language(s) of the country | |W8_princ_langs_B |Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country | |W8_princ_langs_C |Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country | |W9_no_obscure_A |Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps | |W9_no_obscure_B |Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps | |W9_no_obscure_C |Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps | |wast3 |xxxxx for deletion (child wasting, see wast5) | |wast5 |Wasting prevalence in children aged < 5 years (%) (Health inequality monitor) | |WHOSIS_000001 |Life expectancy at birth (years) | |WHOSIS_000002 |Healthy life expectancy (HALE) at birth (years) | |WHOSIS_000003 |Neonatal mortality rate (0 to 27 days) per 1000 live births) (SDG 3.2.2) | |WHOSIS_000004 |Adult mortality rate (probability of dying between 15 and 60 years per 1000 population) | |WHOSIS_000005 |Low-birth-weight newborns (%) | |WHOSIS_000006 |Infants exclusively breastfed for the first six months of life (%) | |WHOSIS_000007 |Healthy life expectancy (HALE) at age 60 (years) | |WHOSIS_000008 |xxxxx for deletion: (child underweight, see NUTUNDERWEIGHTPREV) | |WHOSIS_000009 |Children aged <5 years overweight (%) | |WHOSIS_000010 |Adults aged &#8805; 20 years who are obese (%) | |WHOSIS_000012 |Prevalence of smoking any tobacco product among adults (&#8805;15 years) (%) | |WHOSIS_000013 |Prevalence of current tobacco use among adolescents (13-15 years) (%) | |WHOSIS_000014 |Stillbirth rate (per 1000 total births) | |WHOSIS_000015 |Life expectancy at age 60 (years) | |WHOSIS_000016 |Mortality rate among children ages 5 to 9 years (per 1000 children aged 5) | |WHS_PBR |Preterm birth rate (per 100 live births) | |WHS10_1 |Most recent census (year) | |WHS10_10 |International Statistical Classification of Diseases and Related Health Problems (ICD) | |WHS10_2 |Number of cause-of-death registration years available | |WHS10_3 |Number of national population surveys - child anthropometry | |WHS10_4 |Number of national population surveys - child mortality | |WHS10_5 |Number of national population surveys - maternal mortality | |WHS10_6 |Number of national population surveys - HIV prevalence | |WHS10_7 |Number of national population surveys - adult health | |WHS10_8 |Civil registration coverage of cause-of-death (%) | |WHS10_9 |Ill-defined causes in cause-of-death registration (%) | |WHS2_126 |Distribution of years of life lost by major cause group | |WHS2_131 |Age-standardized NCD mortality rate (per 100 000 population) | |WHS2_138 |Deaths due to HIV/AIDS (per 100 000 population) | |WHS2_152 |Deaths due to malaria (per 100 000 population) (see MALARIA_EST_MORTALITY) ( void WHS2_152) | |WHS2_160 |Age-standardized mortality rate by cause (per 100 000 population) - Cancer | |WHS2_161 |Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular | |WHS2_164 |Distribution of causes of death among children aged <5 years (%) - Malaria | |WHS2_165 |Distribution of causes of death among children aged <5 years (%) - Pneumonia | |WHS2_166 |Distribution of causes of death among children aged <5 years (%) - Injuries | |WHS2_167 |Distribution of causes of death among children aged <5 years (%) - Diarrhoea | |WHS2_168 |Distribution of causes of death among children aged <5 years (%) - Measles | |WHS2_170 |Distribution of causes of death among children aged <5 years (%) - HIV/AIDS | |WHS2_171 |Distribution of causes of death among children aged <5 years (%) - Other diseases | |WHS2_174 |Distribution of years of life lost by broader causes (%) - Injuries | |WHS2_514 |Distribution of causes of death among children aged <5 years (%) - Prematurity | |WHS2_515 |Distribution of causes of death among children aged <5 years (%) - Neonatal sepsis | |WHS2_516 |Distribution of causes of death among children aged <5 years (%) - Congenital anomalies | |WHS2_523 |Distribution of causes of death among children aged <5 years (%) - Birth asphyxia | |WHS3_40 |Cholera - number of reported cases | |WHS3_41 |Diphtheria - number of reported cases | |WHS3_42 |Japanese encephalitis - number of reported cases | |WHS3_43 |Pertussis - number of reported cases | |WHS3_45 |Number of new leprosy cases | |WHS3_46 |Total tetanus - number of reported cases | |WHS3_47 |Meningitis - number of reported cases | |WHS3_48 |Malaria - number of reported confirmed cases | |WHS3_49 |Poliomyelitis - number of reported cases | |WHS3_50 |Yellow fever - number of reported cases | |WHS3_51 |H5N1 influenza - number of reported cases | |WHS3_52 |Plague - number of reported cases | |WHS3_522 |Number of reported cases of tuberculosis | |WHS3_53 |Mumps - number of reported cases | |WHS3_54 |Number of reported cases of tuberculosis (DOTS) | |WHS3_55 |Congenital Rubella Syndrome - number of reported cases | |WHS3_56 |Neonatal tetanus - number of reported cases | |WHS3_57 |Total rubella - number of reported cases | |WHS3_62 |Measles - number of reported cases | |WHS4_100 |Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) | |WHS4_106 |Care-seeking for children with symptoms of acute respiratory infection (%) | |WHS4_107 |Children aged <5 years with diarrhoea receiving ORT (%) | |WHS4_108 |Children aged <5 years with ARI symptoms who took antibiotic treatment (%) | |WHS4_111 |Antenatal care coverage - at least one visit (%) | |WHS4_111_AGE1519 |Antenatal care coverage - at least one visit, among girls aged 15-19 (%) | |WHS4_115 |Births by caesarean section (%) | |WHS4_117 |Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) | |WHS4_124 |Children aged 6-59 months who received vitamin A supplementation (%) , 2015 | |WHS4_128 |Neonates protected at birth against neonatal tetanus (PAB) (%) | |WHS4_129 |Hib (Hib3) immunization coverage among 1-year-olds (%) | |WHS4_154 |Antenatal care coverage - at least four visits (%) | |WHS4_543 |BCG immunization coverage among 1-year-olds (%) | |WHS4_544 |Polio (Pol3) immunization coverage among 1-year-olds (%) | |WHS4_99 |Antiretroviral therapy coverage among HIV-infected pregnant women for PMTCT (%) | |WHS5_512 |Population using solid fuels (%) | |WHS6_100 |Radiotherapy units (per 1 000 000 population) | |WHS6_101 |Median availability of selected generic medicines (%) - Private | |WHS6_102 |Hospital beds (per 10 000 population) | |WHS6_116 |Median consumer price ratio of selected generic medicines - Private | |WHS6_123 |Number of dentistry personnel (see HWF_0011) (void WHS6_123) | |WHS6_127 |Number of nursing and midwifery personnel (see HWF_0007) (void WHS6) | |WHS6_140 |Number of community health workers, 2010 | |WHS6_144 |Dentistry personnel density (per 10 000 population) | |WHS6_148 |Nursing and midwifery personnel density (per 10 000 population) | |WHS6_150 |Community health workers density (per 10 000 population) | |WHS6_517 |Number of pharmaceutical personnel (see HWF_0015) (void WHS6) | |WHS6_518 |Number of environment and public health workers (see HWF_0017) (void WHS6) | |WHS6_519 |Density of pharmaceutical personnel (per 10 000 population) | |WHS6_520 |Density of environment and public health workers (per 10 000 population) | |WHS7_103 |Private prepaid plans as a percentage of private expenditure on health | |WHS7_104 |Per capita government expenditure on health at average exchange rate (US\))
WHS7_105 Per capita total expenditure on health (PPP int. $)
WHS7_108 Per capita government expenditure on health (PPP int. \() | |WHS7_113 |General government expenditure on health as a percentage of total government expenditure | |WHS7_120 |External resources for health as a percentage of total expenditure on health | |WHS7_134 |Social security expenditure on health as a percentage of general government expenditure on health | |WHS7_139 |Out-of-pocket expenditure as a percentage of private expenditure on health | |WHS7_143 |Total expenditure on health as a percentage of gross domestic product | |WHS7_147 |Private expenditure on health as a percentage of total expenditure on health | |WHS7_149 |General government expenditure on health as a percentage of total expenditure on health | |WHS7_150 |Out-of-pocket expenditure as a percentage of total expenditure on health (see GHED_OOPSCHE_SHA2011) (void WHS7) | |WHS7_156 |Per capita total expenditure on health at average exchange rate (US\))
WHS8_110 Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%)
WHS9_85 Literacy rate among adults aged >= 15 years (%) (void WHS9_85)
WHS9_86 Population (in thousands) total
WHS9_87 Net primary school enrolment ratio (%)
WHS9_88 Population median age (years)
WHS9_89 Population proportion under 15 (%)
WHS9_90 Population living on <$1 (PPP int. $) a day (%)
WHS9_91 Civil registration coverage of births (%)
WHS9_92 Population proportion over 60 (%)
WHS9_93 Gross national income per capita (PPP int. $)
WHS9_94 Civil registration coverage of causes of deaths (%)
WHS9_95 Total fertility rate (per woman)
WHS9_96 Population living in urban areas (%)
WHS9_CS Cellular subscribers (per 100 population)
W-MM_Group Anti-tobacco mass media campaigns
WSH_1 WASH deaths (number) (SDG 3.9.2)
WSH_10 Number of diarrhoea deaths from inadequate water, sanitation and hygiene
WSH_10_HYG Number of diarrhoea deaths from inadequate hygiene
WSH_10_SAN Number of diarrhoea deaths from inadequate sanitation
WSH_10_WAT Number of diarrhoea deaths from inadequate water
WSH_2 Water, sanitation and hygiene attributable deaths (’000) in children under 5 years
WSH_20 Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene
WSH_20_HYG Attributable fraction of diarrhoea to inadequate hygiene
WSH_20_SAN Attributable fraction of diarrhoea to inadequate sanitation
WSH_20_WAT Attributable fraction of diarrhoea to inadequate water
WSH_3 Water, sanitation and hygiene attributable deaths per 100’000 capita
WSH_30 Number of diarrhoea DALYs from inadequate water, sanitation and hygiene
WSH_30_HYG Number of diarrhoea DALYs from inadequate hygiene
WSH_30_SAN Number of diarrhoea DALYs from inadequate sanitation
WSH_30_WAT Number of diarrhoea DALYs from inadequate water
WSH_4 Water, sanitation and hygiene attributable deaths per 100’000 children under 5 years
WSH_5 Water, sanitation and hygiene attributable DALYs (’000)
WSH_6 Water, sanitation and hygiene attributable DALYs (’000) in children under 5 years
WSH_7 Water, sanitation and hygiene attributable DALYs per 100’000 capita
WSH_8 Water, sanitation and hygiene attributable DALYs per 100’000 children under 5 years
WSH_DOMESTIC_WASTE_SAFELY_TREATED SDG 6.3.1 Proportion of safely treated domestic wastewater flows (%)
WSH_HYGIENE_BASIC Population with basic handwashing facilities at home (%)
WSH_SANITATION_BASIC Population using at least basic sanitation services (%)
WSH_SANITATION_OD Population practising open defecation (%)
WSH_SANITATION_SAFELY_MANAGED Population using safely managed sanitation services (%)
WSH_WATER_BASIC Population using at least basic drinking-water services (%)
WSH_WATER_SAFELY_MANAGED Population using safely managed drinking-water services (%)
Youth_survey_title Title of most recent adolescent survey
Youth_svy_age_range Age range of most recent adolescent survey
Youth_svy_national Representativeness of most recent adolescent survey
Youth_svy_yr Year of most recent adolescent survey
Yth_curr_cig_smoking Prevalence of current cigarette smoking among adolescents (%)
Yth_curr_e-cig Prevalence of current e-cigarette use among adolescents (%)
Yth_curr_smokeless Prevalence of current smokeless tobacco use among adolescents (%)
Yth_curr_tob_smoking Prevalence of current tobacco smoking among adolescents (%)
Yth_curr_tob_use Prevalence of current tobacco use among adolescents (%)
Yth_daily_cig_smoking Prevalence of daily cigarette smoking among adolescents (%)
Yth_daily_e-cig Prevalence of daily e-cigarette use among adolescents (%)
Yth_daily_smokeless Prevalence of daily smokeless tobacco use among adolescents (%)
Yth_daily_tob_smoking Prevalence of daily tobacco smoking among adolescents (%)
Yth_daily_tob_use Prevalence of daily tobacco use among adolescents (%)
Yth_nonsmoked_age_grp Age range of latest youth prevalence survey (nonsmoked)
Yth_nonsmoked_national Representation of latest youth prevalence survey (nonsmoked)
Yth_nonsmoked_svy_title Name of latest youth prevalence survey (nonsmoked)
Yth_nonsmoked_svy_yr Year of latest youth prevalence survey (nonsmoked)